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ABSTRACT
The acetylation status of lysine residues on histone proteins has long been attributed to a
balance struck between the catalytic activity of Histone Acetyl Transferases and Histone
Deacetylases (HDAC). HDACs were identified as the sole removers of acetyl post-translational
modifications (PTM) of histone lysine residues. Studies into the biological role of HDACs have also
elucidated their role as removers of acetyl PTMs from lysine residues of non-histone proteins.
These findings, coupled with high-resolution mass spectrometry studies that revealed the
presence of acyl-group PTMs on lysine residues of non-histone proteins, brought forth the
possibility of HDACs acting as removers of both acyl- and acetyl-based PTMs. We posited that
HDACs fulfill this dual role, and sought to investigate their specificity. Utilizing a fluorescencebased assay and biologically relevant acyl-substrates, the selectivity of zinc-dependent HDACs
toward these acyl-based PTMs were identified. These findings were further validated using
cellular models and molecular biology techniques. As a proof of principal, an HDAC3 selective
inhibitor was designed using HDAC3’s substrate preference. This resulting inhibitor demonstrates
nanomolar activity and >30 fold selectivity toward HDAC3 compared to the other class I HDACs.
This inhibitor is capable of increasing p65 acetylation, attenuating NF-κB activation and thereby
preventing downstream nitric oxide signaling. Additionally, this selective HDAC3 inhibition allows
for control of HMGB-1 secretion from activated macrophages without altering the acetylation
status of histones or tubulin.
In addition to this substrate-driven design of a novel HDAC3 selective inhibitor, we sought to
tackle one of the biggest hurdles yet to be overcome for the continued improvement of HDAC
inhibitors. First generation HDAC inhibitors frequently utilize a metal binding hydroxamic acid
4

moiety. The N-hydroxyl group of this motif is highly subject to sulfation/glucuronidation-based
inactivation in humans; compounds containing this motif require much higher dosing in clinic to
achieve therapeutic concentrations. With the goal of developing a second generation of HDAC
inhibitors, lacking this hydroxamate, we designed a series of potent and selective class I HDAC
inhibitors using a hydrazide motif. These inhibitors are impervious to glucuronidation and
demonstrate allosteric inhibition. In vitro and ex vivo characterization of our lead analogs’
efficacy, selectivity, and toxicity profiles demonstrate they possess low nanomolar activity
against models of Acute Myeloid Leukemia (AML) and are at least 100-fold more selective for
AML than solid immortalized cells such as Hek293 or human peripheral blood mononuclear cells.
Further, these compounds seem to kill through a non-caspase-mediated mechanism with
possible involvement of p53. Lead analogs demonstrate favorable half lives in vivo (>3 hours) and
are possess promising bioavailabilty profiles. Lastly, these compounds are non-inferior to current
FDA approved HDAC inhibitors, vorinostat and panobinostat, in causation of mutagenesis.
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Chapter 1: INTRODUCTION
1.1. Histone Deacetylases: a brief history and background
In the early 1970s, researchers interrogated the effects of an enzyme isolated from calf
thymus. The enzyme in question was shown to produce free acetyl groups in the presence of
acetylated histones. Due to its early discovered function, this enzyme was aptly named Histone
Deacetylase (HDAC).1 Before the discovery of HDAC, and even before the discovery there was
more than one HDAC, it was known that the reverse process, the acetylation of histones and
other proteins, involved an enzyme family known as Histone Acetyl Transferases (HAT).2 In
addition to this enzymatic-based ligation, acetyl groups have also been shown to be ligated onto
the ε-nitrogen termini of lysine residues via a forward favored reaction involving the charged
primary amines of lysine and CoA bound acetyl groups.3-5 So why does your body consume all of
this energy to put on and remove these acetyl groups from histones? They, after all, must be
somewhat important due to their homologous presence in eukaryotes as basic as yeast.6 More
specifically, what is the difference between acetylated and non-acetylated histones?
Well, one thing our bodies are known for is their incredibly efficient usage of space. The
function of acetylated and non-acetylated histones fills a very valued space saving purpose.
Unwound DNA is far too large to be stored in the nucleus of cells without further compaction and
compression. As such, the human body utilizes a protein known as a histone to condense the
DNA further, allowing for efficient storage, but also fulfilling another function. If your DNA was
always unwound, you’d have very limited control over transcription of the very accessible DNA.
So our bodies use histones to wrap the DNA around, akin to a thread around a spool, or a garden
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hose around its rack, to allow for very compact storage while simultaneously regulating
transcription.
Looking more into the mechanics of the DNA:Histone interaction, we know that there are
eight subtypes of histones that form an octameric structure.7 How tightly the DNA coils around
the histones depends on the post-translational modification status of the histone bound lysine
residues. With the vast majority of ε-nitrogens on non-modified lysines residues carrying a
positive charge at physiological pH, they are naturally ionically attracted to the negativelycharged phosphate groups found in DNA. As such, when no acetyl group, or other posttranslational modification, is present on these lysine residues, they are able to form tight ionic
interactions with negatively charged phosphate groups of DNA. If the histone bound lysine
residues are extensively modified, and thus lacked their usual positive charge, the DNA will be
relatively weakly bound to the histone. This state, referred to as euchromatin, allows access to
the DNA for transcription. However, if largely unmodified, the positively-charged lysine residues
allow for extensive interaction with DNA resulting in very tightly packed heterochromatin. This
heterochromatin allows for very little transcription of DNA (Figure 1.1).
Indeed the post-translational modification state of histones is akin to a tug-of-war between
HDACs and HATs. The resulting balance between the two has produced much interest in the field
of medicine and molecular biology with the most well-known role these enzymes play seen in
cancer. Extensive research has been performed on the roles of HDACs in cancers. Nearly
universally, HDACs are seen upregulated in a wide variety of cancers ranging from breast to lung
to hematologic malignancies.8-11
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Furthering the complexity into research surrounding the role of HDACs in cancer biology, 18
HDAC isozymes have been identified in the past 50 years.12 These enzymes can be broken down

Figure 1.1 Microscopic and Mechanistic Overview of HDAC- and HAT-Based Chromatin
Remodeling. Figure adapted from McGraw Hill.
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phylogenetically into four classes. Class I contains HDACs 1-3 and HDAC8. Class II is comprised of
HDACs 4-7 and HDACs 9 and 10. Class III is commonly referred to as the Sirtuin enzymes. Whereas
class I, II, and IV HDACs contain an active Zn2+ metal, which is used for coordination of the posttranslationally modified lysine with the catalytic histidines in the active site, class III Sirtuins are
NAD+ dependent and are generally unaffected by traditional HDAC inhibitors. Class IV contains
only HDAC11 (Figure 1.2). Much debate and research has led to a mixed answer about the
importance, roles, and functions of HDACs 4, 5, 7-11. These isozymes are capable of binding
traditional acetylated substrates, yet seem to have no deacetylase activity toward them.13-15 As
such, it is has been posited that they serve as readers of lysine residue post translational status.16
However, it is evident that HDACs 1-3, and 6 have defined, well studied roles in a multitude of
diseases.17-29 Additionally, as they are the primary erasers of lysine residue modifications, HDACs
1-3 and 6 are often given the most attention as targets for medicinal chemistry.
One last broad topic worth mentioning in this section is the presence of an allosteric site on
certain HDAC isozymes.30 This site, generally occupied by inositol phosphates leads to significant
increases in deacetylase activity, but also complex formation and recruitment.31-32 This is
particularly interesting because it seems to be related to the complexes that the individual
isozymes can take part in and form; that is to say that without Inositol Phosphate, certain HDACcontaining complexes are unable to form. Even more detailed analysis has found that only certain
forms of Inositol Phosphate are capable of fully “engaging” this activity. Particularly Inositol (1,
4, 5, 6) Phosphate forces a different conformation in the allosteric pocket than does Inositol (6)
Phosphate.31 This, along with the HDAC isozyme specific complex formation, becomes relevant
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for the development of HDAC inhibitors and will be discussed more in depth later in the
introduction.
Class I HDACs
HDAC1

482 aa (Nuc)

HDAC2

488 aa (Nuc)

HDAC3

428 aa (Nuc/Cyto)

HDAC8

377 aa (Nuc)

Class I Catalytic Domain
Nuclear Localization Sequence
Class II Catalytic Domain
Ubiquitin Binding Domain
Class IV Catalytic Domain

Class IIa HDACs
HDAC4

1084 aa (Nuc/Cyto)

HDAC5

1122 aa (Nuc/Cyto)

HDAC7

855 aa (Nuc/Cyto)

HDAC9

1011 aa (Nuc/Cyto)
Class IIb HDACs

HDAC6

1215 aa (Nuc/Cyto)

HDAC10

669 aa (Nuc/Cyto)
Class IV HDAC

HDAC11

347 aa (Nuc)

Figure 1.2 Zn-Containing HDAC Classification

1.2. Role of HDACs in the NF-κB inflammatory cascade
Thus far, a good amount of time has been spent generally speaking about HDACs, but not
much time has been spent on why they are worth targeting in the field of medicinal chemistry.
As previously eluded, there are a multitude of disease states and pathways that are becoming
recognized as being controlled wholly, or at least in part, by the actions of HDACs. Once such
pathway is the NF-κB p65 inflammation cascade. The NF-κB family of proteins contains five
transcription factors. These proteins generally form heterodimers that, based on composition,
perform different and sometimes even contradicting roles. The five proteins are p65/RelA,
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p50/NF-κB1, p52/NF-κB2, RelB, and c-Rel. Both p50 and p52 are cleaved from p105 and p100
respectively to form their “active” forms.33 A wide variety of proinflammatory cytokines, such as
TNFα, serve to activate NF-κB.34 This process involves activation of the IκB-kinase complex.
Signaling from a myriad of signaling factors leads to phosphorylation of IκBα by IKK. Once
phosphorylated, IκBα is flagged for proteasomal degradation by subsequent ubiquitinylation.
Once degraded, the NF-κB complex is free from IκBα and considered activated. This activated
complex then forms a larger complex with the NF-κB heterodimer to allow for nuclear
translocation (Figure 1.3).34 Once in the nucleus, NF-κB binds exposed DNA and activates
transcription of proinflammatory chemo and cytokines as well as proteins that are antiapoptotic
in nature.
In more recent literature, it has been shown that specific acetylation sites on p50 and p65
subunits of NF-κB dictate nuclear translocation, DNA transcription, and to some extent, what
proteins are transcribed after entering the nucleus.35-41 Following these studies, it was shown
that HDACs 1, 2, and 3 are largely responsible for the deacetylation of these subunits, and even
more specifically, the individual HDACs have preferred lysine residues that they will deacetylate.
Taken together, this finding pointed toward selective HDAC inhibition leading toward selective
control over the NF-κB inflammation cascade at a transcriptional level. Indeed, preliminary data
holds this to be true. HDAC3 alone controls the acetylation status of K122 and K123 of p65.
Acetylation on these lysine residues is associated with decreased DNA binding time.42 As such it
should be considered that an uninhibited HDAC3 promotes NF-κB:DNA binding through ways of
removing acetyl groups on these lysine residues. It has been postulated, and previously shown,
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Figure 1.3 Depiction of NF-κB signaling and activation cascade
that selective HDAC3 inhibition can reduce NF-κB:DNA binding.43 Uninhibited HDACs 1 and 2
were deemed to be anti-inflammatory in nature as they control acetylation status of K218 and
K221 of p65.
When acetylated, these lysine residues diminish binding of NF-κB to IκBα and thus increase
nuclear binding time. As such, when inhibited, the cells enter a largely inflamed state.38
Combining these findings, we can see that if achievable, selective HDAC3 inhibition that does not
affect the deacetylation function of HDACs 1 or 2 would lead to an ideal, anti-inflammatory state.
This selective inhibition would be defined by hyperacetylation of K122 and K123 leading to
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decreased nuclear binding of NF-κB as well as normal acetylation of K218 and K221. The latter
leading to increased NF-κB:IκBα interaction, and thus diminished NF-κB:nuclear binding.
Unfortunately, designing an HDAC3 selective inhibitor that is >100 fold selective compared
to HDACs 1 or 2 has largely been unachieved. The primary method of attempting to achieve
selectivity was performed based on small alterations in protein pockets gleaned from crystal
structures. This venture has been largely unfruitful with only one established and well
documented inhibitor possessing more than 30 fold selectivity.44 This, in turn, has complicated
the design of an HDAC3 selective inhibitor for use in inflammatory diseases. One of the aims of
this paper, which will be more formally written later on in this chapter, is the design of an HDAC3
selective inhibitor using a substrate-driven medicinal chemistry approach rather than a crystal
structure one.

1.3. Role of HDACs in Human Cancers
Naturally when one thinks of cancer biology they probably associate it with the word
complex. Indeed, the role of HDACs in cancers further adds to this complexity. It’s been shown
that nearly every type of cancer has some form of aberrant HDAC biology, be it a significant
overexpression, hyperactivity, or even mutants that lack activity.45-48 That’s not to say that HDAC
status is the only thing that feeds into the pathogenesis of cancers, but it’s certainly too common
of a theme to be dismissed easily. Further muddying the waters regarding their role is the
realization that HDACs don’t control only the acetylation status of histones as their name would
imply, but rather the acetylation status of many different lysine residues associated with many
proteins.49 Even more complicated still is the idea that on top of all of these different ways HDACs
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can affect cancer growth, one could have normally active, normally concentrated HDACs that are
aberrantly recruited to target genes. This is indeed the case in Acute Myeloid Leukemia with
HDACs 1, 2, and 3 and the oncogenic proteins AML1-ETO and PML-RAR.46, 50 To demonstrate the
effect this has on defining potential targets for the treatment of hematologic malignancies, the
combination of HDAC inhibitors with retinoids has been met with some success. The inhibition of
HDACs allowing for the normal expression of Trans Retinoic Acid Receptor and concomitant
activation of these receptors with their natural retinoid ligands allows for the cell to undergo a
“detransformation” back to a non-cancerous state.51-52
In addition to the role that class I HDACs play in hematologic malignancies, they’ve also been
shown to be overexpressed in many solid tumor cells. This, however, should be interpreted
carefully as little clinical efficacy has been shown thus far, only in vitro and lower phyla have
shown promising and/or consistent results. This is in contrast to the rather surprising clinical
successes of HDAC inhibitors in hematologic malignancies/non-solid tumors. HDACs 1 and 2 are
seen to be overexpressed individually in prostate, gastric, colon, breast, colorectal, and cervical
cancers among others.53-58
So what exactly differentiates solid from non-solid tumors? Further, why have HDAC
inhibitors struck such resounding success with one, but not so much the other? Before discussion
of biological differences between the cancer types, it is relevant to discuss the methods by which
HDAC inhibitors can kill cells, and indeed there are several. One such way, and in no particular
order of importance, is their role in autophagy.59 Autophagy can be a two-edged sword when it
comes to treating cancer.60 Forcing a cell to upregulate autophagy may cause it to surveil its
damaged or aberrant organelles and neatly succumb to apoptosis. On the other hand it may allow
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the cell to evade treatments or conditions that induce metabolic stresses that would normally
kill the cell. Indeed it has been proposed that upregulated autophagy is the explanation for
resistance and refraction to treatment in clinic for a variety of cancers.61-62 HDAC6 in particular
has a unique role in this pathway due to its ability to sense and bind free ubiquitin. As such, it
serves as a link between the cell’s proteasomal degradation pathway and autophagic clearance.63
If HDAC6 senses increased concentrations of free ubiquitin, indicative of low amounts of
ubiquitinylated proteins and therefore low metabolic stress, it may downplay or inactivate
autophagic pathways. However, in the absence of these free ubiquitins, it may serve to
upregulate or activate autophagic pathways to aid in the clearance of misfolded proteins through
a non-proteasomal mechanism.64 While a fascinating and complex target for neurodegenerative
diseases and resistant/refractory multiple myeloma, HDAC6’s role in autophagy exceeds the
scope of this work. More relevant to this work, however, is the role of HDACs 1 and 2 in
autophagy. Knockdown/inhibition of HDACs 1 and 2 concomitantly blocks autophagic flux in
skeletal muscle.65 Additionally, inhibition of HDAC1 can promote autophagy by accumulation of
the autophagosomal marker LC3.66 These data prove as promising pathways to further
interrogate as more about the roles of HDACs as individual enzymes and as an aggregate becomes
increasingly recognized and established in the biological underpinnings of cancer, both the
growth and sustenance thereof.
Another, and perhaps more familiar, pathway that HDACs utilize to affect cancer growth is
through the cell cycle. Inhibition of HDACs has been shown to induce G1 cell cycle arrest via cyclindependent kinase induction.67 HDACs 1 and 2 are known to directly bind promoters of p21, 27,
and 57 and negatively affect their expression.68-69 Inhibition of these isozymes is conversely

17

associated with increased expression of p21, 27, and 57.70 In addition to this prevention of Sphase transition is the impaired mitotic cell growth that ultimately can also halt the cell between
the G2/M phases. The pan-HDAC inhibitor panobinostat is capable of doing just this, with its
mechanism being attributed to the degradation of Aurora A and Aurora B kinases via inhibition
of HDACs 3 and 6.71-72
Lastly, but certainly not an exhaustion of the pathways HDACs affect, it’s been well
demonstrated that HDACs regulate apoptosis through the change of expression of pro- and antiapoptotic proteins.73 This includes both increased susceptibility to apoptosis as well as directly
engaging the extrinsic and intrinsic pathways of apoptosis.74-75 For the extrinsic pathway
activation, this has been shown in mice, transcending the possibility it was an in vitro
phenomenon.76 Further giving weight to the findings, and demonstrating the effect of medicinal
chemistry efforts towards HDACs, inhibition of HDACs 1-3 is necessary for both caspase-8
activation as well as expression of an apoptotic protein known as FLICE-like inhibitory protein.7778

Perhaps the best known, most studied, and therefore least understood proapoptotic protein,

p53, also has been shown to be controlled by HDACs.79-81 Acetylation of p53 has been shown to
stabilize the protein, as well as allow for its nuclear translocation and thus transcriptional
activation.82-83 p53 is crucial in regulating damaged cells and preventing the continued growth of
an otherwise abnormal or oncogenic cell.84-85 As this is a crucial role in ensuring the host doesn’t
succumb to the chronic mutations that would otherwise lead to a cancerous growth, p53 is very
tightly regulated. In a healthy, normally functioning cell, p53 is kept at low concentrations. When
the cell is exposed to a wide variety of stresses, p53 is activated, its cellular concentration
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increases, and as such, the cell is more likely to undergo neat, programmed cell death,
apoptosis.85
You may have previously gathered that HDAC inhibitors have a seeming selectivity for
hematologic malignancies and other “soft” cancers compared to solid tumor. This, after all, is
very apparent just by looking at the very narrow window of diseases that all FDA-approved HDAC
inhibitors fall within. So what is the primary difference that separates the two? Why are HDAC
inhibitors seemingly less effective against solid tumor cells when compared to hematologic
cancers? To answer this at a 10,000 foot view, one of the broadest answers may be the
pathogenesis of the two types. Solid tumors, unlike hematologic malignancies, do not stem from
a stem cell type progenitor. As such, this transformation process, in some cases several steps, is
thus a perfect area to look towards for answers. Further, and more importantly to the rationale
behind this body of evidence is if HDACs affect the transformation process?
Indeed this question has been recently looked at in acute promyelocytic leukemia (APL). The
researchers demonstrated that HDAC3 selectively controls the initiation step of APLs progression.
This comes as a very novel finding, as until this publication, there was no previous evidence that
HDACs can directly control oncogenesis, they were previously thought to be controllers of
maintenance. Furthering their claim, selective HDAC3 inhibition was found to abrogate
completely oncogenesis in vivo.20
In addition to this rather novel finding, the p53 acetylation status and activity have also been
heavily studied in acute myeloid leukemia (AML). In this cancer, p53 is found to be mutated in
only 5-8% of patients.86-88 Upwards of a log fold lower than all cancers as an aggregate.89
Furthering this connection, there has been a fair amount of research into the role p53 plays in
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the initiation, development, and maintenance of AML. p53 expression is well associated with
outcomes in clinic, with a strong correlation between increased expression and shorter survival
times.90 Research into how HDAC inhibitors affect AML growth has thus far been largely clinic to
bench side driven. That is, much of what we learn is whether or not these agents work rather
than how they work.91 Essentially all typical methods of inducing cell death, apoptosis, lethal
autophagy, stabilization of p53, etc. been attributed to HDAC inhibitors effect on leukemia cells
in vitro, but an exact mechanism remains to be elucidated.

1.4. Development of inhibitors for Zn2+-dependent HDACs
Now that we’re more familiar with some general ideas and in some cases more exacts of
diseases that HDACs can play a role in, and to what degree, we can begin to see the rationalization
of their inhibitor design. The design of HDAC inhibitors started with a very humble and common
compound. Certainly anyone reading this has worked with the very first, very non-potent HDAC
inhibitor, Dimethyl Sulfoxide (DMSO). Charlotte Friend discovered DMSO’s ability to differentiate
erythroleukemia cells into normal cells in 1971.92 It would be another 25 years before the
mechanism of hyperacetylation of the histones with DMSO treatment was discovered. While an
interesting finding, the effective dose of DMSO was ~0.25M. However this curious discovery
unknowingly sparked the initial efforts into HDAC drug discovery. The first improvement from
DMSO was N-methylacetamide. This compound was able to achieve effective differentiation at
30 mM, an approximate log decrease compared to DMSO. Further efforts were then focused on
building off of this rather small molecule. Addition of a hexyl chain and capping each end with
acetamides led to HMBA. Already we can start to see the long alkyl chain that is present in
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vorinostat (SAHA). It was after more rounds of medicinal chemistry efforts that SAHA was born.
Replacing one acetamide with a benzamide and the other with a hydroxamate, researchers were
able to obtain a 2 µM inhibitor, roughly 2500 times more potent than HMBA.93
SAHA wasn’t instantly known to be an HDAC inhibitor. Indeed, based on the structure and
activity it was nearly instantaneously ruled out as a DNA intercalating agent, however what target
it bound to was anyone’s guess. The hydroxamic acid was thought to be binding to a metal ion,
and was deemed the “active” end of the molecule, with the opposite benzamide serving as an
anchor and the connecting alkyl chain serving as an area of highly flexible linkage.
Since SAHA’s FDA approval for Cutaneous T-cell Lymphoma, three additional HDAC inhibitors
for two different hematologic malignancies have entered the market. Thereby marking HDACs
and their inhibitors as demonstrably relevant targets and efficacious inhibitors for cancers
affecting the blood in particular (Figure 1.4). However, all approvals thus far have been for panHDAC inhibitors. This non-specific inhibition naturally has led to several problems with off-target
toxicities and unfavorable side effect manifestations for patients. More recent ventures into
selective HDAC inhibitor design, as demonstrated by the interest in specificity with pipeline drugs,
has focused on developing inhibitors selective for HDACs 1, 2, 3, and 6, as these have been shown
to be the major targets of acylation-level control.
Despite being a class I HDAC, HDAC8 is largely overlooked due to its markedly decreased
ability to deacylate biologically relevant substrate compared to the other isozymes in its class.94
Throughout this writing, any reference to class I HDACs or specific inhibitors of class I HDACs will
not include HDAC8 unless otherwise mentioned.

21

Figure 1.4 FDA Approved HDAC Inhibitors and Approved Uses.
The development of HDAC6 specific inhibitors has proven to be fairly achievable. By far the
most commonly used example is Tubastatin A. By utilizing a three fused ring system, this inhibitor
selectively inhibits HDAC6 through a steric bulk mechanism. Its three-ring structure prevents its
hydroxamate moiety to reach the Zn2+ atom in the longer tunnels of HDACs 1-3. However, it is
freely available to reach the Zn2+ atom in the shorter tunnel of HDAC6’s catalytic pocket.95 The
necessity of HDAC6 specific inhibitors has become increasingly important as a key mechanism of
Multiple Myeloma drug resistance is realized. As it currently stands, standard of care for Multiple
Myeloma utilizes a Proteasome Inhibitor such as bortezomib. This agent demonstrates very high
increases in disease free progression time frames for patients. However, nearly 100% of patients
become resistant and refractory to its treatment. The mechanism underlying this has not been
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fully delineated, but is thought to be secondary to upregulated autophagic clearance of misfolded
proteins.96 Bortezomib, by preventing a major source of misfolded protein clearance, essentially
works by clogging up the cell with “junky” misfolded proteins. Cancerous cells avoid the apoptosis
this build up would normally induce by upregulation of an alternative pathway that can relieve
the cell’s stress. This autophagic clearance is largely due to HDAC6’s unique ability, via its
ubiquitin binding domain, to coordinate the transport of these misfolded proteins to lysosomal
structures to be cleared by autophagosomes.63 As such, it was hypothesized that HDAC6
inhibition may be useful in combatting bortezomib-resistant/refractory forms of Multiple
Myeloma. Indeed, there was some truth to this hypothesis with the FDA approval of panobinostat
for resistant/refractory Multiple Myeloma. Panobinostat, however, is a pan-HDAC inhibitor.
Pipeline therapies as well as agents in Phase I-III clinical trials that are truly HDAC6 selective have
showed mixed results or were used at doses that negated their HDAC6 selectivity.97
The design of class I specific inhibitors, and sub-class I specific inhibitors has proved to be
much more challenging than HDAC6, and will receive an overwhelming majority of the focus of
this body of evidence. To begin, HDACs 1-3 have an extremely high level of homology (Figure
1.5). This homology has been largely the driving force preventing adequate discovery of selective
inhibitors of these isozymes. Not only do the isozymes display this high level of homology, but
their catalytic pockets are identical with respect to amino acid residues. This, and the inability to
discern key differences between the pockets of HDACs 1-3 derived from their respective crystal
structures, has led to very little success from a medicinal chemistry standpoint.
Further complicating these attempts are the abilities of class I HDACs to form complexes invivo. HDACs 1 and 2 are even able to be interchangeably used in the NuRD, CoREST, MiDAC, and
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SIN3 complexes, meaning if one was to achieve truly selective inhibition of HDAC 1 or 2, the body
could utilize the other in these complexes, abrogating the effects of the inhibitor. Taken together,
selective inhibition of these isozymes may not necessarily equate to selective effects in vivo.98-103
Inhibition of a class I HDAC isozyme in one complex may have a desired effect but be completely
offset by a negative aspect of its inability to act in another complex that performs a different role.
One unifying theme between all class I HDACs is their recruitment to these complexes comes
through the ELM2-SANT domain that, while diverse, is present in these isozymes. Interestingly,
HDAC3 is uniquely able to enter the SMRT/NCoR complex due to the inter isozyme variability in
this region. As such, much more effort has been placed into designing HDAC3 selective inhibitors
compared to inhibitors of HDACs 1 or 2 (Figure 1.6). That being said, it is important to discuss the
functions these complexes have to better understand the complementary or often times clashing
roles they play in the cell.
The NuRD complex is known to participate in replication and repair of DNA.104-105 In addition
to this function, KO and transgenic mouse models lacking key components of the NuRD complex
show its function in tumorigenesis and the embryonic development.106 In particular, it seems to
be a tight regulator of hematopoietic differentiation, especially in the differentiation of myeloid
lineage cells.107 Closely related to this are the findings that this complex also greatly impacts the
transformation process into B and T cells alike.108-110
The CoREST complex tends to interact with the chromatin more than the NuRD complex.
Further, its role seems to be more neuronally centered. It has been shown to regulate both gene
expression and stem cell fate of neurons.111 Further, unlike the dimerized single active enzyme
NuRD complex, CoREST maintains a monomer conformation while having two active enzymes,
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HDAC1/2 and LSD1. As such, it maintains a much more chromatin focused role, with the SANT2
domain of CoREST interacting directly with the DNA.112-113
The MiDAC complex is tightly associated with cyclin A. As such, it demonstrates much more
of a role in cell cycle control.114 Further, with its presence seemingly only in mitotic cells, this
strongly correlated to the findings that HDAC affects the cell-cycle, particularly the G1/S and G2/M
phases.115
The last HDAC1/HDAC2 complex SIN3 is essential to T cell development in addition to embryo
development.116 Other roles include the growth regulation of tumors. Unique to this complex is
the lack of ELM2-SANT domain,117 thereby suggesting recruitment and formation of this complex
is mediated through an atypical mechanism compared to other known complexes.
Finally, the SMRT/NCoR complex is unique in the sense that the only class I HDAC that is
recruited to it is HDAC3. Furthering itself in uniqueness from the other complexes, is its ability to
recruit class IIa HDACs, the “readers.” Although, to date, this purpose has not been fully
elucidated.118 This complex, like the NuRD and MiDAC complexes, is activated by Inositol
Phosphates.30, 103 This activation is done through an allosteric site that is found on both HDACs 1
and 3 (Figure 1.7) shown in bright green. Interestingly, however, different Inositol Phosphates
activate these two isozymes individually. HDAC1 is activated by InsP6 whereas HDAC3 is activated
by Ins(1,4,5,6)P4.31 Furthering this vexing matter is the effect of mutating a key Arginine residue
(Arg270) for HDAC1 and (Arg265) for HDAC3. Mutation of this amino acid for HDAC3 results in a
functioning enzyme that is able to form complexes, however, mutating the homologous amino
acid in HDAC1 results in an inactive complex.31 These rather novel findings may lead to the design
of inhibitors that are complex specific while abusing these subtle, but important, differences.
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Figure 1.5 Sequence Alignment of Human class I HDACs.
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One last issue plaguing drug discovery efforts with class I HDACs is the continued use of archaic
metal-chelating groups such as the hydroxamate (hydroxamic acid) or ortho-aminoanilide
(benzamides). These motifs are commonly used for developing inhibitors of HDACs as they
chelate dicationic metals and “neutralize” the ability of the active site Zn2+ to successfully
coordinate with modified lysines, thereby preventing deacylation. The hydroxamate group, until
the FDA approval of vorinostat, was considered to be an undesirable motif in medicinal
chemistry.119 The non-selective metal chelating properties of the hydroxamate are what allow it
to bind the catalytic Zn2+ metal that HDACs rely on, but also cause compounds containing these
groups to be associated with many undesirable effects secondary to non-targeted active site
metal chelation.120-135 While all FDA approved inhibitors demonstrate very strong efficacy in the
sub-micromolar range, the doses given in clinic are relatively much higher. The reason for this
increased required dose, and the subsequent side effects due to off-target effects, could be in
part to a metabolic inactivation of some of these compounds. The hydroxamic acid that is present
on three of the four FDA approved HDAC inhibitors, vorinostat, panobinostat, and belinostat, is
known to be sulfated or glucuronidated extensively, specifically by UDP glucuronosyltransferase
1A1.136-138 In the case of vorinostat, the process of glucuronidation has been demonstrated to
abrogate its HDAC inhibition activity, and is further evidenced with its issues concerning achieving
therapeutic concentrations in clinic. As belinostat and panobinostat also share this hydroxamic
acid motif, and have subsequently been shown to be glucuronidated in vivo, a safe assumption
can be made that this metabolism causes inactivation for these compounds as well.
Attempts to generate novel, non-hydroxamic acid metal-chelating motifs have resulted in the
use of ortho-aminoanilide-based HDAC inhibitors, most notably MS-275 (entinostat). However,
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Figure 1.6 Depiction of all known class I HDAC complexes.
the benzylic primary amine of this motif is also subject to glucuronidation-based inactivation.139
Further, this inhibitor was shown to be hepatotoxic in mice.140 In a more recent attempt to
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Figure 1.7 Crystal structure of HDAC3 (PDB:4A69) with Ins(1,4,5,6)P4 bound and Corepressor
generate non-hydroxamic acid metal-chelating motifs, Wang and colleagues demonstrated a
novel, potent, class I HDAC-specific inhibitor series based around a hydrazide motif.141 Their
synthetically refined, lead analog from their initial publication possessed 60 nM HDAC3
inhibition, 500 nM and 100 nM for HDACs 1 and 2 respectively, and at least 20 fold selectivity for
class I HDACs compared to HDAC6. Further, their lead compound possessed higher potency than
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the similarly selective ortho-aminoanilide-based inhibitor entinostat, and contained a novel
moiety that would not likely be subject to glucuronidation/sulfation, making it an attractive
starting point for the development of second generation HDAC inhibitors.
Additional efforts have focused on the role of HDACs in complexes and the role of various
forms of Inositol Phosphate with HDAC function and complexation.
These previous findings and gaps in knowledge led to two different hypotheses to approach
a similar problem: developing novel HDAC inhibitors that broke the mold from the traditional
method of designing inhibitors around very slight changes in crystal structure active sites to
achieve selectivity. The first hypothesis to arise was that, if indeed HDACs were capable of more
than just deacetylation and participated in deacylation, do they have some level of specificity
towards one or more substrates in vitro and ex vivo? If so, could this selectivity be used to
develop substrate-driven inhibitors rather than crystal-structure driven inhibitors? The second
hypothesis stemmed from the novel hydrazide moiety. Is the hydrazide motif discovered by
Wang et al. actually chelating Zn2+ or is it the first instance of an allosteric HDAC inhibitor?

1.5. Aims of this study
The aims of this study are largely related to the study of class I HDACs as well as designing
inhibitors selective for this class, as well as selective for individual isozymes of class I. The current
state of literature and knowledge regarding the ability of zinc-dependent HDACs to function as
deacylases is nearly completely absent. Further, with the relatively recent focus on class I HDACs
in both inflammation and leukemias, developing novel inhibitors for class I HDACs/HDAC3 could
prove to be very relevant in clinic. Lastly, the continued use of metal-chelation based HDAC
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inhibitors has become too detrimental to continue. The nonspecific binding, drug:drug
interactions, poor bioavailability in clinic, and general intolerability of these agents demonstrates
the many flaws with which HDAC inhibitors currently hold. As such, my Aims are as follows:

Aim 1: Determine if zinc-dependent Histone Deacetylases have deacylase activity outside of
acetyl-, trifluoroacetyl-, and crotonyl-based modifications.
Aim 1.1: If so, determine if there are groups that are selectively removed by a class or
sub-class of isozymes.
Aim 2: Develop an HDAC3 selective inhibitor utilizing a substrate-based design approach.
Aim 3: Further enhance the hydrazide-based HDAC inhibitors beyond their current ~150 nM
potency and determine if they are impervious to glucuronidation.
Aim 3.1: If a novel compound utilizing this structure can be obtained, determined its
efficacy in a multitude of hematologic malignancies.
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2 MATERIALS AND METHODS
2.1 Materials
Flasks and Plates
96 well “U” bottom black plates were purchased from Greiner (Ref: 650209)
96 well “U” bottom clear plates were purchased from Falcon (Ref: 353910)
Sterile, 6 well clear flat bottom plates were purchased from Greiner (Ref: 657 160)
Sterile, 24 well clear flat bottom plates were purchased from Greiner (Ref: 662 160)
75 cm2 sterile cell culture flasks were purchased from Greiner (Ref: 658 175)

Buffers
Tris-HDAC buffer was made from: 50 mM Tris-Base purchased from Fisher Scientific (Ref: BP1521), 137 mM NaCl purchased from Fisher Scientific (Ref: S671-3), 2.7 mM KCl purchased from
Sigma (Ref: P-4504), 1mM MgCl2 purchased from VWR (Ref: 0288-100G), in sterile filtered RNAase free water purchased from Gibco (Ref: 15230-162).
RIPA buffer is made from: 50 mM Tris-Base, 150 mM NaCl, 5 mM EDTA purchased from Gibco
(Ref: 15575), 0.1% (w/v) SDS purchased from Sigma (Ref: L3490-100G), 0.5% (w/v) Sodium
Deoxycholate purchased from Sigma (Ref: D6750-100G), 1% (v/v) Triton X-100 purchased from
Sigma (Ref: T-8532) in sterile filtered RNA-ase free water, 1% (v/v) Protease/Phosphatase
inhibitor purchased from Thermo (Ref: 1861280) is added.

Cell Lines and Media
MV4-11 cells were purchased from ATCC (Ref: CRL-9591)
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RAW 264.7 cells were purchased from ATCC (Ref: TIB-71)
Hek293 cells were purchased from ATCC (Ref: CRL-1573)
HeLa cells were purchased from ATCC (Ref: CRM-CCL-2)
RPMI-8226 cells were purchased from ATCC (Ref: CCL-155)
RS4;11 cells were purchased from ATCC (Ref: CRL-1873)
K-562 cells were purchased from ATCC (Ref: CCL-243)
HL-60 cells were purchased from ATCC (Ref: CCL-240)
MOLM-14 cells were purchased from DSMZ (Ref: ACC 777)
Fetal Bovine Serum was purchased from HyClone (Ref: SH30396.03)
Antibiotic-Antimycotic solution was purchased from Gibco (Ref: 15240-062)
MV4-11 media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in Iscove’s
Modified Dulbecco’s Medium purchased from Gibco (Ref: 12440-053)
Hek293 media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in Dulbecco’s
Modified Eagle Medium purchased from Gibco (Ref: 11995-065)
HeLa media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in Dulbecco’s
Modified Eagle Medium purchased from Gibco (Ref: 11995-065)
RAW 264.7 media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in RPMI +
GlutaMAX (RPMI 1640 Medium) purchased from Gibco (Ref: 61870-036)
HL-60 media was made from 20% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in Iscove’s Modified
Dulbecco’s Medium purchased from Gibco (Ref: 12440-053)
RS4-11 media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in RPMI +
GlutaMAX (RPMI 1640 Medium) purchased from Gibco (Ref: 61870-036)
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MOLM14 media was made from 20% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in RPMI +
GlutaMAX (RPMI 1640 Medium) purchased from Gibco (Ref: 61870-036)
RPMI-8226 media was made from 10% (v/v) Fetal Bovine Serum, 1% (v/v) Anti-Anti in RPMI +
GlutaMAX (RPMI 1640 Medium) purchased from Gibco (Ref: 61870-036)
Peripheral Blood Mononuclear Cells were a generous gift from the laboratory of Dr. Nathan
Dolloff (MUSC, Charleston SC)
Hanks’ Balanced Salt Solution without Ca2+ or Mg2+ was purchased from Corning (Ref: 21-022-CV)

Materials for Chemical Synthesis
Ethanol was purchased from Decon labs (Ref: 2701)
Methanol was purchased from Fisher Scientific (Ref: A452-4)
Acetonitrile was purchased from Fisher Scientific (Ref: A996-4)
Methylene Chloride was purchased from Acros (Ref: 61005-0040)
Dimethylformamide was purchased from Acros (Ref: 34843-0010)
Ethyl Ether was purchased from Fisher Scientific (Ref: E138-4)
Ethyl Acetate was purchased from Fisher Scientific (Ref: E196-4)
Tetrahydrofuran was purchased from Acros (Ref: 61045-0010)
4 Angstrom Molecular sieves were purchased from Sigma (Ref: 208604-1kg)
Butyraldehyde was purchased from Acros (Ref: 108090010)
Sodium cyanoborohydride was purchased from Oakwood (Ref: 044871)
4-methoxybenzohydrazide was purchased from Oakwood (Ref: 018771)
Benzofuran-2-carboxylic acid was purchased from Sigma (Ref: 307270)
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Oxalyl chloride was purchased from Acros (Ref: 129611000)
Hydrazine monohydrate was purchased from TCI (Ref: H0172)
4-phenoxybenzohydrazide was purchased from Sigma (Ref: PH011385)
Nicotinoyl chloride was purchased from Sigma (Ref: 213381-256)
Triethylamine was purchased from Fisher Scientific (Ref: 04885-1)
methyl [1,1’]-biphenyl-4-carboxylate was purchased from Sigma (Ref: P5501)
Thiophene-2-carbonyl chloride was purchased from Sigma (Ref: 288985-256)
2-Furoyl chloride was purchased from Sigma (Ref: 149861)
Hydrocinnamoyl chloride was purchased from Acros (Ref: 134380250)
trans-Cinnamic acid was purchased from Sigma (Ref: 133760-1006)
1-hydroxybenzotriazole was purchased from Oakwood (Ref: M02875)
N, N' –dicyclohexylcarbodiimide was purchased from Acros (Ref: 113901000)
1-napthoic acid was purchased from Acros (Ref: 128180250)
2-naphthohydrazide was purhcasaed from Sigma (Ref: PH009906)
Methyl 4-(aminoethyl)benzoate was purchased from Sigma (Ref: 479993-5g)
Benzoyl chloride was purchased from Alfa Aesar (A14107)
4-(aminomethyl)benzoic acid was purchased from Sigma (Ref: 283746)
Crotonaldehyde was purchased from Acros (Ref: 427181000)
Isobutyraldehyde was purchased from Sigma (Ref: 240788)
Propanal was purchased from Acros (Ref: 220511000)
Pentanal was purchased from Acros (Ref: 149561000)
3,3,3-trifluoropropanal was purchased from Sigma (Ref: TMT00492)

35

Cyclopropanecarboxaldehyde was purchased from Sigma (Ref: 272213)
Heptanal was purchased from Acros (Ref: 120320500)
Octanal was purchased from Acros (Ref: 129481000)
Hexanal was purchased from Alfa Aesar (Ref: A16265)
Decanal was purchased from Alfa Aesar (Ref: AAA11656AE)
Acetaldehyde was purchased from Acros (Ref: AC149512500)
Cyclobutanecarboxaldehyde was purchased from Sigma (Ref: CDS017876)
Methyl 4-(aminomethyl)benzoate HCl was purchased from Ark Pharm (Ref: AK691510G)
2,2,2-trifluoroethyl formate was purchased from Oakwood (Ref: 037821)
Propionyl chloride was purchased from Sigma (Ref: P51559-25G)
Butyryl chloride was purchased from Sigma (Ref: 236349)
Crotonyl anhydride was purchased from MP Biomed (Ref: 211133)
Valeryl chloride was purchased from Acros (Ref: 169121000)
Hexanoyl chloride was purchased from Acros (Ref: 169040050)
Heptanoyl chloride was purchased from Alfa Aesar (Ref: AAL0331518)
Octanoyl chloride was purchased from Acros (Ref: 129430050)
Trifluoroacetic anhydride was purchased from Acros (Ref: 14781-1000)
Glutaric anhydride was purchased from Acros (Ref: 119970050)
Adipic acid was purchased from Flukar (Ref: 02130-50G)
Nα-(tert-Butoxycarbonyl)-L-Lysine-7-amido-4-methylcoumarin was purchased from Shanghai
Scientific (Ref: 28726)
o-Phenylenediamine was purchased from Acros (Ref: 130552500)
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(E)-2-pentenoic acid was purchased from Alfa Aesar (Ref: A12689)
Thiophene-2-carboxylic acid was purchased from Sigma (Ref: T32603)
1H-pyrrole-2-carboxylic acid was purchased from Sigma (Ref: P73609)
Oxazole-5-carboxylic acid was purchased from Alfa Aesar (Ref: H3017906)
Isoxazole-5-carboxylic acid was purchased from Alfa Aesar (Ref: 1373903)
Benzofuran-2-carboxylic acid was purchased from Ark Pharm (Ref: AK293015G)
4-fluorobenzene-1,2-diamine was purchased from Matrix (Ref: 004671)
4,5-difluorobenzene-1,2-diamine was purchased from Acros (Ref: 449810010)
3,4-difluorobenzene-1,2-diamine was purchased from Matrix (Ref: 004667)
3,5-difluorobenzene-1,2-diamine was purchased from Matrix (Ref: 007008)
Methyl orange was purchased from Sigma (Ref: 11,451-0)
Sodium hydroxide was purchased from Lancaster (Ref: 13094)
Lithium hydroxide was purchased from Sigma (Ref: 40297-4)
Hydrochloric acid was purchased from Fisher Scientific (Ref: A144SI-212)
Magnesium Sulfate was purchased from Sigma (Ref: 208094-12kg)
Potassium carbonate was purchased from Acros (Ref: 19804-0010)
Formic acid was purchased from Fisher Scientific (Ref: A117-50)
12g RediSepRf High Performance gold Silica prepacked columns were purchased from Teledyne
Isco (Ref: 69-2203-345)
5.5g RediSepRf Gold C18 Silica prepacked columns were purchased from Teledyne Isco (Ref: 692203-328)
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5.5g RediSepRf Gold C18Aq Silica prepacked columns were purchased from Teledyne Isco (Ref:
69-2203-570)
TLC silica gels bound on aluminum were purchased from Merck (Ref: 1.05554.0001)
Thermo Fisher LCQ Fleet HPLC-MS using an Accucore RP-MS HPLC Column, 2.6 µM particle size,
30x4.6 mm was used for mass spectrometry.
Bruker 400 Mhz was used for 1H, 13C, and 19F NMR collection.
Teledyne Isco Combiflash Rf200 was used for all purification sequences.
DMSO-d6 was purchased from Acros (Ref: 321290100)

Biological Assay Materials
All recombinant human HDAC isozymes were purchased from BPS biosciences. Lot numbers for
HDACs 1-11 respectively: 140113, 110922G, 120524, 130115, 100414, 140110-G20mM, 90402,
110913, 91020-D, 101011, 141104.
2-Mercaptoethanol was purchased from Sigma (Ref: 63689-100ML-F)
LDS Sample Buffer was purchased from Novex (Ref: NP0008)
Pierce BCA Protein Assay Reagent A was purchased from Thermo (Ref: 23228)
Pierce BCA Protein Assay Reagent B was purchased from Thermo (Ref: 1859078)
MES/SDS Running buffer was purchased from Bioland Scientific (Ref: MES01-03)
Transfer buffer for Bis-Tris gels was purchased from Bioland Scientific (Ref: TB01-03)
Tween 20 was purchased from Acros (Ref: 23336-0010)
Bovine Serum Albumin Fraction V was purchased from Fisher (Ref: BP1605-100)
Clarity Western ECL Substrate peroxide solution was purchased from BioRad (Ref: 102030801)
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Clarity Western ECL Substrate luminol/enhancer solution was purchased from BioRad (Ref:
102030799)
Mixed gender human liver microsomes were purchased from Xenotech (Ref: H0160)
Alamethacin was purchased from Cayman (Ref: 11425)
Uridine 5’-diphosphoglucuronic acid trisodium salt was purchased from Sigma (Ref: U6751)
Amicon Ultra-2 mL Centrifugal Filters were purchased from Millipore (Ref: UFC201024)
Nitric Oxide detection kit was purchased from Promega (Ref: G2930)
HDAC1 siKO was purchased from IDT (Ref: 121666180)
HDAC3 siKO was purchased from IDT (Ref: 122029888)
HDAC6 siKO was purchased from IDT (Ref: 121666183)
HDAC1 OE plasmid was purchased from AddGene (Ref: 13820)
HDAC3 OE plasmid was purchased from AddGene (Ref: 13819)
HDAC6 OE plasmid was purchased from AddGene (Ref: 13823)
Tecan M200 Pro Spectrophotometer
Resazurin sodium salt was purchased from Sigma (Ref: R7017)
Balb/c mice were purchased through Jackson Laboratories

Antibodies
Acetylated tubulin antibody was purchased from Santa Cruz (Ref: sc-23950)
Actin antibody was purchased from Santa Cruz (Ref: sc-8432)
Acetylated Histone H3 antibody was purchased from Santa Cruz (Ref: sc-56616)
Acetylated Histone H4 antibody was purchased from Santa Cruz (Ref: sc-515319)
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Histone H3 antibody was purchased from Santa Cruz (Ref: sc-8654)
p53 antibody was purchased from Santa Cruz (Ref: sc-126)
Hsp90 antibody was purchased from Santa Cruz (Ref: sc-13119)
HDAC6 antibody was purchased from Santa Cruz (Ref: sc-28386)
HDAC1 antibody was purchased from Santa Cruz (Ref: sc-81598)
HDAC3 antibody was purchased from Santa Cruz (Ref: sc-130319)
Acetylated-p65 K122/123 antibody was purchased from Santa LSBio (Ref: LS-C387648)
Acetylated-p53 K382 antibody was purchased from Cell Signaling (Ref: 2525)
p65 antibody was purchased from Santa Cruz (Ref: sc-8009)
conjugated Formyl antibody was purchased from Advanced Targeting (Ref: AB-T100)
conjugated Valeryl antibody was purchased from Advanced Targeting (Ref: AB-T089)
HMGB-1 antibody was purchased from Abcam (Ref: ab18256)

Premade Inhibitors
Tubastatin A was purchased from Biovision (Ref: 1724-1,5)
TrichostatinA was purchased from Cayman (Ref: 89730)
SAHA was purchased from Cayman (Ref: 10009929)
PD-106 was purchased from Cayman (Ref: 13212)
Panobinostat was purchased from Selleck Chem (Ref: S1030)
Entinostat was purchased from Selleck Chem (Ref: S1053)
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2.2 Methods
En bloc recombinant HDAC acyl substrate screening
10 µL (2 ng) of recombinant human HDAC isozyme was added to 96 well black plate and briefly
centrifuged. 10 µL of acyl-substrate solution (200 µM) was added to their respective wells. The
plate was briefly centrifuged and incubated at 30°C for 2 hours. 5 µL of 30 mg/mL trypsin with 6
µM Trichostatin A was added to the solution and briefly centrifuged. After 1 hour, the plate was
read via Tecan M200 Pro spectrophotometer at 360 nm (ex.)/460 nm (em.)

Vmax analysis of recombinant human HDAC isozymes
100 µL (1 ng) of recombinant human HDAC isozyme solution was added to each well of a 96 well
black plate. After centrifugation, 100 µL of serially diluted inhibitor at 2.5x desired concentration
or 100 µL of 2x desired concentration serially diluted substrate added and incubated for 2 hours
at 30°C for 2 hours. If substrate not yet added, 50 µL of serially diluted substrate at 5x
concentration added and allowed to incubate at 30°C for an additional 2 hours. If substrate was
already present for 2 hours, 50 µL of 30 mg/mL of trypsin and 6 µM TrichostatinA added and
allowed to incubate at room temperature for 1 hour. The plate was read via Tecan M200 Pro
spectrophotometer at 360 nm (ex.)/460 nm (em.). Vmax and Km values were calculated by
GraphPad Prism’s Michaelis-menten function.

Western blot analyses
Cells were cultured according to ATCC guidelines. Cells were plated at 500k cells/mL x 3 mL in
clear, flat bottom 6 well plates. Cells were pre-incubated for 24 hours before addition of inhibitor
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at various concentrations. The cells were allowed to incubate for 24 additional hours before
being harvested, pelleted, and stored at -80°C. Cell pellets were lysed with 120 µL of RIPA buffer.
After lysing, the suspension is ultra-sonicated and centrifuged at 15000 RPM for 15 minute at
4°C. 80 µL of supernatant was mixed with 40 µL of 15:85 (v/v) β-mercaptoethanol:LDS solution.
The mixture was heated at 90°C for 15 minutes and stored for loading at -20°C. Prior to loading,
the solution was flash thawed at 90°C. Lysates were based on BCA standard curves. Lysates were
run on Invitrogen NuPAGE 4-12% Bis-Tris 15 well gels at 170V for approximately 60 minutes in
MES buffer. Gels were transferred to methylcellulose and ran in transfer buffer at 30V for 180
minutes. Primary antibodies were added in 5% (w/v) Bovine Serum Albumin Fraction V. The
respective antibody was incubated with the cellulose overnight at 4°C before addition of
secondary antibody in 5% (w/v) Bovine Serum Albumin. Blots were incubated with 1:1 mixture
of Peroxide/Luminol solution. Images were acquired using a GE ImageQuant LAS 4000. Global
lighting adjustments of resulting images were made using Adobe Photoshop CC. Quantification
was performed using Image Studio Lite 4.0.

Hek293 lysate deacylase activity
100 µL (1 ng protein) of Hek293 lysates were added to 96 well black plates. After brief centrifuge,
100 µL buffer solution or 2.5x concentrated inhibitor solution added to respective wells. The plate
was briefly centrifuged and incubated at 30°C for 2 hours. 50 µL of 250 µM fluorogenic acyl
substrate was added and the plate briefly centrifuged before 2 hour additional incubation at
30°C. 50 µL of 30 mg/mL of trypsin and 6 µM TrichostatinA added and allowed to incubate at
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room temperature for 1 hour. The plate was read via Tecan M200 Pro spectrophotometer at 360
nm (ex.)/460 nm (em.).

Hek293 HDAC 1, 3, and 6, siRNA knockdown
Hek293 cells were cultured in ATCC recommended conditions. siRNAs selective for their
respective HDACs were transfected and the cells were harvested 24 hours afterwards.
Knockdown was confirmed with Western Blot analysis methodology.

Hek293 overexpression of HDACs 1, 3, 6, and NCoR2
Hek293 cells were cultured in ATCC recommended conditions in antibiotic free media. At 70%
confluence in a 75 cm2 culture flask the overexpression plasmids were transfected with
lipofectamine LTX with plus reagent according to manufacturer’s protocol over a 48 hour period.
Overexpression was verified with Western Blot analysis methodology.

Acylation of Fatty Acid Free Bovine Serum
10 mg of Fatty Acid Free Bovin Serum Albumin was reacted with 1 mL of Valeryl Chloride (Sigma)
or Acetic Anhydride (Acros) overnight at room temperature. These solutions were spun at 4°C at
15,000G for 15 minutes. The supernatant aspirated and the pelleted BSA resuspended in 1 mL of
methanol. These washing and centrifugation steps were repeated 4 additional times. Residual
volatiles were removed via lyophilization and the resulting dried pellet was resuspended in 1 mL
of deionized water.
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33.3 mg of Fatty Acid Free Bovine Serum was suspended in 5 mL of 99% Formic Acid (Sigma). The
solution was raised to 65°C. 1.2 mL of Acetic Anhydride (Acros) was slowly dropped in via injection
over 30 minutes. The solution was allowed to stir for 5 additional minutes before quenching with
1.5 mL of distilled ice water. Volatiles were removed under reduced pressure at room
temperature. Residual solution was removed via lyophilization. The resulting pellet was
resuspended in 3.3 mL of distilled water. This methodology was adapted from du Vigneaud,
Dorfmann, and Loring (1932).

Cross Sensitivity Verification of Formyl-, Acetyl-, and Valeryl-Lysine Antibodies
0.5 µL of each solution (10 mg/mL) was dotted onto nitrocellulose using a 0.25 µL – 2 µL pipette
fitted with 10 µL pipette tip. After the cellulose was dried, it was transferred into a 5% (w/v)
solution of Bovine Serum Albumin. 1:1000 (v/v) of respective primary antibody was added and
allowed to rock overnight at room temperature. The cellulose was washed several times and
appropriate secondary antibody was added (1:1000 (v/v)). This solution was rocked for 1 hour at
room temperature before washing and imaging. The nitrocellulose was incubated with a 1:1
solution of peroxide/luminol enhancer. Imaging was performed on GE ImageQuant LAS 4000.

IC50 determination of potential HDAC inhibitors with recombinant human HDACs
50 µL of enzyme solution (1 ng of enzyme) added to desired wells of 96 well black plate. 50 µL of
serially diluted inhibitor solution added and the plate briefly centrifuged before 5-120 minute
incubation at 30°C. 25 µL of 250 µM fluorogenic acyl substrate added, the plate briefly
centrifuged, and allowed to incubate for an additional 2 hours at 30°C. 50 µL of 30 mg/mL of
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trypsin and 6 µM TrichostatinA added and allowed to incubate at room temperature for 1 hour.
The plate was read via Tecan M200 Pro spectrophotometer at 360 nm (ex.)/460 nm (em.).

Nitric Oxide production assay
RAW246.7 cells were cultured at 500,000 cells/mL for 24 hours according to ATCC guidelines. The
culture media was refreshed and treatments were added three hours before the LPS (200 ng/mL)
challenge. 50 µL of media was collected from each treatment and the media NO concentrations
were determined using Griess reagents and Tecan M200 Pro spectrophotometer at 550 nm (em.).
Concentrations were calculated based on a standard curve.

HMGB-1 detection
RAW246.7 cells were cultured at 500,000 cells/mL for 24 hours according to ATCC guidelines. The
culture media was refreshed and treatments were added three hours before the LPS (200 ng/mL)
challenge. Cell media was collected and concentrated using Amicon Ultra-4 spin column. The
concentrated lysates were then mixed with 4x LDS loading buffer and run on a 4-12%
polyacrylamide gel. The HMGB-1 levels were determined using HMGB-1 monoclonal antibody.

ESI-LCMS Glucuronidation Assays
A buffer solution containing 100 mM Tris HCl buffered to a pH of 7.5 at 37°C was used to dilute
HLMs to a concentration of 250 µg/mL. To this solution was added 1 µg/mL (final) of alamethicin
and 5 mM MgCl2 (final). This solution was rocked gently at 4°C for 15 minutes to allow pore
formation. 180 µL of this solution was added to 10 µL of 5 mM inhibitor + 10 µL of 50 mM UDPGA
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in H2O or just 10 µL H2O. This solution was gently rocked at 37°C for 12 hours before being
quenched with a 47:50:3 (v/v/v) solution of water, acetonitrile and formic acid. After a 15 minute
centrifugation at 15000g in 37°C conditions, 20 µL of supernatant was directly injected into
Thermo LTQ Fleet LCMS.

ESI-LCMS Protocol
Water and methanol with 0.1% (v/v) formic acid were used as mobile phase. A gradient of 10%
methanol 90% water was run isocratically for 2 minutes at 500 µL/min. The gradient then
increased to 100% methanol over 15 minutes before returning to 10% methanol 90% water over
the next three minutes. Capillary temperature was 350°C, with a spray voltage of 5 kV.

Molecular Docking against HDAC3
Modeling and simulations were performed using MOE 2014.09 (Chemical Computing Group, Inc)
using structural PDB: 4A69, HDAC3 bound to human NCOR2 corepressor. Before analysis,
proteins were protonated at pH 7.4 and structures energy minimized with heavy atoms
constrained using the Amber12:ETH forcefield. Initial surface probe simulations focused on using
13b as a probe for potential interaction sites, docking to the heterodimers using the entire
surface as a target. The surface probe simulations left the protein dimer rigid and flexed the
ligand. Initial placement calculated 200 poses using triangle matching with London dG scoring;
the top 100 poses were then refined using forcefield and Affinity dG scoring. The consensus
docking site was determined using Protein Ligand Interaction Fingerprint (PLIF) analysis. The
HDAC3 bound to corepressor structure described above was used to estimate the propensity for
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ligand binding (PLB) for the entire surface. Settings for MOE SiteFinder were: Probe Radius1: 1.5,
probe radius 2: 1.8, isolated donor/acceptor: 3, connection distance: 2.5, minimum site size: 3,
radius: 3. The consensus site between the surface probe and PLB analysis was used to create
docking dummies for site focused docking simulations with an additional 4.5 angstrom radii. The
focused dock used induced fit for the protein, allowing protein and ligand flexing. Initial
placement calculated 200 poses using triangle matching with London dG scoring, the top 100
poses were then refined using forcefield and Affinity dG scoring.

MV4-11 EC50 Analysis
The cells were grown according to ATCC protocol. Cells were plated at 20k cells/well in 96-well
clear U-bottom plates and pre-incubated for 24 hours. Addition of serially diluted inhibitor (in
medium) was performed followed by 48 hours of additional incubation. Addition of CellTiterBlue occurred to a final concentration of 0.125 mg/mL. The mixture was allowed to incubate
until sufficient color changed occurred. Cell viability was measured as a function of resorufin
intensity using a Tecan M200 Pro spectrophotometer, 560 nm (ex.)/590 nm (em.). Data were
normalized to control wells and background was removed. EC50 values were determined using
GraphPad Prism’s “log(inhibitor) vs. normalized response – Variable slope” function.

Human Peripheral Blood Mononuclear Cell Analysis
Cells were flash thawed from liquid nitrogen using RPMI-1640 media + Glutamax and 15% Fetal
Bovine Serum and allowed to incubate overnight at 37°C, 5% CO2. Cells were centrifuged at 1000
RPM for 5 minutes. Pelleted, healthy cells were reseeded at 50k cells/well and treated
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immediately with serially diluted inhibitors (diluted in medium). Cells were allowed to incubate
with inhibitor or vehicle for 24 hours before addition of 0.125 mg/mL (final) CellTiter-Blue. The
mixture was allowed to incubate until sufficient color changed occurred. Cell viability was
measured as a function of resorufin intensity using a Tecan M200 Pro spectrophotometer, 560
nm (ex.)/590 nm (em.). Data were normalized to control wells and background was subtracted.

in-vivo MTD studies of 12d, 13b, and 14a
Mice were injected once daily with 100-200 µL of solution suspended in 95% sterile PBS/5%
DMSO or 95% Neobee M5/5% DMSO with compounds of interest at either 10 or 20 mg/kg for 14
days. Mice were continually monitored for signs of moribund. Mice were humanely sacrificed if
body mass decreased by more than 20% of baseline. Mice were sacrificed by CO2 asphyxiation
followed by cervical dislocation.
in vivo PK/PD studies of 13b and 14a
Animals (rat or mouse) are fed a standard laboratory rodent diet and housed in individual cages
on a 12-hour light and 12-hour dark cycle with room temperature maintained at 22 ± 30C and
relative humidity at 50 ± 20%. Animals are typically fasted overnight before dosing, with food
returned after the 6 hour blood samples are obtained. Water is provided ad libitum throughout
the study. The dosing solution of each test compound is prepared in a desired formulation. Three
animals were dosed via intraperitoneal injection at 20 mg/kg. All blood samples (100-300 μL per
sample) are taken via appropriate vein (saphenous, jugular, or submandibular vein) at 5, 15, and
30 min and 1, 2, 4, 6, 8, and 24 h after dosing. Fluid replacement (1.5 mL of 0.9% sodium chloride
injection, USP) will be administered subcutaneously once after the 2 hr blood sampling. Blood
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samples are collected in BD Microtainer tubes coated with anticoagulant, placed on ice, and
within 30 minutes, centrifuged at 15,000g for 5 min to obtain plasma samples. All plasma samples
are stored at –70°C until analysis. Bioanalysis of PK/PD Samples Plasma samples are prepared as
follows. Two or three volumes of acetonitrile containing internal standard is added to one volume
of plasma to precipitate proteins. Samples are centrifuged (3000 g for 10 min) and supernatant
removed for analysis by LC-MS/MS. Calibration standards and quality controls are made by
preparation of a 1 mg/mL stock solution and subsequently a series of working solutions in
methanol : water (1/:1, v/v) which are spiked into blank plasma to yield a series of calibration
standard samples in the range of 1 ng/mL to 10 μg/mL and quality control samples at three
concentration levels (low, middle and high). All incurred PK/PD plasma samples are treated
identically to the calibration standards and quality control samples. LC-MS-MS analysis is
performed utilizing multiple reaction monitoring for detection of characteristic ions for each drug
candidate, additional related analytes and internal standard. Pharmacokinetic Data Analysis
Plasma concentrations are measured as described above to determine a concentration vs. time
profile. The area under the plasma concentration vs time curve (AUC) is calculated using the
linear trapezoidal method. Fitting of the data to obtain pharmacokinetic parameters is generally
carried out using non-compartmental analysis. Key PK parameters reported following
intravenous administration are as follows: terminal half-life t1/2, initial plasma concentration C0,
area under the plasma concentration vs. time curve AUC, volume of distribution at steady-state
Vss, total plasma clearance CLp, and mean residence time MRT. Key PK parameters reported
following extravascular administration are as follows: terminal half-life t1/2, maximum plasma
concentration Cmax, time to reach maximum plasma concentration tmax, area under the plasma
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concentration vs. time curve AUC, mean residence time MRT, and bioavailability F. All parameters
are expressed for individual animals as well as mean, standard deviation, and coefficient of
variation.
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3 RESULTS AND DISCUSSION
3.1. Role of Histone Deacetylases as Lysine Deacylases: impact in medicinal
chemistry and inflammatory diseases.
Rationale. Increasing evidence suggests that lysine post-translational modifications (PTMs)
play multiple and extensive roles in cell signaling, akin to the well-studied phosphorylation,
methylation, or ubiquitinylation PTMs.142 Initial proteomic studies using high-resolution mass
spectrometry have identified at least 3,600 lysine acetylation sites on over 1,750 proteins.129 In
addition to lysine acetylation, a wider array of lysine acylations have gradually become
recognized as important PTMs that control key cellular processes.143 These modifications include
lysine-formylation, acetylation, propionylation, butyrylation, crotonylation, glutarylation,
malonyl/succinylation, and myristoyl/palmitoylation.136, 144-151 A common feature of these lysine
acylations is most of them originate from coenzyme A (CoA) metabolites. The even numbered
acyl groups such as acetyl and butyryl are likely derived from ß-oxidation pathways, and the more
complex succinyl modification likely stems from succinyl-CoA, most commonly used in regulation
of cellular energy homeostasis. This crosstalk between metabolism and PTM status suggest a role
for these lysine modifications to regulate enzymes in metabolic pathways.50 Further, the
identification of the diverse acyl-based PTMs has sparked studies focusing on the conditions
under which they are attached and removed, leading to the demonstration that acylation of
lysines is a non-specific process performed either through promiscuous Histone Acetyl
Transferases or simply by non-catalytic chemical ligation.152 Unlike the promiscuous and even
equilibrium-based ligation of acyl groups to lysines, the removal of these groups seems to be
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more carefully controlled.152 One enzyme family shown to be able to remove glutaryl,
malonyl/succinyl, and myristoyl/palmitoyl groups is the Sirtuins.136, 151, 153 As class III members of
the Histone deacetylase (HDAC) family of enzymes, Sirtuins are NAD+-dependent deacylases.
Contrarily, class I, II, and IV HDACs are metal-containing deacetylases. It has been suggested that
class I, II, and IV HDACs possess the ability to also deacylate lysines rather than an isolated ability
to deacetylate them. With this knowledge, we asked if these relatively novel acyl groups were
substrates for any Zn2+-dependent HDAC, and if so, questioned whether there was any level of
specificity these isozymes displayed toward certain acyl substrates.
HDAC isozyme deacylase kinetic profiling. Our study began by developing 12 different
aminomethylcoumarin-based fluorogenic substrates that would mimic biologically relevant acylgroup PTMs (Figure 3.1a). These substrates were developed based on either known acids/acylCoA bound esters that have been found in the blood stream in high concentrations and are likely
to be ligated to the ε-N terminus of lysine or known PTMs shown to exist via mass spectrometry
ex vivo. The non-biologically relevant Trifluoroacetyl (TFA) substrate was utilized as a positive
control for class IIa HDACs and HDAC8 as it is the best-known substrate to be efficiently removed
by these HDAC isozymes.154 Utilizing these substrates and recombinant human HDACs, all zincdependent HDAC isozymes were tested en bloc for their ability to deacylate each substrate, with
particular interest for substrate cleaved over time with constant enzyme and substrate
concentrations (Figure 3.1b).
As previously reported, HDACs 1, 2, 3, and 6 demonstrated the most robust deacetylase
activity compared to all other HDAC isozymes.94 Also in line with external findings, class IIa HDACs
and HDAC8 only displayed the ability to deacylate the TFA-based substrate.15 No appreciable
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Figure 3.1. Acyl-substrate synthesis and en bloc profiling.
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a) Chemical structures of 12 acyl-based substrates synthesized for kinetic profiling purposes. b) All synthesized acylsubstrate data against Zinc-dependent HDAC enzymes. n = 3; error bars are S.E.M.

deacylase activity was seen for HDACs 10 and 11 which falls in line with a similarly performed
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study.94 In addition to this, we saw no appreciable activity of any isozyme toward our heptanoyl, octanoyl-, glutaryl-, or adipoyl-based substrates (Figure 3.1b). As such, the results of this
experiment directed our focus toward more rigorous interrogation of the deacylase capacity of
HDACs 1, 2, 3, and 6.
HDACs 3 and 6 demonstrated appreciable deformylase activity with HDAC6 demonstrating
higher catalytic activity as a deformylase than as a deacetylase with the concentrations of enzyme
and substrate used; HDAC3 possessed by far the most diverse ability to deacylate a variety of
substrates, including the TFA-based substrate, with a particular preference for deacylating the
butyryl-, crotonyl- and valeryl-based substrates compared to HDACs 1 and 2; and lastly, HDACS
1-3 were able to depropionylate with high catalytic efficiency (Figure 3.1b and Figure 3.2a).
While there have been previous reports of HDAC3 possessing the ability to deacylate the TFAbased substrate94, we sought to determine if this finding was due to an impurity of one or more
class IIa HDACs in our HDAC3 solution. Briefly, HDAC3 was coincubated with TFA-substrate and
vorinostat or diphenyl acetic hydroxamic acid (dPAHA). It has been previously shown that
vorinostat possesses no appreciable inhibitory activity for class IIa HDACs94 while dPAHA only
possesses the ability to inhibit class IIa HDACs.155 As expected, and in line with previous
publications156, vorinostat, but not dPAHA, was capable of altering HDAC3’s ability to deacylate
TFA substrate (Figure 3.3). Therefore, we are confident in associating this deacylase ability with
HDAC3.
To further investigate the key findings from our initial screen, we performed Vmax kinetic
analyses on HDACs 1, 2, 3, and 6 versus substrates that were deacylated by one or more of these
isozymes. We determined values of Km, Vmax, kcat, and kcat/Km, the latter being the most well
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accepted measurement of catalytic efficiency (Table 3.1). Interestingly, the Km values of our
formyl-based substrate vs HDACs 3 and 6 is nearly a log lower than the corresponding values for
HDACs 1 and 2. The Vmax value for HDAC1, despite being higher than the value for HDAC6 is not
likely to be achieved in vivo, as the concentration required to achieve this would be in the
millimolar range. (Figure 3.2b and Table 3.1). HDAC6 is the most catalytically efficient
deformylase, however, it is still a more efficient deacetylase. Surprisingly, HDACs 1-3 displayed
remarkable catalytic efficiency as depropionylases. Despite this, there appears to be very little
difference in selectivity or efficiency between the three isozymes. The last intriguing finding from
this kinetic study was the deacylation ability of HDAC3 toward butyryl-, crotonyl-, and valerylbased substrates. It has been previously reported that HDAC3 was capable of deacylating
crotonyl-substrates.157 Unlike the depropionylase ability of HDACs 1-3, the deacylase activity
toward these substrates was very specific to HDAC3. This seems to stem from HDAC3’s ability to
both bind these substrates more efficiently (lower Km values) as well as efficiently cleave these
substrates (higher kcat/Km values) from the ε-N of lysine than HDACs 1 or 2 (Figure 3.2c and Table
3.1). Most interestingly, the crotonyl-substrate binds to HDAC3 with very high affinity, however,
there is little substrate turnover (kcat) compared to the canonical acetyl-substrate (Table 3.1).

Interrogation of HDACs 3 and 6 as deformylases. Utilizing Hek293 cell lysates and various HDAC
inhibitors, we sought to determine if this newly discovered deformylase activity both translated
into a more robust cellular-based model and if it was affected by traditional small molecule
inhibitors. Vorinostat, a class I and HDAC6 inhibitor94; Tubastatin A (tubA), an HDAC6 specific

55

Figure 3.2. Acyl-substrate profiling.
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inhibitor95; and PD106, an HDACs 1-3 inhibitor158 were all used to interrogate the individual and
combined inhibitory effects of these small molecules against HDAC isozymes’ cellular
deformylase activity (Figure 3.4a). The pan-inhibition of vorinostat at 1 µM demonstrated the
ability to inhibit both deacetylation and deformylation, in line with our kinetics study. The
selective HDAC6 inhibitor Tubastatin A at 0.5 µM, well above its IC50 of <50 nM, did not affect
overall deacetylation activity, but did lower deformylation activity (Figure 3.4b). This is due to
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TFA-substrate cleavage rate

Figure 3.3. HDAC3 purity test.
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the ability of HDACs 1-3 to fulfill the deacetylase role in the cell even with an inhibited HDAC6.159
The HDACs 1-3 inhibitor PD106 at 1 µM also showed a deformylase inhibition profile akin to
Tubastatin A, once again showing that selective inhibition of HDAC3 or HDAC6 is not enough to
affect global deacetylation, but can affect deformylation. Lastly, when Tubastatin A and PD106
were combined, additional lowering in deformylation activity was seen while leaving
deacetylation activity nearly unaffected (Figure 3.4b). Despite inhibiting HDACs 1, 2, 3, and 6, the
combined treatment only affected deformylation. This, unlike vorinostat’s effect on
deacetylation, can be explained through the concentrations used to achieve this result. At 1 µM,
PD106 is below its IC50 value for HDACs 1 and 2 in Hek293 cells. As such, it is not likely to be
inhibiting these enzymes strongly enough to induce a physiologic effect that would be seen with
less discriminate class I HDAC inhibition at higher doses.
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With the results of small molecule inhibition matching the data from our initial screening, we
next interrogated the roles of HDACs 3 and 6 as deformylases utilizing siRNA knockdown and
Table 3.1. Key isozyme profiling values

HDAC1
Formyl
Acetyl
Propionyl
Butyryl
Crotonyl
Valeryl
HDAC2
Formyl
Acetyl
Propionyl
Butyryl
Crotonyl
Valeryl
HDAC3
Formyl
Acetyl
Propionyl
Butyryl
Crotonyl
Valeryl
HDAC6
Formyl
Acetyl
Propionyl
Butyryl
Crotonyl
Valeryl

Km (µM)
342
36.6
13.1
49.1
2.40
102
Km (µM)
313
36.6
8.53
21.9
3.20
122
Km (µM)
39.1
17.3
8.06
1.03
0.114
9.99
Km (µM)
37.2
1.93
161
N.D.
N.D.
N.D.

Vmax (pmole · s-1 ·
mg protein)
12300
24800
9850
1910
802
5330
Vmax (pmole · s-1 ·
mg protein)
5980
4.00x10^3
4.90x10^3
804
1010
2880
Vmax (pmole · s-1 ·
mg protein)
15600
26900
13900
2560
758
11100
Vmax (pmole · s-1 ·
mg protein)
1.00x10^4
2130
9.00x10^2
N.D.
N.D.
N.D.

kcat (min-1)
8.24
16.6
6.62
1.28
0.380
3.56
kcat (min-1)
4.01
2.69
3.29
0.540
0.485
1.93
kcat (min-1)
9.30
16.0
8.31
1.53
0.362
6.63
kcat (min-1)
19.1
4.04
1.72
N.D.
N.D.
N.D.

kcat/Km (M-1 · s-1)
402
7580
8410
435
2670
582
kcat/Km (M-1 · s-1)
214
1230
6440
412
2520
264
kcat/Km (M-1 · s-1)
3970
15400
17200
24700
53700
11100
kcat/Km (M-1 · s-1)
8580
34800
178
N.D.
N.D.
N.D.

lipofectamine-induced transfection for overexpression in Hek293 cells (Figure 3.4c-f). Utilizing
HDAC1 as a negative control, we see its knockdown bears no impact on deformylation activity.
Knockdown of HDAC3, however, led to an approximate 35% decrease in deformylation activity
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of the cell lysate; knockdown of HDAC6 led to a more robust 55% decrease in deformylation, and
the concomitant knockdown of both isozymes led to a similar effect (Figure 3.4d). These data
support the previous findings that HDACs 3 and 6 are majority or possibly even sole controllers
of deformylation in the cell with their suppression leading to extensive loss of activity. Following
up these studies, we performed overexpression of HDACs 1, 3, and 6 (Figure 3.4e). Again, using
HDAC1 as a negative control we see its overexpression bears no effect on deformylase activity.
Initial overexpression of HDAC3 without its required co-enzyme NCoR2 led to no appreciable
increase in deformylase activity. However, simultaneous overexpression of both enzymes led to
an approximate doubling in activity. Overexpression of HDAC6 in similar fashion displayed a much
more robust increase in deformylation activity, leading to a near 10-fold increase in activity.
These increases were not seen in the control pcDNA3.1 plasmid (Figure 3.4f). Taken together,
these data suggest that HDACs 3 and 6 are both controllers of deformylation, however, HDAC6
seems to be a more active deformylase in vitro.

Interrogation of HDAC3’s role as a selective devalerylase. We next chose to probe HDAC3’s
seemingly selective ability to remove short chain fatty acids four to five carbons in length. As
carbon chain length for our synthesized substrates exceeded three, deacylation activity
decreased for all isozymes but HDAC3 (Figure 3.1b and Table 3.1). In particular, we were
interested in the potential devalerylase activity of this isozyme. Traditionally, short chain fatty
acids created in vivo contain an even number of carbons. Valeryl groups, confirmed to exist in
human serum as its fatty acid form in the high micromolar range160, are the result of bacterialbased metabolism of sloughed intestinal cells from gut dwelling flora.161 Combining these data
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Figure 3.4. Role of HDACs 3+6 in cellular deformylation
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Deformylase activity of siRNA treated Hek293 lysates; data normalized to scramble deacetylase activity. e) Western
blot analysis of Hek293 cells transfected with various vectors to overexpress targeted HDACs. f) Deformylase activity
of transfected Hek293 cells; data normalized to pcDNA3.1+ vector transfected cells. b, d, and f are n = 3; error bars
are S.E.M. c and e are representative of n ≥ 2 experiments. * = p-value < 0.01. ** = p-value < 0.0001. All statistical
analyses were Dunnett’s multiple comparisons of means to the means of their respective controls.
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with our findings that HDAC3 may serve as a devalerylase, we discovered a potentially clinically
relevant finding and chose to interrogate this observation further.
We proceeded to study the effect of HDAC isozyme inhibition with small molecule inhibitors
on HDAC3’s potential devalerylase activity using Hek293 lysates. Similar to the prior experiment,
the pan-HDAC inhibition of vorinostat led to a lowering in both deacetylation as well as
devalerylation (Figure 3.5a). The HDAC6 selective inhibitor Tubastatin A displays no effect on
deacetylation and devalerylation, in line with our previous experiments that suggest HDAC3 is
the only HDAC isozyme capable of devalerylation (Figure 3.2a). The utilization of the HDACs 1-3
inhibitor PD-106 demonstrates selective inhibition of devalerylation. The addition of Tubastatin
A to this dosage leads to seemingly no difference in overall effect. Taken together, these data
give further validity to our initial discovery that HDAC3 possesses devalerylase activity. To further
test this finding, we again utilized our Hek293 lysates with HDAC isozymes knocked down (Figure
3.4c). With the selective knockdown of HDAC3, but not HDACs 1 or 6, we see an approximately
40% decrease in global deformylation activity (Figure 3.5b). Using the Hek293 lysates with
overexpressed HDAC1, HDAC3, HDAC3/NCoR2, and HDAC6 (Figure 3.4e), we indeed see that
increased cellular concentrations of HDAC3 and its co-enzyme NCoR2 led to substantial increases
in the devalerylation activity of our Hek293 lysates while overexpression with other plasmids did
not (Figure 3.4c).

Interrogation of HDAC inhibitors on global protein formylation and valerylation. A potential
pitfall for all previous experiments was that it relied on artificially synthesized fluorogenic
substrates. To assuage this possible confounding factor, we utilized antibodies specific toward
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Figure 3.5. Role of HDAC3 in cellular devalerylation.
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a) Comparison of effect on devalerylase and deacetylase activities of Hek293 lysates with various inhibitors; data
normalized to control deacylase activity; vorinostat and PD-106 used at 1 µM, tubA used at 0.5 µM. b) Devalerylase
activity of siRNA treated Hek293 lysates; data normalized to scramble deacetylase activity. c) Devalerylase activity
of transfected Hek293 cells; data normalized to pcDNA3.1+ vector transfected cells. Data collected after 24 hours of
treatment. n = 3; error bars are S.E.M. * = p-value < 0.01. ** = p-value < 0.0001. All statistical analyses were Dunnett’s
multiple comparisons of means to the means of their respective controls.

62

acetyl-, formyl-, and valeryl-lysine PTMs and measured the effect of small molecule inhibition
and siRNA knockdown of individual HDAC isozymes on these levels. In agreeance with previous
results, the pan-HDAC inhibitor vorinostat induced hyper-acetylation of tubulin and histones H3
and H4. Also in line with published research, we see that entinostat162 and PD106 induced hyperacetylation of histones without affecting tubulin acetylation levels. The HDAC6 specific inhibitor
Tubastatin A, conversely, only affected acetylated tubulin levels (Figure 3.6a).
Translating from our previous findings, we see that the pan-HDAC inhibitor vorinostat causes
global protein hyper-formylation due to its concomitant inhibition of HDACs 3 and 6, however its
increase was not statistically significant with a p-value of 0.072. Entinostat and PD-106 are also
capable of this effect, although their mechanism is likely to be through HDAC3 inhibition, without
inhibition of HDAC6 at the concentrations used. Lastly, the HDAC6-specific inhibitor Tubastatin A
also induced global protein hyper-formylation through its inhibition of HDAC6 (Figure 3.6b). The
combination of PD-106 and Tubastatin A led to a non-significant decrease compared to either
agent alone.
Following these experiments, we utilized siRNA knockdowns of HDACs 3 and 6 to determine
the effect of each isozyme more specifically. Knockdown of HDAC3 alone led to a significant rise
in global protein formylation levels. Compared to HDAC3, knockdown of HDAC6 led to an even
greater, arguably significant, increase in global formylation with a p-value of 0.049. The
concomitant knockdown of HDACs 3 and 6 together had no significant effect compared to HDAC6
alone, further suggesting HDAC6’s dominant role as a deformylase (Figure 3.6c).
Moving our attention toward global protein valerylation, we repeated these experiments
using antibodies specific for valerylated lysine. Inhibition of HDAC3 with vorinostat, entinostat,
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Figure 3.6. Roles of HDACs 3 and 6 on global cellular formylation and valerylation.

HH3

a) left: Western blot analysis of Hek293 cells treated with small molecule HDAC inhibitors. right: Quantification of
histone and tubulin acetylation normalized to HH3 levels. b) left: Global formylation levels of Hek293 cells treated
with HDAC inhibitors. right: Quantification of global formylation normalized to HH3 levels. c) left: Global formylation
levels of Hek293 cells treated with siRNA. right: Quantification of global formylation normalized to HH3 levels. d)
left: Global valerylation levels of Hek293 cells treated with HDAC inhibitors. right: Quantification of global
valerylation normalized to HH3 levels. e) left: Global valerylation levels of Hek293 cells treated with siRNA. right:
Quantification of global valerylation normalized to HH3 levels. All inhibitors used at 1 µM, except tubA at 0.5 µM.
Data recorded after 24 hours of treatment, representative western blots of n ≥ 3 experiments; error bars are S.E.M.
* = p-value < 0.01. ** = p-value < 0.0001. All statistical analyses were Dunnett’s multiple comparisons of means to
the means of their respective controls.
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or PD-106 led to global protein hyper-valerylation, however the increase for PD-106 was nonsignificant with a p-value of 0.120. We also see that selective inhibition of HDAC6 with Tubastatin
A leads to a non-significant hypo-valerylation (p-value 0.073). Further, combined HDAC3 and
HDAC6 inhibition with PD-106+Tubastatin A leads to an even more pronounced, significant hypovalerylation effect (Figure 3.6d). One explanation for this discrepancy was off-target effects of
either Tubastatin A or PD-106. We used siRNA to study this, hypothesizing that specific
knockdown of either isozyme would more readily determine each isozyme’s effect on
valerylation levels. Knockdown of HDAC3 led to the expected result of hyper-valerylation,
however, knockdown of HDAC6 alone led to a hyper-valerylation as well. Even more interesting
still is the hypo-valerylation that occurs when both HDACs 3 and 6 are knocked down together
(Figure 3.6e). One possible explanation for this discrepancy could lie with the translatability of
our valeryl-based substrate in vitro and in cellular lysate models versus the natural substrate.
Another explanation is that knockdown of HDAC6 may lead to a dissolution of a key complex
required for maintenance of lysine acylation levels.163 Lastly, another possibility may be a nonselective antibody. To assuage this possibility we performed dot blot analyses with each antibody
against formylated-, acetylated-, or valerylated-bovine serum albumin. The results demonstrate,
and in findings with the manufacturer’s ELISA specifications, that each antibody is highly selective
for its appropriate acyl-group (Figure 3.7).

Substrate driven development of HDAC3 specific inhibitor. We realized that the crotonylsubstrate possessed very unique properties with HDAC3, but not HDACs 1, 2, or 6. Its nanomolar
Km value led to HDAC3 binding very tightly to the substrate, however, very little substrate
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turnover (kcat) was seen. Further, the crotonyl-substrate’s binding affinity was over 20-fold
selective for HDAC3 compared to HDACs 1 or 2 (Table 3.1). Taken together, we hypothesized that
the crotonyl-substrate could act as a competitive inhibitor against the canonical acetyl substrate.
Further, we wondered if this specificity in Km translated to specificity in inhibition. Our data show
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Figure 3.7. Antibody cross reactivity comparison with acylated Bovine Serum Albumin.

Formyl Ab
Acetyl Ab
Valeryl Ab
Solutions (10 mg/mL) of acylated BSA were dotted onto nitrocellulose (0.5 µL) and incubated with various antibodies.
There is little appreciable cross-reactivity between all used antibodies indicating a high level of specificity toward
advertised target. Representative blot, n = 2.

that indeed the crotonyl-substrate is a notably selective HDAC3 inhibitor (Figure 3.8a).
Encouraged with this result, and recognizing the potential of developing a novel, selective
chemical tool to study the HDAC3 isozyme selectively10, 164, we performed a rudimentary SAR
analysis based around the trans-geometry of the crotonyl acyl-group, the length of the HDAC3
selective valeryl acyl-group, and the HDAC 1, 2, 3 selective benzamide metal-chelation moiety
(Table 3.2).
We began simplistically with a benzamide structure with an attachment to mimic the
crotonyl- and valeryl-modifications simultaneously, compound 1. We gained potency by utilizing
a trans-cyclopentadiene ring which further forced proper conformation. Between all
heterocycles tried, the oxygen containing furan ring of 1a seemed most promising from its
potency and mild selectivity toward HDAC3. Building off of 1a, addition of a fused benzene ring
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led to compound 1f which demonstrated nanomolar HDAC1 and HDAC3 IC50 values with its
benzofuran group. While 1f was our best lead from the first round of SAR, it lacked the selectivity
we believed possible for HDAC3, only demonstrating a 2 fold preference for HDAC3 over HDAC1.
Looking back at our initial acyl-substrate screen, we also noted HDAC3’s ability to deacylate the
TFA-substrate which HDACs 1 and 2 lacked. Additionally, a recent publication also reported on
fluorination based HDAC3 selectivity.165 As such, we utilized these findings by incorporation of a
fluorine to 1f which resulted in compound 2. This inhibitor possessed 15 fold selectivity for
HDAC3 compared to HDAC1 (Figure 3.8b) while also increasing its inhibitory potency further
toward HDAC3. We added a second fluorine to 2 to generate 2a which resulted in a slightly
weaker HDAC3 inhibitor, but established even greater selectivity of the molecule for HDAC3
(Figure 3.8c). Curious to test the effect of fluorination in other positions around the benzene ring,
we also developed and interrogated 2b and 2c. These inhibitors, possessing different fluorine
positioning than 2a show very little efficacy in vitro (Figures 3.8d and 3.8e). Concluding our
substrate driven SAR, compound 2a possessed an IC50 for HDAC3 of 170 nM and was over 30 fold
selective for HDAC3 compared to other class I HDACs. Further testing of 2a revealed it possessed
interestingly selective slow-binding toward HDAC3 but not HDACs 1 or 2 (Figure 3.9).

Effects of 2a on NF-κB acetylation, NO signaling, and HMGB-1 secretion. A previous study has
shown that cytosolic localization of HDAC3 depends on its interaction with IκBα within an intact
NF-κB complex, thereby suggesting that it plays a potential role in the NF-κB signaling.166 Using
2a, 2b, 2c and other known HDAC inhibitors with different HDAC isozyme selectivity, we
examined these HDAC inhibitors’ relative effects on acetylation of NF-κB p65, p53, histones H3
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Figure 3.8. Substrate-specificity driven development of HDAC3 selective inhibitor.
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Table 3.2. SAR of substrate-driven HDAC3 specific inhibitors.

Name

R-Group

HDAC1 IC50

HDAC3 IC50

1

16.7 µM

4.00 µM

1a

3.20 µM

0.721 µM

1b

5.31 µM

1.43 µM

1c

6.92 µM

1.80 µM

1d

2.12 µM

0.418 µM

1e

4.11 µM

1.37 µM

1f

0.357 µM

0.209 µM

and H4, and tubulin. The selective HDAC3 inhibitor 2a induced NF-κB p65 Lys122 and p53 Lys382
acetylation without the induction of histone H3/H4 or tubulin acetylation (Figure 3.10a). This
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result is consistent with previous studies that demonstrated that deacetylation of Lys122/123 of
NF-κB p65 is controlled by HDAC3, and that inhibition of HDACs 1 or 2 has little effect on their
acetylation status.42 However, our finding that selective HDAC3 inhibition with a small molecule
is capable of inducing hyperacetylation of p53 Lys382 is novel. Ryu et al. recently demonstrated
that HDAC6 is also capable of controlling the acetylation status of Lys382 of p53.28 Unfortunately,
they did not have an HDAC inhibitor capable of targeting HDAC3 without HDAC6 to delineate out
the impact of HDAC3 inhibition vs HDAC6 inhibition on this residues acetylation status. Further,
they demonstrated the use of tubA at 2 µM for 24 hours was able to induce hyperacetylation of
Lys382 in their tested HCT116 and HT29 cells. Our findings do not demonstrate this increase
(Figure 6a), but could be a result of a cell-line specific effect or our use of a lower dose
comparatively. Further, and against the findings by Ryu et al., the class I selective inhibitor,
romidepsin, was shown to induce hyperacetylation of Lys373 and Lys382 at reasonable
concentrations in the A549 cell line.167
We furthered our investigation on the significance of HDAC3 inhibition and its effects on NFκB activation, nitric oxide (NO) production, and HMGB-1 secretion in RAW264.7 macrophages
challenged with bacterial lipopolysaccharide (LPS). 2a decreases NO production after LPS
induction in RAW264.7 while all other inhibitors, including 2b and 2c, failed to affect NO
production (Figure 3.10b). It should be noted that PD-106, vorinostat, and entinostat, being
HDAC3 inhibitors, did lower Nitric Oxide release. However, when cell viability was taken into
account, as these inhibitors proved to be more lethal than 2a-c, it was found this decrease was
completely offset when we normalized the data to cell count/viability. LPS also induces HMGB-1
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Figure 3.9. Time dependent Kinetics of HDACs 1-3 vs 2a.
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Figure 3.10. Effects of HDAC inhibition on NF-κB p65 acetylation and inflammatory responses.
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a) Western blot analysis of RAW264.7 cells treated with various HDAC inhibitors; vorinostat and PD-106 used at 1
µM, tubA at 0.5 µM. b) NO concentration secreted from RAW264.7 treated cells; normalized to control treated
viable cell concentration. 1 µM used for all inhibitors. n ≥ 3. c) Western blot analysis of RAW264.7 cells. HMGB-1
secretion monitoring with ponceau stain as loading control. Cells were treated for six hours. 1 µM vorinostat and
0.5 µM tubA used. d-f) Western blot analysis of LPS-treated RAW264.7 cells. Nuclear and cytosolic fractions split. 2a
and vorinostat used to assess regulation of HDACs on Ac-p65 subcellular localization. Representative westerns of n
≥ 2 experiments; error bars are S.E.M. ** = p-value < 0.0001.
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secretion, a late mediator of lethality in sepsis, in RAW264.7 cells.168-169 Previous studies have
shown that the HMGB-1 protein contains multiple acetylation and formylation modifications,
which control its cellular localization and secretion.145, 170 2a, but not 2b or 2c, also blocked
HMGB-1 secretion from the activated macrophage cells (Figure 3.10c and Figure 3.11). These
data suggest that HDAC3 activity is required for proper inflammatory activation and response.
As HDAC3 activity is linked to IκBα and NF-κB activation, we further investigated the effect of
2a on NF-κB p65 and HDAC3 after LPS induction. As previously reported, LPS induced the nuclear
localization of p65 and HDAC3.166 Cells treated with 2a had significantly shorter p65 nuclear
retention times as well as diminished nuclear localization of HDAC3 (Figure 3.10d). Interestingly,
in the 2a-treated cells, the nuclear localization of HDAC3 decreased slowly with time after LPS
treatment (Figure 3.10e). This effect was not as pronounced in the vorinostat treated cells (Figure
3.10f). This suggests that HDAC3 activity is likely involved in multiple regulatory functions, such
as its own cellular localization, in addition to p65 acetylation status and gene transcription
regulation. Further, selective inhibition of HDAC3, but not pan HDAC inhibition as seen with
vorinostat,
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Figure 3.11. Western blot analysis of RAW264.7 cells.
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Ponc
LPS
HMGB-1 secretion monitoring with ponceau stain as loading control. Cells were treated for six hours. 1 µM
vorinostat used. Representative blot of n = 2 experiments.

73

3.2. Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase
Inhibitors for Use in Acute Myeloid Leukemia.
The goal of our structure-activity relationship studies for the hydrazide-based compounds
was to develop a potent and selective inhibitor of class I HDACs, with particular emphasis on
HDAC3 inhibition. HDAC3 has shown increasing promise as a novel target to combat leukemia as
its inhibition controls hematopoiesis. As such, lead analogs from these studies were tested in preclinical leukemia models to determine efficacy and tested against solid tumor models and PBMCs
to demonstrate selectivity.

Chemistry of butylhydrazide analogs. We began our structure-activity relationship studies by
attempting to identify an ideal substituent for the carbonyl of the hydrazide motif. As shown in
Scheme 3.1, we began with either an aromatic carboxylic acid, acyl chloride, or ester. Using
commercially available starting materials, we generated the corresponding hydrazide molecule
through reactions a, b, and c, depending on the composition of the starting molecule. Target
hydrazide compounds were reacted with butylaldehyde to generate the compound of interest.
Carboxylic acids were reacted with oxalyl chloride in methylene chloride with catalytic amounts
of dimethylformamide (Scheme 3.1, reaction a). The resulting acyl chloride, or commercially
purchased acyl chlorides were stirred in methanol to give the corresponding methyl ester
(Scheme 3.1, reaction b). The generated or commercially purchased methyl esters were refluxed
in methanol with a hydrazine water salt to generate a hydrazide of interest (Scheme 3.1, reaction
c). The resulting compounds were then refluxed in ethanol in the presence of magnesium sulfate
and butylaldehyde followed by a reduction with sodium cyanoborohydride in acidified methanol
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to give the desired products 11a-11l (Scheme 3.1, reactions d and e). A notable exception to this
scheme was the synthesis of 11d, which was unable to be esterified from the commercially
available corresponding acyl chloride until the addition of two equivalents of triethylamine.
Additionally, compound 11i spontaneously formed the corresponding pyrazolidinone when
reacted with the hydrazine salt due to the presence of an unsaturated bond alpha to the ester
carbonyl. Instead, the carboxylic acid starting material was reacted with HOBt and DCC in
acetonitrile. The resulting intermediate was reacted with the hydrazine water salt in acetonitrile
to yield the corresponding hydrazide. Lastly, compound 11l was the result of reacting methyl 4(aminomethyl)benzoate with benzoyl chloride to generate the methyl ester corresponding to 11l.
From here, the reaction carried on as shown in Scheme 3.1, reactions d and e.
Scheme 3.1. Butylhydrazide Derivatives Synthesis

Reagents and conditions: (a) methylene chloride, rt, oxalyl chloride, cat. DMF; (b) MeOH, rt; (c) MeOH, reflux,
NH2NH2·H2O; (d) EtOH, reflux, butaldehyde, MgSO4; (e) MeOH, rt, NaBH3CN, conc. HCl

HDAC inhibition of series 11 inhibitors. With the primary goal of designing a potent and ideally
selective series inhibitor of class I HDAC inhibitors, we screened compounds 11a-11l against
HEK293 cell lysates using a fluorogenic acetylated lysine substrate. All compounds were tested
thrice against HEK293 lysate and recombinant HDAC3. If the compound was found to possess an
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IC50 less than 100 nM against HDAC3 and less than 1000 nM against HEK293 lysate, it was tested
thrice against recombinant HDACs 1 and 2 to determine selectivity for class I. The summation of
the corresponding findings are summarized in Table 3.3, with data for HDACs 1 and 2 in Table
3.4.
The relatively inefficacious compounds 11b, 11d, 11f, and 11g demonstrated that
heterocyclic substitution was not favored compared to phenyl groups. Further, a para position
oxygen provided mild benefit as seen in compounds 101 and 11c. However, a carbon, whether
aliphatic or aromatic, was superior in this position, as seen in 11e and 11l. Interestingly, the
creation of an unsaturated bond at the alpha position to the carbonyl, as seen in compound 11i,
provided ~6-fold increased HDAC3 inhibition when compared to its saturated counterpart 11h.
This can be explained as it creates an acrylamide-like structure which is likely capable of forming
covalent bonds with cysteine residues on the HDAC enzyme; allowing for enhanced inhibition
ability. While neither compound was particularly potent, it was interesting to see the sharp
difference in activity between 11j and 11k. This possibly demonstrates that the binding pocket
near this position is relatively narrow and the wider surface area of the 1-naphthyl group of 11j
is unable to bind adequately, whereas the 2-naphthyl group of 11k is able to fit more reasonably
or is less sterically hindered. The compound 11l possessed the most potent carbonyl attachment,
with an IC50 of less than 10 nM and Ki of less than 2 nM for HDAC3 and 8- to 10-fold selectivity
for HDAC3 compared to HDACs 1 and 2. Using this finding, we next pursued structure activity
relationships on substitutions of the β-nitrogen relative to the hydrazide.
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Table 3.3. In vitro inhibition of Hek293 lysates and recombinant HDAC3 for series 11 inhibitors.
O
R

Name

11a

R Group

O

11b

O

11c

11d

O

N

11e

11f

S

N
H

IC50a (nM)

H
N

Name

HDAC3

Hek293

156.7 ±
28.55

727.3 ±
10.75

11g

1362 ±
197.3

1688 ±
38.05

311.7 ±
42.82

R Group

IC50a (nM)
HDAC3

Hek293

5001 ±
372.5

>10000

11h

1892 ±
227.3

>10000

1691 ±
298.3

11i

294.5 ±
32.64

1440 ±
86.09

1547 ±
429.8

4676 ±
909.0

11j

>10000

>10000

68.85 ±
9.39

1307 ±
210.0

11k

892.0 ±
72.47

2844 ±
948.0

903.9 ±
154.3

3461 ±
669.0

8.56 ±
2.06

292.6 ±
8.68

11l

O

H
N
O

IC50 values (bold) are the mean of at least three experiments. Values after are the Standard Error of the Mean.
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Table 3-4. Class I HDAC and Hek293 lysate IC50 values for 11l.
O
R

Name

N
H

H
N

IC50a (nM)

R Group

11l

H
N

HDAC1

HDAC2

HDAC3

Hek293

18.87 ±
2.74

65.19 ±
10.41

8.56 ±
2.06

260.6 ±
8.68

O

IC50 values (bold) are the mean of at least three experiments. Values after are the Standard Error of the Mean.

Chemistry of N-(4-(hydrazide)benzyl)benzamide analogs. We began our second refinement
synthetic scheme by generating the N-(4-(hydrazinecarbonyl)benzyl)benzamide which would be
used in all subsequent reactions for this group. This was achieved as shown in Scheme 3.2,
reactions a-c. Briefly, the starting material, 4-(aminomethyl)benzoic acid, was refluxed in
methanol and concentrated acid to generate the much more soluble corresponding methyl ester
hydrochloride salt (Scheme 3.2, reaction a). This intermediate was reacted with benzoyl chloride
in ethyl acetate and water in the presence of potassium carbonate to form an amide bond and
afford 4-(benzamidomethyl)benzoate (Scheme 3.2, reaction b). This was in turn refluxed with the
hydrazine water salt in methanol to generate the desired intermediate (Scheme 3.2, reaction c).
Lastly, this intermediate was N-methylated using various aldehydes in ethanol and magnesium
sulfate followed by reduction using sodium cyanoborohydride in acidified methanol to yield the
desired products, 12a-12m (Scheme 3.2, reactions d and e).
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HDAC inhibition of series 12 inhibitors. We screened compounds 12a-12m thrice against Hek293
lysates and recombinant human HDAC3; the resulting data is summarized in Table 3.5.
Compounds demonstrating an IC50 less than 100 nM against HDAC3 and less than 1000 nM
against Hek293 lysates were then tested thrice against recombinant HDACs 1 and 2 to determine
selectivity profiles. Data from HDACs 1 and 2 can be found in Table 3.6. Generally, branched alkyl
substitution, as seen in 12b, provided inferior inhibition compared to non-branched analogs such
as 12d. There was an overall decrease in inhibition as the chain length increased past six carbons
seen with compounds 12h, 12i, and 12k. Cyclic additions at the end of alkyl chains, such as those
seen in 12g and 12m, provided negligible effects. Lastly, the addition of a trifluoro group for
compound 12f provided worse HDAC3 inhibition compared to the non-fluorinated 12d. Overall,
very little potency was gained from this refinement series, seeing the slight benefit of an Nsubstituted propyl chain of 12d compared to the corresponding butyl chain of 11l which dropped
the IC50 to less than 5 nM and lowered the Ki to the sub-nanomolar range for HDAC3.
Scheme 3-2. N-(4-(hydrazide)benzyl)benzamide Derivatives Synthesis

Reagents and conditions: (a) MeOH, reflux, conc. HCl; (b) AcOEt:H2O (1:1), rt, K2CO3; (c) MeOH, reflux, NH2NH2·H2O;
(d) EtOH, rt, aldehyde of interest, MgSO4; (e) MeOH, NaBH3CN, conc. HCl
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Table 3.5. In vitro inhibition of Hek293 lysates and recombinant HDAC3 for series 12 inhibitors.
O
N
H

H
N

H
N

R

O

Name

R Group

IC50a (nM)

Name

HDAC3

HEK293

12a

1533 ±
227.5

>10,000

12b

>10,000

12c

IC50a (nM)

R Group

HDAC3

HEK293

12h

568.7 ±
84.9

2161 ±
895.5

>10,000

12i

1093 ±
334.4

>10,000

>10,000

>10,000

12j

184.1 ±
74.54

550.2 ±
133.9

12d

3.47 ±
0.48

155.3 ±
27.64

12k

>10,000

>10,000

12e

18.74 ±
4.3

263.6 ±
28.52

12l

187.3 ±
0.6

427.1 ±
110.5

69.10 ±
0.52

1229 ±
136.5

12m

84.44 ±
7.22

1883 ±
212.4

39.93 ±
0.25

1621 ±
196

F

12f
F

12g

F

IC50 values (bold) are the mean of at least three experiments ± the Standard Error of the Mean.
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Table 3.6. Class I HDAC and Hek293 lysate IC50s for series 12 inhibitors
O
N
H

H
N

H
N

R

O

Name

IC50a (nM)

R Group
HDAC1

HDAC2

HDAC3

Hek293

12d

13.16 ±
2.01

77.59 ±
9.52

3.47 ±
0.48

155.3 ±
27.64

12e

20.20 ±
5.04

43.65 ±
33.16

18.74 ±
4.3

263.6 ±
28.52

IC50 values (bold) are the mean of at least three experiments ± the Standard Error of the Mean.

Chemistry N-(4-(hydrazide)benzyl)cinnamamide analogs. With the information from our second
structure-activity relationship study providing insight that a non-branched propyl chain
substitution on the β-nitrogen of the hydrazide seemingly is ideal, we moved forward by further
modifying the carbonyl substituent. We noticed an increase in the use of N-hydroxylated
acrylamide groups for HDAC inhibitors, present even in panobinostat and belinostat, as well as a
multitude of pre-clinical inhibitors. This motif is a known Michael acceptor and likely forms
covalent bonds with the sulfhydryl group of cysteines on proteins in vivo. Curious to see the effect
on efficacy of incorporating an α, β unsaturated ketone, a similar Michael acceptor, we developed
a cinnamamide derivative to build off of. This was achieved by again refluxing 4(aminomethyl)benzoic acid in acidified methanol (Scheme 3.3, reaction a). Cinnamoyl chloride
was formed using cinnamic acid and performing an acyl chlorination using oxalyl chloride in
methylene chloride with catalytic amounts of dimethylformamide (Scheme 3.3, reaction b). The
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product of this reaction was mixed with the benzoate from reaction a in a 1:1 (v/v) mixture of
ethyl acetate and water with potassium carbonate to form the corresponding amide bond
(Scheme 3.3, reaction c). Here, we reacted this compound with lithium hydroxide in a solution of
methanol, water, and tetrahydrofuran (2:1:2 v/v) to generate the corresponding carboxylic acid
(Scheme 3.3, reaction d). While it was never attempted, reactions c and d may theoretically be
combined using lithium hydroxide in place of potassium carbonate in reaction c to cleave the
methyl ester while also simultaneously forming the amide bond. With the carboxylic acid
generated, we performed an amine coupling with HOBt and DCC in dimethylformamide (Scheme
3.3, reaction e). This intermediate was then reacted with a hydrazine water salt at 0°C. Finally,
the hydrazide was reacted with the aldehyde of interest in ethanol with addition of magnesium
sulfate and subsequently reduced using sodium cyanoborohydride in acidified methanol to yield
compounds 13a-13e (Scheme 3.3, reactions f and g).

HDAC inhibition of series 13 inhibitors. We ended our in vitro screening by interrogating the IC50
values of 13a-13e against Hek293 lysates and recombinant human HDACs 1, 2, and 3. The results
from these studies are listed in Table 3.7. The most striking change when comparing this
cinnamamide derivative to the benzamide derivatives are their potencies. All compounds tested
display less than 40 nM IC50 values against HDAC3 with the exception of the hexyl chain
containing 13e. The lead candidate from this study was the propyl chain containing 13b,
possessing a sub-nanomolar IC50 and Ki against HDAC3 with 10- and 100-fold selectivity toward
HDACs 1 and 2, respectively. The butyl chain derivative, 13c, that mimicked the substituent of
the very potent 11l provided single-digit nanomolar potency against HDAC3, yet was
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approximately 3-5 fold weaker when compared to 13b. These findings suggest that a β-nitrogen
alkyl substituent chain length of 3-4 carbons provides ideal conditions, with the ethyl, pentyl, and
hexyl groups of 13a, 13d, and 13e, respectively, having diminished inhibitory prowess when
compared to 13b or 13c.

Scheme 3-3. N-(4-(hydrazide)benzyl)cinnamamide Derivatives Synthesis

Reagents and conditions: (a) MeOH, reflux, conc. HCl; (b) DCM, rt, Oxalyl Chloride, cat. DMF; (c) EtOAc:H2O (1:1), rt,
K2CO3; (d) MeOH:H2O:THF (2:1:2), rt, LiOH; (e) DMF, rt, HOBt, DCC; (f) DMF, 0°C, NH2NH2·H2O; (g) EtOH, rt, aldehyde
of interest, MgSO4; (h) MeOH, rt, NaBH3CN, conc. HCl

Mass spectrometric analysis of select hydrazide-based inhibitors in glucuronidating
environments. To demonstrate that these compounds were indeed highly unlikely to be
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Table 3.7. In vitro inhibition of recombinant HDACs 1, 2, and 3 and HEK293 Lysate for series 13
inhibitors
O
N
H

H
N

H
N

R

O

Name

IC50a (nM)

R Group
HDAC1

HDAC2

HDAC3

HEK293

13a

29.49 ±
10.71

76.57 ±
9.74

19.71 ±
1.41

171.1 ±
34.23

13b

11.81 ±
4.16

95.45 ±
34.15

0.95 ±
0.19

124.4 ±
14.02

13c

60.17 ±
20.97

70.03 ±
26.38

3.67 ±
2.86

494.3 ±
209.6

13d

47.36 ±
16.79

99.56 ±
17.44

32.55 ±
1.15

690.7 ±
54.67

81.36 ±
11.96

139.2 ±
29.9

149.8 ±
81.63

1718 ±
139.1

13e

IC50 values (bold) are the mean of at least three experiments ± the Standard Error of the Mean.
glucuronidated in vivo, we adapted and performed an ex vivo assay using a protocol derived from
Walsky and colleagues.171 Briefly, vorinostat, 11l, 12d, and 13b were incubated with human liver
microsomes, UDP Glucuronic acid, and alamethicin (a pore-forming antibiotic) for 12 hours at
37°C. The reaction was quenched with a 47:50:3 (v/v/v) mixture of water:acetonitrile:formic acid.
The vessel was subjected to centrifugation and the supernatant filtered and examined via
electrospray ionization liquid chromatography mass spectrometry. A parallel study that lacked
UDP Glucuronic acid was performed with each inhibitor as a negative control. Comparing Figure
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Figure 3.12. ESI-LCMS glucuronidation assay.

ESI-LCMS TIC spectra of vorinostat incubated with human liver microsomes without UDPGA (blue, A) and with
UDPGA (red, B). Both spectra contain parent compound (m/z = 265), a hydrolyzed metabolite (m/z = 250), only the
UDPGA addition vessel contained the glucuronidated metabolite (m/z = 441). ESI-LCMS TIC spectra of 12d human
liver microsomes without UDPGA (blue, C) and with UDPGA (red, D). Neither vessel contained any detectable
metabolites other than parent compound. Representative spectra and mass analyses of n ≥ 3 repeats.
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3.12A (blue) and Figure 3.12B (red) demonstrates the presence of the o-glucuronidated
metabolite of vorinostat with a (m+H+)/z of 441.04 (Figure 3.12B, bottom right), in line with
previous findings.172 This mass shift was not present in the corresponding negative control lacking
UDP Glucuronic acid (Figure 3.12B, middle right). There are no differences between masses or
ionization patterns in any of the hydrazide-containing compounds (Figures 3.12 C-D, Figure 3.13),
suggesting these compounds are not readily glucuronidated in environments where vorinostat is
extensively glucuronidated. It was also noted that 13b, possessing an unsaturated bond, was
reduced in this model, despite no NADPH being added to the reaction vessel (Figures 3.13 C-D).
This may demonstrate a potential metabolite of this compound.

Interrogation of in vitro binding kinetics of hydrazide-containing HDAC inhibitors. Generally
speaking, the very reason why groups like ortho-aminoanilide or hydroxamates are able to
chelate zinc and other dicationic metals is the same reason why they are prime glucuronidation
targets. Their possession of primary alcohols and primary amines not only allow them to ionically
complex with the positively charged zinc, but also allows them to be extensively inactivated via
glucuronidation. After demonstrating that the hydrazide motif was not glucuronidated in ex vivo
environments, we questioned whether it was inhibiting HDACs through a direct active zinc
chelation. We hypothesized that the compound should demonstrate typical Michaelis-Menten
competitive inhibition, similar to vorinostat, if it was truly chelating zinc in the active site of
HDACs. Thus, we performed in vitro Vmax studies using recombinant HDACs 1 and 3 and
compounds 12d and 13b. Applying a double reciprocal conversion of the data yielded
Lineweaver-Burke plots. Surprisingly, and contrary to previous data, our hydrazide-containing
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Figure 3-13. ESI-LCMS glucuronidation assay of 11l and 13b

A and B) TIC of inhibitor 11l without (blue) and with (red) addition of UDPGA. One peak at 10.2 minutes with mass
analysis demonstrating m/z = 326, indicative of parent compound. No additional metabolites found. C and D) TIC of
inhibitor 13b without (blue) and with (red) addition of UDPGA, several peaks spanning 10.1-10.5 minutes. The first
peak is the reduced metabolite, lacking the double bond the parent compound possesses, m/z = 340. The second,
more prominent peak is the parent compound, m/z = 338. Figures are representative of n ≥ 3 experiments.

compounds clearly demonstrate a convergence in the 2nd quadrant, indicative of mixed inhibition
(Figures 3.14 A-B) and non-competitive inhibition (Figures 3.14 C-D). This is in direct contrast to
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the initial findings published by Wang and colleagues.141 Their published data seem to match a
canonical competitive inhibitor, with their corresponding Lineweaver-Burke plots demonstrating
all doses and control intersecting directly on the y-axis, representative of 1/Vmax. However, the
corresponding Vmax plots from which these graphs were derived display changes in Vmax. This
would mean the y-intercepts on the double reciprocal Lineweaver-Burke plots should be
different as well. To further ensure our findings were valid, we used vorinostat as a positive
control, a known competitive inhibitor with extensive kinetic analyses published
independently.173 Matching established data, our results demonstrated complete convergence
directly on the y-axis, indicative of competitive inhibition (Figures 3.14 E-F), which is in direct
agreement with the very similar Vmax values seen at each dose. This finding, coupled with the
lack of glucuronidation ex vivo, points to an allosteric binding site on class I HDACs that is strongly
inhibited by our hydrazide-containing inhibitors, and has little to do with catalytic site zinc
chelation. The Vmax plots from which these Lineweaver-Burke plots were derived may be seen in
Figures 3.15 A-F.
HDAC3 molecular docking study of HDAC inhibitors. With the results thus far suggesting an
allosteric binding site, we were curious if we could identify a potential site at which our inhibitors
were binding. Using the solution structure of HDAC3 bound to Ncor2, pdb: 4A69, we probed the
HDAC3 surface with 13b resulting in a heavy concentration of poses near the interface with the
Ncor2 coenzyme (Figure 3.16). We then calculated the propensity for ligand interaction which
revealed a very positive binding region directly overlapping with the high density 13b binding
area (Figure 3.16). Using this pocket, we performed a flexible induced fit binding of 12d, 13b, and
vorinostat and calculated binding scores from the top 20 (lowest energy) poses from each set.
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Figure 3.14. Lineweaver-Burke plots of 12d, 13b, and vorinostat vs. recombinant HDACs 1 and 3

Y-axes units (pmoles acetylated substrate cleaved/min)-1. X-axes units (µmoles)-1. A and B) 12d and HDACs 1 and 3
respectively. Intersection in 2nd quadrant indicative of mixed inhibition. C and D) 13b and HDACs 1 and 3 respectively.
Intersection on x-axis and in 2nd quadrant indicative of mixed and non-competitive inhibition. E and F) vorinostat
and HDACs 1 and 3. Intersection directly on y-axis indicative of competitive inhibition. Representative plots of n ≥ 3
experiments.
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Figure 3-15. Vmax plots of 12d, 13b, and vorinostat vs. recombinant HDACs 1 and 3

A and B) Vmax plots of 12d vs HDACs 1 and 3 respectively. A notable decrease in Km and Vmax is seen as the
concentration of inhibitor increases. C and D) Vmax plots of 13b vs HDACs 1 and 3 respectively. A more noticeable
drop in Vmax can been seen, as well as a negligible shift in Km. This is indicative of the more non-competitive binding
seen with 13b compared to 12d. E and F) Vmax plots of vorinostat vs HDACs 1 and 3. No differences in Vmax are
perceived, all plots reach the same Vmax, however, a notable shift in Km occurs, indicative of class competitive
inhibition. Representative figures of n ≥ 3 experiments.

Our lead inhibitors 12d and 13b display nearly identical binding scores, which is line with their
near identical in vitro activity and electrospatial occupancies. The canonical binder vorinostat
bound less tightly to this pocket, as evidenced by its higher energy posing scores (Figure 3.16).
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Figure 3.16. Molecular modeling and binding study of HDAC3

A) Rigid target probe of 13b against HDAC3. PDB file 4A69 used. HDAC3 shown in orange, Ncor2 coenzyme shown
in purple. Poses of 13b shown in carbon grey. An area of high pose density was seen near the 1 o’clock position of
this image. B) Propensity for ligand interaction function (PLIF). The light grey and red alpha spheres represent three
dimensional occupancy of the pocket found. Amino acids in cyan blue represent key interacting residues. Both the
13b site find study and the PLIF study overlap here, with significant interaction with M78. C) Binding scores for top
20 poses of 13b, 12d, and vorinostat (lower is better). 13b and 12d both demonstrate very similar, superior scores
compared to vorinostat, representing a lower binding energy.

Lastly, when we posed the lowest energy poses for 2d and 3b, we see significant overlap in
electrospatial occupancy, indicative of homologous modes of binding (Figure 3.17A), whereas
the lowest pose for vorinostat results in a completely different orientation, with the hydroxamic
acid exposed to solvent and its phenyl group serving as the main area of interaction (Figure
3.17B). Additionally, a narrow tunnel can be seen where the propyl hydrazide of both 12d and
13b fit nicely. This matches the in vitro and ex vivo data demonstrating that adding branching
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Figure 3.17. Molecular modeling of 12d, 13b, and vorinostat against HDAC3

A) HDAC3 molecular docking. PDB: 4A69 used. HDAC3 is seen in orange, Ncor2 seen in purple. Lowest binding energy
poses for 12d (green) and 13b (carbon grey). Significant electrospatial overlap between these two poses indicative
of a key pose the propyl hydrazide group is capable of conforming to. B) Lowest binding energy pose for vorinostat
(carbon grey). Conformation has its hydroxamic acid interacting with solvent, away from a pocket, with its phenyl
group interacting with hydrophobic amino acids. This pose, and all other poses seen, possess much weaker binding
interaction than lead analogs 12d and 13b.
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alkyl chains, or extending the alkyl chains past a length of four carbons leads to markedly
diminished inhibition activity. Taken together, these findings illustrate the potential for a novel,
allosteric binding site that the propyl hydrazide motif is particularly astute at fitting into. Further,
the inhibitors in this dock are nearly 20 angstroms away from the opening of the zinc-containing
binding pocket, as such it be expected that these inhibitors are not directly impacting the ability
of substrate to enter nor be cleaved by the HDAC isozyme.

Efficacy of lead analog in ex vivo cell models. Satisfied with results of our three structure activity
studies and the potential for allosteric inhibitors that are impervious to glucuronidation, we
transitioned from recombinant enzyme pre-screening to cellular treatment. Given that HDAC
inhibitors are most successful in hematologic malignancies such as lymphomas and myelomas,
as shown by their FDA approvals, we screened our most potent inhibitor, 13b, against an array
of leukemia and Multiple Myeloma cell lines. Briefly, MOLM-14, an acute monocytic leukemia
cell line174; HL-60, an acute promyelocitic cell line175; RS4-11, an acute lymphoblastic leukemia176;
K562, a chronic myelogenous leukemia177; MV4-11, an acute myeloid leukemia178; and RPMI8226, a Multiple Myeloma cell line179, were all used to determine the efficacy of 13b against a
multitude of different hematologic cancers. Cells were treated for 48 hours before viability was
assessed with CellTiter-Blue Cell Viability Assay. The active fluorescent reagent in this assay is
resazurin. This molecule is converted by the functional mitochondria in the viable cells to
resorufin. Resorufin intensity is therefore directly related to cell viability. The resulting EC50
values from each cell line is summarized in Table 3.8.
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13b demonstrates the highest level of potency against the AML cell line MV4-11, possessing
an EC50 for the cells at less than 50 nM. Taken together with the efficacy toward Molm14 and
RS4-11, both acute myeloid leukemia subsets, we can see that 13b is particularly selective for
acute types of leukemia when compared to its lack of efficacy toward the chronic leukemia cell
Table 3.8. Leukemia and myeloma cell line data for 13b
O
N
H

H
N

H
N

O

EC50 (nM)
MV4-11

Molm14

RS4-11

K562

HL-60

RPMI-8226

36.37 ± 8.83

76.64 ± 18.37

151.7 ± 44.29

2160 ± 128.3

>10,000

>10,000

EC50 values (bold) are the mean of at least two experiments ± the Standard Error of the Mean.

line, K562 or the chromosomal translocation containing HL-60 cell line. Further, when tested
against the classical Multiple Myeloma cell line, RPMI-8226, 13b demonstrated incomplete kill
curves even at mM concentrations. Following the potency findings of 13b in MV4-11 cells, we
assessed the efficacy of 11l, 12d, and 13b in these cells as single agents. Panobinostat, vorinostat,
entinostat, 11l, 12d, and 13b were tested against MV4-11 for 48 hours of treatment. Cells were
treated with CellTiter-Blue to determine viability which was measured using a
spectrophotometer as a function of resorufin intensity. Results from these experiments are
shown as an EC50 cell viability curve in Figure 3.18A. As a negative control, we also performed
this experiment using 12c, a compound whose structure very closely matches 12d, differing only
by a non-reduced nitrogen-carbon bond, while possessing no appreciable inhibition against
recombinant HDAC3. Matching its weak prowess as an HDAC inhibitor from our recombinant
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Figure 3.18. Ex vivo analysis of lead compounds as single agents against AML

A) EC50 of HDAC inhibitors against MV4-11 cells after 48 hour treatment. 11l, 12d, and 13b all display lower EC50
values than vorinostat and entinostat, from 38-287 nM. B) Western blot analysis of HDAC inhibitors against MV4-11
cells at 100 nM after 24 hours. 11l, 12d, and 13b cause higher upregulation of Acetylated Histones H3 and H4
(AcHH3/AcHH4) than vorinostat and entinostat. Panobinostat is the only inhibitor to raise Acetylated Tubulin
(AcTub) levels at this concentration. C) Quantifications of AcHH3 and AcHH4 from Western blot B. Values normalized
to actin levels. D) (Top) Western blot analysis of 11l, 12d, and 13b at varied doses after 6 hours. All display a dosedependent increase in AcHH3 and AcHH4. (Bottom) Quantification of Western blot D. Values normalized to actin
levels. Representative plots and blots of n ≥ 2 experiments. As single agents, these compounds possess less than
300 nM EC50 values against MV4-11 with complete kill curves.

HDAC assay, this compound demonstrated no appreciable activity against MV4-11 cells even at
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doses as high as 250 µM (Figure 3.19A).
To demonstrate that our initial HDAC activity pre-screening assay was correlative with
efficacy against MV4-11 cells, we plotted the compounds’ respective potency toward HEK293
lysates as a function of their IC50 with their respective EC50 values against MV4-11 cells (Figure
3.19B). The results demonstrate a linear relationship with considerable correlation,
demonstrating the ability of our HDAC activity pre-screen assay to translate to ex vivo potency in
AML cells.
To further demonstrate the correlation between MV4-11 cell death with hyperacetylation of
histones H3 and H4, we performed Western blot analysis of MV4-11 cell lysates after 24 hour
treatment with 100 nM of inhibitor (Figure 3.19B). The data demonstrate that our lead inhibitors,
11l, 12d, and 13b are more potent at increasing the concentrations of acetylated histones H3 and
H4, markers of HDACs 1, 2, and 3 inhibition, than the FDA approved vorinostat or the orthoaminoanilide-based entinostat (Figure 3.19 B-C). Additionally, this upregulation is dosedependent, with increasing levels of hyperacetylation seen with increasing concentrations of
inhibitor (Figure 3.18D). As a negative control, we once again used 12c to further ensure the
validity of our pre-cellular screening. At a concentration of 100 nM, 12c was also used in MV4-11
cells for western blot analysis and demonstrated no appreciable ability to increase acetylation of
histones H3 and H4 (Figure 3.19C). Further, upregulation of histones H3 and H4 is selective, as
our hydrazide based inhibitors do not demonstrate any effect on levels of acetylated tubulin, a
marker of HDAC6 inhibition (Figures 3.18 B and D). This is an important characteristic, as
upregulation of acetylated histones H3 and H4 is inversely and logarithmically correlated with
EC50 against AML, that is, an increase in acetylated histones H3 and H4 leads to an exponential
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Figure 3.19. Extrapolated analysis and correlation between assay screens and potency of lead
compounds

A) MV4-11 EC50. 48 hour treatment, 12c shows no killing activity. B) Correlation between Hek293 lysate screening
and MV4-11 EC50. Direct, linear relationship between the two. C) Western blot analysis of 100 nM inhibitors in MV411 cells for 24 hours, 12c doesn’t increase acetylated histone H3 (AcHH3) or H4 (AcHH4) levels. D) Correlation
between fold increase in levels of AcHH3 and the EC50 in MV4-11 cells. A direct, inverse relationship is seen in a
logarithmic fashion. A logarithmic increase in acetylation of Histone H3 leads to a logarithmic decrease in
concentration required to kill 50% of MV4-11 cells. E) Correlation between fold increase in AcHH4 and EC50 in MV411 cells. A direct, inverse relationship is seen in a logarithmic fashion. A logarithmic increase in acetylation of Histone
H3 leads to a logarithmic decrease in concentration required to kill 50% of MV4-11 cells. A and C are representative
figures from n = 2 experiments. B, D, and E were plotted from corresponding representative figures in Figure 3.15.
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decrease in EC50 against these cells (Figures 3.19 D-E). This is in sharp contrast to acetylated
tubulin, where increasing levels of acetylation are not as directly correlative with EC50 against
MV4-11 cells (Figure 3.15B).

Selectivity and toxicity profiling of lead analogs. Concluding our experiments, we sought to
determine if the hydrazide based inhibition of HDACs was a non-selective cell death mechanism,
or if it was selective toward non-solid tumor cells, particularly various forms of leukemia. We
examined the ex vivo effect of 11l, 12d, and 13b in Hek293 and HeLa cells, well-studied solid
tumor cell lines. Briefly, cells were pre-incubated for 24 hours prior to treatment. After
treatment, cells were incubated for an additional 48 hours before measurement of cell viability
as a function of resorufin intensity was determined. The corresponding EC50 values demonstrate
at least 100 fold higher selectivity toward the MV4-11 cell line (compare Figures 3.18A and 3.20
A-B). Further, we wanted to examine our lead compounds’ toxicity profile against healthy human
peripheral blood mononuclear cells (PBMCs). PBMCs were treated with titrating doses of
panobinostat, 12d, or 13b for 24 hours followed by treatment with CellTiter-Blue. Cell viability
was determined as a function of resorufin intensity via spectrophotometer, normalized to control
treatment. The data demonstrate 12d and 13b’s superiority over panobinostat from a toxicity
standpoint. Further, the lack of a Michael acceptor group on 12d seems to reduce its toxicity
toward PBMC’s 10 fold compared to 13b (Figure 3.20B). This functional group (present as an
acrylamide) may also explain panobinostat’s much greater toxicity compared to 12d and 13b.
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Figure 3.20. Selectivity and toxicity profiling of lead inhibitors

A) EC50 of HEK293. Neither 11l, 12d, nor 13b display effective killing of this solid tumor cell line after 48 hours of
treatment. B) EC50 of HeLa. Neither 11l, 12d, nor 13b display effective killing of this solid tumor cell line after 48
hours of treatment. C) Human PBMC profiling with panobinostat, 12d, and 13b. 12d and 13b both demonstrate
superior toxicity (less PBMC killing) than panobinostat. 12d shows ~10 fold less toxicity than 13b until the high
micromolar range, well beyond the respective EC50 values of these compounds. Panobinostat displays immediate
toxicity as early as 10 nM. Values normalized to vehicle treatment (DMSO). Figures are representative of n ≥ 2
experiments.
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3.3. In vivo testing and mechanistic determination of Hydrazide-Containing Class
I Histone Deacetylase Inhibitors

With the pre-clinical novelty and successes for inhibitors 12d and 13b, our focus turned
toward optimization for in vivo experimentations. We first sought to test our lead inhibitors for
propensity to cause mutagenesis. We performed a mini-Ames to first ensure that these novel
compounds were not inducing genetic mutations. Our compounds, 12d, and a previously
unpublished compound, 14a, did not induce significant increases in positive mutagenic
responses. This was similar to FDA approved vorinostat and panobinostat. Further, our positive
control, 2-aminoanthracene induced genetic mutations in nearly 100% of the wells, giving validity
to our assay (Figure 3.21)
Figure 3.21. Ames test of lead hydrazide and FDA approved HDAC inhibitors.
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Error bars are presented as 95% confidence intervals. No data except the positive control, 2-AA, are significant. 12d
and 14a are non-inferior to panobinostat or vorinostat. n = 4.

Satisfied with these results, we next performed stability tests in various environments that
mimicked the stomach, small intestine, and blood. Briefly, the stomach environment was
mimicked with hydrochloric acid and pepsin. The intestinal environment was buffered to a
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neutral pH with pancreatin, and human serum was used to mimic a blood environment. 12d, 13b,
and 14a were incubated in these environments and samples taken at various time points.
Samples were examined compared to baseline via mass spectrometry to determine their halflives in these environments. Comparing the Area Under the Curve for Total Ion Concentration
and UV intensity at 254 nm demonstrated that these compounds were stable for >12 hours, >24
hours, and >24 hours in the stomach, intestine, and blood environment respectively. Satisfied
that our lead inhibitors are both non-mutagenic and seemingly stable in vivo, we transitioned to
animal studies to determine their respective maximal tolerated doses. It has been previously
reported that similar compounds, panobinostat and entinostat, had maximum tolerated doses
of 15 and 20 mg/kg/day for 14 days in Balb/c mice. We performed a maximum tolerated dose
study using 15 female Balb/c mice in groups of 3. This set up, referred to as a modified Fibonacci
sequence, or 3+3 sequence, allows for the fastest and safest determination of maximum
tolerated dose.
Compound 12d at 20 mg/kg/day via alternating site IP injection resulted in sacrificed mice at
day 6, at 10 mg/kg/day the mice were sacrificed at day 13 of the study. All reasons of sacrifice
was for signs of moribund/suffering. Mice were nearly immobile, had unkempt fur, were hunched
over, had lost 20% or more of their baseline body mass and were breathing rapidly. The mice
were humanely sacrificed via CO2 asphyxiation followed by cervical dislocation. Blood samples
taken before death were run for basic chemistry as well as liver function tests. All results were
within normal limits with the exception of elevated potassium. This, however, was likely
attributable to 2+ hemolysis of the samples. Autopsy for two of the mice showed a blue, hypoxic
looking stomach/intestinal tract, however reasons for this were not apparent.
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Compound 13b at 20 mg/kg/day via alternating site IP injections resulted in sacrificed mice
on day 2. Two mice died overnight between injections, and the third was found to be moribund
the second morning. Like compound 12d, the blood chemistry panel and liver function test came
back within normal limits. Autopsy revealed no acutely abnormal organ appearance.
Compound 14a, however, was well tolerated at both 10 and 20 mg/kg/day via alternating site
IP injections. All six mice finished the entire treatment with no signs of moribundity or suffering.
All six mice were humanely sacrificed and their brains, livers, kidneys, and spleens stored in
formalin for future study if necessary.
Puzzled by this difference in toxicities, despite very little difference in structure, we sent out
samples for an independent Pk/Pd test for both compounds 13 and 14a. The experiment was
performed in 6 female Balb/c mice, 3 per compound, at 20 mg/kg via one time IP injection. Blood
samples were taken at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after IP injection. Concentrations
were determined via mass spectrometry. Data from all time points and all mice were used to
determine the Cmax, Area Under the Curve, and half-life for both compounds. The resulting data
(Figures 3.22a and b) demonstrate that 13b possesses a half-life of ~3.2 hours with a Cmax of
58,600 ng/mL (174 µM). 14a showed second-order clearance kinetics, with a half-life of ~8 hours.
Its Cmax, however, was much lower at 559 ng/mL (1.43 µM). This extremely high Cmax for 13b is
very likely the reason for the very acute toxicities seen with 12d and 13b. To put the Cmax in
perspective, panobinostat’s Cmax determined via a one-time IV injection was only 1.86 µM at the
same 20 mg/kg dose given for 13b. This ~100 fold difference means our animals were getting 100
times the effective dose as panobinostat.
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Figure 3.22. Pk/Pd profiling of 13b and 14a.
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Data are presented as means of 3 individual mice. Error bars are S.E.M. 13b shows first-order clearance kinetics. 14a
shows second-order clearance kinetics. Note semi-log plots.
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As such, we moved forward with efficacy studies in-vivo using 14a. Using NOD-scid gamma
mice which are devoid of mature B and T cells, Natural Killer Cells, and complement, have
defective macrophages and dendritic cells, and low irradiation tolerance, we injected 5 million
luciferase-tagged MV4-11 cells via tail vein after 2 Gy irradiation exposure. Mice have received IP
injection of 150 mg/kg luciferin doses weekly and imaged to determine rate and extent of
engraftment. Upon engraftment in spine, femur, or cranial area, we will begin daily IP injections
of 14a at the previously tested 20 mg/kg dose.
We have attempted to determine in broad strokes what the mechanism behind these
hydrazide-based inhibitors is for their apparent selective killing of AML cells. Our first efforts were
to determine if these inhibitors either killed AML cells via activation of caspase or if they were
killing the cells via an autophagic pathway. MV4-11 cells were incubated with 20 µM ZVAD-FMK,
a polypeptidic pan-inhibitor of caspases, with or without 12d, 13b, or 14a at various doses for 12,
24, and 48 hours. Cell viability was determined via resazurin and the IC50 values of each inhibitor
was compared to the values with ZVAD-FMK. There was no apparent nor statistically significant
(independent two-sided t-test) difference between the inhibitors alone vs the inhibitor with 20
µM for any of the three time points tested. Inquiries into the autophagic pathway yielded
similarly frustrating results. Similarly performed experiments utilizing 10 and 50 µM of
chloroquine yielded no differences in IC50 values either.
Puzzled by these results, we looked back at our previous data (Table 3.8) and saw an
interesting trend. The three cell lines which compound 13b was most efficacious, MV4-11, RS411, and Molm14 all have non-mutated and present p53. Further, the three cell lines which
showed very little efficacy: K-562, HL-60, and RPMI-8226, all possess either mutated or absent
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p53. Curious to follow-up on this interesting finding, we blotted MV4-11 cells treated with 12d,
13b, or 14a as well as panobinostat, vorinostat, and entinostat (Figure 3.23). Interestingly, at 12
hours we see a marked decrease in p53 that is correlative with the increase in histone H3 and H4
acetylation.
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Figure 3.23. Western Blot Analysis of MV4-11 at 12 hours with various HDAC inhibitors.
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That is to say, as HDACs 1-3 are inhibited with more and more potency, p53 levels decrease in a
similar fashion. Further, this effect seen seems to be irrespective of cell killing, as Hsp90 levels
are approximately equal in all samples. To further test the hypothesis that MV4-11 cells may be
being killed through a p53 mediated mechanism, we have sent out our lead inhibitors to the NIH
for screening in their 60 cell panel. We will cross-reference the efficacy of our compounds in
these cells against the normal, mutated, or absent p53 status. Depending on the results, a sub
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analysis may be performed on the data to determine if certain p53 mutations have no impact on
their efficacy.
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4 SUMMARY
The findings of this body of work are as follows:
Determined the individual isozyme activity for all known zinc-dependent HDACs against a myriad
of known lysine-residue based substrates with acyl modifications. Specifically demonstrating the
role of HDACs 3 and 6 as deformylases, HDAC1-3 as depropionylases, and HDAC3 as a
devalerylase. From this finding we generated a fairly selective HDAC3 inhibitor using a substratebased medicinal chemistry approach. This inhibitor was used as a tool to confirm that selective
HDAC3 inhibition demonstrates anti-inflammatory effects in vitro. These findings met Aims 1,
1.1, and 2.
Additionally, this work covered the further enhancement of hydrazide-based HDAC inhibitors,
achieving 0.95 nM inhibitors in vitro. These inhibitors were later shown to be impervious to
glucuronidation using ex vivo human liver homogenates. Lead analogues from our synthetic
efforts were found to be highly potent and selectively toxic toward acute myeloid leukemia cells.
These findings covered Aims 3 and 3.1.
Lastly, we demonstrated the preliminary PK/PD profiles of lead analogues to be favorable for
further development. The lead hydrazide-based analogues were sufficiently bioavailable and
with appreciable half-lives in vivo. We reported on preliminary and very non-conclusive regarding
possible mechanisms by which these inhibitors are selectively killing leukemia cells.
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5 CONCLUSIONS AND PERSPECTIVES
5.1. Conclusions and Perspectives: Role of Histone Deacetylases as Lysine
Deacylases: Impact in medicinal chemistry and inflammatory diseases.
In this chapter, we investigated HDAC isozyme-specific deacylase activity and demonstrated
a biological relevancy of these findings. We have shown that HDACs 3 and 6 possess
deformylation activity, confirmed previous findings that HDAC3 has decrotonylase activity,
presented preliminary evidence that HDACs 1-3 can remove propionyl groups, and demonstrated
that HDAC3 has specific activity toward butyryl-, and valeryl-substrates (Figure 3.2a). We
developed a selective HDAC3 inhibitor 2a based on the results from our initial deacylase profiling.
This inhibitor induced NF-κB p65 Lys122/Lys123 and p53 Lys382 acetylation without affecting
histone or tubulin acetylation. Additionally, 2a shortened NF-κB p65 nuclear localization duration
and attenuated NO production and HMGB-1 secretion in activated macrophages (Figure 3.10).
The presented data suggest that lysine deformylation is likely to be co-regulated by HDACs 3
and 6, with HDAC6 driving more deformylation activity in vitro than HDAC3 (Figure 3.2b and
Figure 3.4). This process is likely to occur in the cytosol as HDAC6 shows high subcellular
localization fidelity to this compartment.180 This result explains why a previous study utilizing
mass spectrometry indicates that HDAC activity does not affect nuclear and histone formylation
and is refractory to HDAC inhibitor treatments.181 Additionally, upon treatment with HDAC
inhibitors, total protein formylation levels increased in a manner dependent on the selectivity of
the inhibitor (Figure 3.6b).
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The presented data also suggest HDAC3 has the ability to remove butyryl-, crotonyl-, and
valeryl-based PTMs (Figure 3.1b and Figure 3.2a). Only HDAC inhibitors targeting HDAC3 were
capable of inducing an increase in protein valerylation, which is consistent with our in vitro
activity profiling (Figures 3.2a and 3.5a). Interestingly, the highly selective HDAC6 inhibitor
Tubastatin A blocked induction of valerylated protein by other HDAC inhibitors. Global levels of
valerylated cellular proteins also decreased when both HDACs 3 and 6 were concomitantly
silenced, similar to the HDAC inhibitor results. Silencing of either HDAC3 or HDAC6 resulted in an
increase in valerylated protein levels; suggesting that the elimination of HDAC6 likely affects
HDAC3 devalerylase activity (Figure 3.6d). This may be explained through the known complexes
in which HDACs 3 and 6 both have been shown to reside. 163, 182 Another possible explanation
involves acetyl groups and valeryl groups competing for the same lysine residues. If HDAC6 is
inhibited and acetyl groups are either more ubiquitous or are more favorably ligated to free lysine
residues than valeryl groups, we would expect the lysine residues to be stabilized with more
acetyl groups rather than valeryl. This is due to the cross coverage that a multitude of HDACs
perform in the remove of acetyl groups whereas only HDAC3 seems to be able to remove valeryl
modifications. This would in turn lead to an overall decrease in valerylated lysine residues
compared to acetylated. With respect to the knockdown data demonstrating hypervalerylation,
this may be in part to a compensatory mechanism of the cell that behaves differently than
reversible small molecule inhibition.
Traditionally, developing selective HDAC3 inhibitors has led to very limited success. With the
development of entinostat, PD-106, and T326 being the most notable.183 This is largely in part
due to the high level of homology showcased between HDACs 1-3 (Figure 1.4). In this study, we

109

have shown that by maintaining the trans-pentene geometry of the crotonyl-based PTMs and
introducing fluorines around the ortho-aminoanilide ring (Figure 3.8 and Figure 3.9), a highly
potent and selective HDAC3 inhibitor can be achieved. This inhibitor defines a chemotype that
promotes selective HDAC3 inhibition. Interestingly, 2a also showed selective slow-on/slow-off
kinetics for HDAC3 but not HDAC 1 (Figure 3.9). This is in contrast to previous findings that
described benzamide-containing HDAC inhibitors to possess time-dependent binding kinetics vs
class I HDACs.158 It is interesting to note that a previous study presented rationale behind why
fluorination in certain positions around the benzamide ring may lead to HDAC3 selectivity,
postulating that the intramolecular constraints of a pocket dwelling Leucine was different in
HDAC3 compared to HDAC2.165 This difference allowed the authors to develop an inhibitor that
was selective for HDAC3. However, their explanation does not adequately cover the striking
similarities between this conserved Leucine when comparing HDAC3 with HDAC1 (Figure 5.1).
While it is undoubted that fluorination plays a key part in both their inhibitors’ design as well as
ours, there is still much to be studied. Further, the discovery of potent HDAC inhibitors possessing
internal metal chelation groups, the potential to develop even more potent and selective
inhibitors could become more realized.141, 184
The effects on NF-κB, NO production, and HMGB-1 secretion in activated macrophages by
inhibitor 2a indicate that HDAC3 activity plays a key role in pro-inflammatory signaling. HDAC3
itself has been implicated in the regulation of inflammatory gene transcription in
macrophages.185 However, based on our results, HDAC3 activity also plays other roles; such as
regulating its own cellular localization and the duration of NF-κB p65 nuclear localization (Figure
3.10d). Our findings are consistent with previous observations42 which suggest that HDAC3
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controls NF-κB p65 Lys122/123 acetylation status, its cellular localization, and rate of recovery to
its latent state complex in the cytosol. Additionally, NO production is closely linked to NF-κB
Figure 5.1. Crystal structure overlay of key pocket residues in HDACs 1-3.

Crystal structure overlay of HDACs 1-3. Leu133 of HDAC3 and Leu139 of HDAC1 possess a very similar conformation
and intramolecular assembly. HDAC2, however, does demonstrate different geometry as previously reported. PDB
files: 5ICN, 3MAX, and 4A69 for HDACs 1-3 respectively.

activation in macrophages186-188, thus it is not surprising that NO production is attenuated by 2a.
Our findings also demonstrate the ability of HDAC3 to control the acetylation of Lys382 of p53.
There are several reports of the effects of inhibitors demonstrating different effects on this
Lysine. Further study controlling for cell type, concentrations of inhibitors, and length of
treatment is undoubtedly needed.
HMGB-1 contains multiple PTMs, including acetylation and formylation of lysine.170 Upon
stimulation, acetylated HMGB-1 translocates from the nucleus to the cytosol primed for
secretion170 and sequential activation of inflammasomes is required for HMGB-1 secretion.189-191
Selective HDAC3 inhibition prevents HMGB-1 secretion similar to the pan-HDAC inhibition of
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vorinostat (Figure 3.10c). A similar result was observed for IL-1B secretion in macrophages, which
also requires a two-step process for its secretion.192 Since acetylated HMGB-1 accumulates in the
cytosol and HDAC3 activity is required for its secretions, this suggests HDAC3 likely plays a role in
inflammasome activation during the second phase of secretion. Since HDAC3 has both
deacetylase and select deacylase activity, it is likely that the presented anti-inflammatory effects
are due to an increase in lysine acetylation or certain acyl-PTMs of specific lysine substrates.

5.2. Conclusions and Perspectives: Development of Allosteric HydrazideContaining Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid
Leukemia.
To date, all FDA approved HDAC inhibitors or those in clinical trials contain promiscuous
metal-chelating groups. The hydroxamic acid was the first metal-chelating group to be
introduced, and to this day remains the most common, but others such as the disulfide bond of
romidepsin, or the ortho-aminoanilide of entinostat have also been used. These groups are all
generally acidic in nature, and have been shown to be subject to glucuronidation. This addition
of steric bulk and charge neutralization removes the ability of these inhibitors to get into the
narrow active site and ionically bind to the positively charged zinc that is paramount to HDAC
deacylase activity. In this study we demonstrated that very potent and selective inhibition of class
I HDACs is possible with the novel utilization of the metal chelating group, hydrazide. Further, we
demonstrated that these compounds likely work through an allosteric mode of inhibition. This
possibly indicates the presence of a non-catalytic metal-center target of these hydrazide
compounds. Thus far, discoveries of allosteric, small molecule inhibitors of class I HDACs have
not been well established in the literature. Inhibitors that lack a known metal-chelating group
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that have been shown to inhibit HDACs were shown to display canonical competitive MichaelisMenten enzyme kinetics when further interrogated.193
The results in this manuscript suggest our compounds are also highly resistant to
glucuronidation, indicating they possess little anionic charge, and display mixed/non-competitive
inhibition, giving further credibility to the possibility that they may bind to a non-catalytic site on
HDACs irrespective of whether substrate is bound. Further, this allosteric site is present ex vivo,
as their recombinant enzyme inhibition prowess translated directly to cellular efficacy as well.
Discovery of a potential allosteric binding site benefits more than just medicinal chemistry
surrounding HDAC inhibitors. By having a combination of agents that work both at the active site,
and allosterically on HDACs, the possibility of dual mechanism therapies for acute myeloid
leukemia arises.
Lastly, while this paper established a >60 fold improvement in potency over the initial lead
inhibitor generated by Wang and colleagues, our most potent of which breaching the picomolar
range for recombinant human HDAC3 inhibition, further refinement of these inhibitors is also
possible. Further alterations surrounding N-benzylbenzamide group that provided so much of
these molecules’ potencies would be the first place to start. Stepwise methylation at key sites,
or the introduction of electron donating or withdrawing groups around either of the phenyl rings
could provide additional potency.
Our lead inhibitors 11l, 12d, and 13b, were used ubiquitously throughout the manuscript. All
of these agents display higher levels of ex vivo potency than vorinostat or entinostat. The most
potent, 13b, contains a Michael-acceptor group in the form of an α, β-unsaturated ketone. While
once a forbidden group in medicinal chemistry, recently approved effective therapies such as
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dimethyl fumarate demonstrate that not all Michael-acceptors are detrimental to patient health,
even in long term use. However, when comparing 13b’s potency to that of 12d, we see an
approximate 2.5 fold decrease in EC50 in MV4-11 cells at the cost of a 10 fold increase in PBMC
based toxicity. Further, this was the only one of our compounds tested in human liver
microsomes to demonstrate a metabolite, being reduced about its unsaturated bond. This was
surprising, as no external reducing substrates such as NADH or NADPH were added to the
reaction vessel. This indicates that even the residual concentrations of these reducing agents
leftover from extraction were enough to metabolize this compound. As such, the superior
metabolic stability, and better toxicity profiles of 12d make it a more beneficial candidate worth
pursuing.

5.3. Conclusions and Perspectives: In vivo testing and mechanistic determination
of Hydrazide-Containing Class I Histone Deacetylase Inhibitors.
The stability of our lead inhibitors, determined via liver microsomes, stomach acid
environments, intestinal environments, and human serum all demonstrated no appreciable
glucuronidation or degradation as far out as 24 hours. These results were also seen with in vivo
Pk/Pd studies in mice. Compounds 13b and 14a both demonstrated appreciably long half-lives
(3.2 and 8 hours respectively) highly indicative of daily or less frequent dosing in humans. With
efficacy studies on-going in vivo, it’s difficult to definitively draw conclusions regarding the
degree to which these compounds are likely to show effect in higher order animals including
humans. An interesting question raised by the results of the Pk/Pd study is that of dosing
frequency and intensity. That is, AML cells respond to high dose, infrequent therapy, or lower
dose constant therapy. A similar phenomena is seen in bacteria. Antimicrobials are notoriously

114

dosed based on Cmax or time above minimal inhibitor concentration. A follow-up to the ongoing
efficacy study would be to determine if it’s better to treat daily, biweekly, or weekly at
appropriate and safe doses for each regimen. Maximal tolerated doses for each frequency would
have to be established before this could be done.
Transitioning to the inquiry of mechanism, the lack of effect of ZVAD-FMK and chloroquine
on the efficacy of the hydrazide-based inhibitors in the Acute Myeloid Leukemia cell line is
certainly interesting. It implies that a non-caspase, non-autophagy mediated pathway is
responsible for the potent and selective killing seen in these cells. Neither 12d, 13b, or 14a were
affected by the presence of these inhibitors. An alternative explanation may lie with p53,
however, further analysis is needed. The results of the large scale NIH cell panel screen will
quickly give more validity to this hypothesis or render it flawed.
Lastly, it’s interesting to note a structural difference between panobinostat and other
transcinnamic acids with hydroxamates. It uses a slightly modified tryptophan that seemingly has
little bearing on its efficacy. Instead, I believe this group was added to improve Pk/Pd profiles,
particularly to improve drug penetrance into cells and its half-life in vivo. A similar scenario was
seen with a compound valacyclovir. This compound, differing from acyclovir only by addition of
a valine group increased the drug’s half-life 5 fold, turning it from a 5 times per day dose
(acyclovir) to the once daily dose (valacyclovir). This is due to the amino acid receptors in the
kidney recognizing the valine and recycling it, preventing excretion. It is interesting to note that
panobinostat, possessing a different amino acid mimetic in the way of tryptophan has a 27 hour
half-life in humans. As such, I believe addition of a para-position hydroxyl group to the benzamide
on the “left” side of 12d or 13b may produce a mimetic tyrosine that possesses similar effects to
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panobinostat and valacyclovir in terms of kidney recycling in vivo. This simple change may yield
very large dividends on druggability with minimal effect on efficacy.
Individuals familiar with isoniazid may have associated the presence of its hydrazide motif
and liver toxicity to our hydrazide motif. Lesser known compounds containing this moiety also
include: benmoxin, iproclozide, iproniazid, isocarboxazid, nialamide, pivhydrazine. Nearly all of
these compounds, excluding isocarboxazid, have been shown to induce hepatitis or acute liver
damage. Interestingly, many of them have been associated with Monoamine oxidase inhibition
as well. The hepatotoxicity seems to stem from cleavage about the nitrogen-carbonyl bond
yielding an aldehyde and primary amine. The primary amine can be acetylated forming
acetylhydrazide, a rather hepatotoxic compound. Secondary acetylation to the remaining
primary nitrogen, however, nullifies this toxicity. In an effort to prevent this cleavage, I propose
the acrylamide group present in 13b be repositioned to generate the following molecule. This
molecule retains the propylhydrazide structure but possibly thwarts cleavage of the nitrogencarbonyl bond of hydrazide by way of inductive resonance stabilizing the bond (Figure 5.2).
Figure 5.2. Proposed Hydrazide Derivative with transcinnamic acid and tyrosine mimetic.
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6.1. Detailed Synthetic Procedures.
Acylated substrates synthesis:
Formyl-substrate.

O
O

methylcoumarin

O

O

(100mg,

0.25

mmole)

was

dissolved

in

Dimethylformamide with catalytic amount of DIPEA. Formyl-

NH

HN

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-amido-4-

O
N
H

H

O

substrate was generated by adding 2,2,2-Trifluoroethyl Formate
(128 mg, 1 mmole 4 equiv) and reacted for 12 hours. The reaction
mixture was injected directly into Combiflash instrument in HPLC

format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.43 (s, 1H), 7.99 (s, 2H),
7.78 (d, 1H, J = 2 Hz), 7.73 (d, 1H, J = 8 Hz), 7.50 (d, 1H, J = 8 Hz), 7.13 (d, 1H, J = 8 Hz), 6.27 (s,
1H), 4.06 (m, 1H), 3.07 (m, 2H), 2.41 (s, 3H), 1.66-1.60 (m, 2H), 1.42-1.39 (m, 11H), 1.30-1.27 (m,
2H); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.4, 115.7, 112.7, 106.1, 55.7, 37.4, 31.7, 29.3,
28.7, 28.6, 18.5. [(m+H+)/z = 432.1]
Propionyl-substrate.

O
O

amido-4-methylcoumarin (100mg, 0.25mmole) was dissolved in

O

Dimethylformamide with catalytic amount of DIPEA. Propionyl-

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-

O
N
H

O

substrate was generated by adding propionyl chloride (92mg,
1mmole 4equiv) and reacted for 12 hours. The reaction mixture
was injected directly into Combiflash instrument in HPLC format

to obtain the desired product. 41% yield. 1H NMR (400 MHz, DMSO): δ 10.42 (s, 1H), 7.79 (d, 1H,
J = 2 Hz), 7.75-7.71 (m, 2H), 7.72 ( d, 1H, J = 8 Hz), 7.11 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.08-4.03 (m,
1H), 3.05-3.00 (m, 2H), 2.41 (s, 3H), 2.07-2.01 (q, 2H, J = 8 Hz), 1.69-1.60 (m, 2H), 1.42-1.37 (m,
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11H), 1.32-1.28 (m, 2H), 0.97 (t, 3H, J = 8 Hz); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.4,
115.7, 112.7, 106.1, 55.7, 38.6, 31.7, 29.0, 28.7, 28.6, 23.5, 18.5, 10.5. LC/MS: [(m+H+)/z = 460.2]
Butyryl-substrate.

O
O

amido-4-methylcoumarin (100mg, 0.25 mmole) was dissolved

O

in Dimethylformamide with catalytic amount of DIPEA. Butyryl-

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-

O

substrate was generated by adding butyryl chloride (107mg, 1

N
H
O

mmole 4 equiv) and reacted for 12 hours. The reaction mixture
was injected directly into Combiflash instrument in HPLC

format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.42 (s, 1H), 7.79 (s, 1H),
7.75-7.73 (m, 2H), 7.50 (d, 1H, J = 8 Hz), 7.11 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.07-4.04 (m, 1H), 3.053.01 (m, 2H), 2.41 (s, 3H), 2.00 (t, 2H, J = 7 Hz), 1.69-1.55 (m, 2H), 1.53-1.45 (m, 2H), 1.44-1.40
(m, 11), 1.31-1.28 (m, 2H), 0.82 (t, 3H, J = 8 Hz); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.4,
115.7, 112.7, 106.1, 55.7, 38.5, 37.9, 31.7, 28.7, 28.6, 23.5, 19.2, 18.5, 14.2. LC/MS: [(m+H+)/z =
474.1]
Crotonyl-substrate.

O
O

amido-4-methylcoumarin (100mg, 0.25 mmole) was dissolved

O

in Dimethylformamide with catalytic amount of DIPEA.

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-

O
N
H

O

Crotonyl-substrate was generated by adding crotonyl
anhydride (105mg, 1 mmole 4 equiv) and reacted for 12 hours.
The reaction mixture was injected directly into Combiflash

instrument in HPLC format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.42 (s,
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1H), 7.86 (t, 1H, J = 6 Hz), 7.78 (s, 1H), 7.73 (d, 1H, J = 8 Hz), 7.50 ( d, 1H, J = 8 Hz), 7.12 (d, 1H, J =
8 Hz), 6.61-6.55 (m, 1H), 6.27 (s, 1H), 5.87 (d, 1H, J = 11 Hz), 4.07-4.04 (m, 1H), 3.12-3.07 (m, 2H),
2.41 (s, 3H), 1.77 (d, 3H, J = 7 Hz), 1.67-1.60 (m, 2H), 1.45-1.39 (m, 11H), 1.32-1.29 (m, 2H); 13C
HSQC (400MHz, 100MHz, DMSO): δ 137.8, 126.5, 126.4, 115.7, 112.7, 106.1, 55.8, 31.7, 29.4,
28.7, 28.6, 23.5, 18.5, 17.8. [(m+H+)/z = 572.3]
Valeryl-substrate.

O
O

amido-4-methylcoumarin

O

0.25

mmole)

was

O
N
H

O

(100mg,

dissolved in Dimethylformamide with catalytic amount of

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-

DIPEA. Valeryl-substrate was generated by adding valeryl
chloride (121mg, 1 mmole 4 equiv) and reacted for 12 hours.
The reaction mixture was injected directly into Combiflash

instrument in HPLC format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.43 (s,
1H), 7.79 (d, 1H, J = 2 Hz), 7.74-7.73 (m, 2H), 7.51 (d, 1H, J = 9 Hz), 7.11 (d, 1H, J = 8 Hz), 6.28 (s,
1H), 4.08-4.03 (m, 1H), 3.04-3.00 (m, 2H), 2.41 (s, 3H), 2.02 (t, 2H, J = 8 Hz), 1.65-1.62 (m, 2H),
1.47-1.40 (m, 13H), 1.29-1.22 (m, 4H), 0.84 (t, 3H, J= 8 Hz); 13C HSQC (400MHz, 100MHz, DMSO):
δ 126.4, 115.7, 112.7, 106.1, 55.7, 38.6, 35.6, 31.7, 27.9, 28.8, 28.7, 23.5, 22.3, 18.5, 14.2.
[(m+H+)/z = 488.3]
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Hexanoyl-substrate. Nα-(tert-Butoxycarbonyl)-L-Lysine-

O
O

7-amido-4-methylcoumarin (100mg, 0.25 mmole) was

O
HN
O

dissolved in Dimethylformamide with catalytic amount of

NH

O

DIPEA. Hexanoyl-substrate was generated by adding

N
H
O

hexanoyl chloride (135mg, 1 mmole 4 equiv) and reacted
for 12 hours. The reaction mixture was injected directly

into Combiflash instrument in HPLC format to obtain the desired product. 1H NMR (400 MHz,
DMSO): δ 10.42 (s, 1H), 7.79 (d, 1H, J = 1 Hz), 7.75-7.73 (m, 2H), 7.50 (d, 1H, J = 9 Hz), 7.11 (d, 1H,
J = 8 Hz), 6.28 (s, 1H), 4.07-4.04 (m, 1H), 3.04-3.00 (m, 2H), 2.41 (s, 3H), 2.01 (t, 2H, J = 8 Hz), 1.671.60 (m, 2H), 1.45-1.39 (m, 13H), 1.29-1.18 (m, 6H), 0.84 (t, 3H, J = 7 Hz); 13C HSQC (400MHz,
100MHz, DMSO): δ 126.4, 115.7, 112.7, 106.0, 55.7, 38.5, 35.9, 31.7, 31.4, 28.7, 28.5, 23.5, 22.3,
18.5, 14.3. [(m+H+)/z = 502.2]
Heptanoyl-substrate.

O
O

Lysine-7-amido-4-methylcoumarin

O

0.25

O
N
H

O

(100mg,

mmole) was dissolved in Dimethylformamide with

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-

catalytic amount of DIPEA. Heptanoyl-substrate was
generated by adding Heptanoyl Chloride (149mg, 1
mmole 4 equiv) and reacted for 12 hours. The reaction

mixture was injected directly into Combiflash instrument in HPLC format to obtain the desired
product. 1H NMR (400 MHz, DMSO): δ 10.42 (s, 1H), 7.79 (d, 1H, J = 2 Hz), 7.75-7.73 (m, 2H), 7.50
(d, 1H, J = 8 Hz), 7.10 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.08-4.03 (m, 1H), 3.04-3.00 (m, 2H), 2.41 (s,
3H), 2.01 (t, 2H, J = 8 Hz), 1.69-1.61 (m, 2H), 1.44-1.39 (m, 13H), 1.29-1.20 (m, 8H), 0.85 (t, 3H, J
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= 7 Hz); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.4, 115.8, 112.8, 106.1, 55.7, 38.5, 35.9, 31.7,
31.4, 28.8, 28.7, 28.5, 25.7, 23.4, 22.5, 18.5, 14.4. [(m+H+)/z = 516.4]
Octanoyl-substrate.

O
O

Lysine-7-amido-4-methylcoumarin

O

(100mg,

0.25

mmole) was dissolved in Dimethylformamide with

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-

O

catalytic amount of DIPEA. Octanoyl-substrate was

N
H
O

generated by adding Octanoyl Chloride (163mg, 1
mmole 4 equiv) and reacted for 12 hours. The

reaction mixture was injected directly into Combiflash instrument in HPLC format to obtain the
desired product. 1H NMR (400 MHz, DMSO): δ 10.42 (s, 1H), 7.79 (d, 1H, J = 2 Hz), 7.75-7.73 (m,
2H), 7.50 (d, 1H, J = 8 Hz), 7.10 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.07-4.03 (m, 1H), 3.04-3.00 (m, 2H),
2.41 (s, 3H), 2.01 (t, 2H, J = 8 Hz), 1.64-1.60 (m, 2H), 1.46-1.39 (m, 13H), 1.29-1.21 (m, 10H), 0.870.83 (m, 3H); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.3, 115.7, 112.7, 106.1, 55.7, 38.6, 35.9,
31.7, 31.6, 29.4, 28.9, 28.7, 28.5, 25.8, 23.4, 22.5, 18.5, 14.4. [(m+H+)/z = 530.2]
TFA-substrate.

O
O

methylcoumarin (100mg, 0.25 mmole) was dissolved in

O

Dimethylformamide with catalytic amount of DIPEA. TFA-

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-Lysine-7-amido-4-

O
N
H

O

F
F

F

substrate was generated by adding trifluoroacetic anhydride
(210mg, 1 mmole 4 equiv) and reacted for 12 hours. The reaction
mixture was injected directly into Combiflash instrument in HPLC

format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.46 (s, 1H), 9.42 (t, 1H, J =
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2 Hz), 7.78 (d, 1H, J = 2 Hz), 7.74 (d, 1H, J = 9 Hz), 7.50 (d, 1H, J = 9 Hz), 7.14 (d, 1H, J = 8 Hz), 6.28
(s, 1H), 4.09-4.05 (m, 1H), 3.20-3.16 (m, 2H), 2.41 (s, 3H), 1.69-1.60 (m, 2H), 1.55-1.46 (m, 2H),
1.39 (s, 9H), 1.34-1.25 (m, 2H); 13C HSQC (400MHz, 100MHz, DMSO): δ 126.5, 115.7, 112.8,
106.1, 55.6, 39.5, 31.6, 28.7, 28.5, 28.4, 18.5. [(m+H+)/z = 500.2]
Glutaryl-substrate. Nα-(tert-Butoxycarbonyl)-L-Lysine-

O
O

7-amido-4-methylcoumarin (100mg, 0.25 mmole) was

O
HN
O

dissolved in Dimethylformamide with catalytic amount

NH

O
N
H

O
OH

O

of DIPEA. Glutaryl-substrate was generated by adding
glutaric anhydride (114mg, 1 mmole 4 equiv) and
reacted for 12 hours. The reaction mixture was injected

directly into Combiflash instrument in HPLC format to obtain the desired product. 1H NMR (400
MHz, DMSO): δ 10.43 (s, 1H), 7.81-7.78 (m, 2H), 7.73 (d, 1H, J = 9 Hz), 7.50 (d, 1H, J = 9 Hz), 7.11
(d, 1H, J = 8 Hz), 6.27 (s, 1H), 4.08-4.03 (m, 1H), 3.34-3.01 (m, 2H), 2.41 (s, 3H), 2.18 (t, 2H, J = 8
Hz), 2.07 (t, 2H, J = 8 Hz), 1.73-1.60 (m, 4H), 1.45-1.38 (m, 13H); 13C HSQC (400MHz, 100MHz,
DMSO): δ 126.4, 115.7, 112.7, 106.1, 55.7, 38.6, 35.0, 33.6, 31.7, 29.4, 28.7, 28.6, 21.2, 18.5.
[(m+H+)/z = 518.2]
Adipoyl-substrate,

O
O

Lysine-7-amido-4-methylcoumarin

O

O
N
H

O

(100mg,

0.25mmole) was dissolved in Dimethylformamide

NH

HN
O

Nα-(tert-Butoxycarbonyl)-L-

OH
O

(DMF),

2-(1H-benzotriazol-1-yl)-1,1,3,3-

tetramethyluronium hexaﬂuorophosphate (HBTU),
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Hydroxybenzotriazole (HOBt), and adipic acid (1:1:1 equiv.) with catalytic amount of DIPEA were
dissolved in DMF. Adipoyl-substrate was generated by dripping Boc-Lys-AMC solution slowly into
the activated adipic acid solution (four equiv.) and reacted for 2 hours. The reaction mixture was
stopped by adding water into the reaction and injected directly into Combiflash instrument in
HPLC format to obtain the desired product. 1H NMR (400 MHz, DMSO): δ 10.46 (s, 1H), 7.797.77 (m, 2H), 7.74 (d, 1H, J = 9 Hz), 7.51 (d, 1H, J = 9 Hz), 7.11 (d, 1H, J = 6 Hz), 6.28 (s, 1H), 4.064.04 (m, 1H), 3.04-3.01 (m, 2H), 2.41 (s, 3H), 2.18 (t, 2H, J = 7Hz), 2.03 (t, 2H, J = 7 Hz), 1.69-1.59
(m, 2H), 1.41-1.45 (m, 4H), 1.39 (s, 9H), 1.30-1.28 (m, 4H); 13C HSQC (400MHz, 100MHz, DMSO):
δ 126.4, 115.7, 112.7, 106.1, 55.8, 38.6, 35.6, 34.0, 31.7, 29.4, 28.7, 28.6, 24.8, 23.6, 18.5.
[(m+H+)/z = 532.2]
Inhibitor synthesis (Families 1 and 2)
NH2
O
+
R

NH2
NH2

OH

R1

HOBt, DCC, Et3N
DMF, RT

R2
RA1

H
N

R
O

R1
R2

RA2

Carboxylic acid RA1 (2 mmol, 1 equiv), HOBt (4 mmol, 2 equiv), and DCC (4 mmol, 2 equiv) were
dissolved in 50 mL DMF, to which was added Et3N (4mmol, 2 equiv), and the resulting solution
was stirred at room temperature for 30 mins. o-Phenylenediamine RA2(2 mmol, 1 equiv) was
then added to the solution, and the mixture was stirred overnight. Pour the mixture into 100 mL
water, and extract it with 250 mL ethyl acetate. The organic phase was washed with saturated
NaHCO3 and brine successively, and it was then dried over MgSO4 and filtered. The filtrates were
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concentrated under vacuum, and the residue was purified by Combiflash instrument to obtain
the desired product.
HDAC3 Inhibitor Characterization
Compound 1, (E)-N-(2-aminophenyl)pent-2-enamide, white solid, 28%

O
N
H

NH2

yield. 1H NMR (400 MHz, DMSO): δ 9.23 (s, 1H), 7.24-7.22 (d, J = 7.6 Hz,

1H), 6.92-6.78 (m, 2H), 6.73 (dd, J1 = 8.0 Hz, J2 = 0.8 Hz, 1H), 6.55 (td, J1 = 7.2 Hz, J2 = 1.6 Hz, 1H),
6.15 (d, J = 15.2 Hz, 1H), 4.85 (br, 1H), 2.23-2.17 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, DMSO) δ 172.2, 164.1, 145.9, 142.2, 126.2, 125.4, 123.8, 116.8, 116.5, 25.0, 12.9. LC/MS:
[(m+H+)/z = 191.25].
Compound 1a, N-(2-aminophenyl)furan-2-carboxamide, white solid, 70%

O
N
H

O

NH2

yield. 1H NMR (400 MHz, CDCl3): δ 8.20 (br, 1H), 7.45-7.44 (m, 1H), 7.34 (d, J

= 8.0 Hz, 1H), 7.18 (d, J = 3.2 Hz, 1H), 7.04-7.01 (m, 1H), 6.80-6.76 (m, 2H), 6.52-6.51 (m, 1H), 3.91
(br, 2H); 13C NMR (100 MHz, CDCl3) δ 156.6, 147.6, 144.5, 140.8, 127.2, 125.3, 123.6, 119.5, 118.1,
115.3, 112.4. LC/MS: [(m+H+)/z = 203.33].
Compound 1b, N-(2-aminophenyl)thiophene-2-carboxamide, white solid,

O

S

N
H

NH2

62% yield. 1H NMR (400 MHz, DMSO): δ 9.74 (s, 1H), 7.98-7.97 (m, 1H), 7.79

(dd, J1 = 4.8 Hz, J2 = 1.2 Hz, 1H), 7.21-7.19 (m, 1H), 7.13-7.11 (m, 1H), 7.01-6.97 (m, 1H), 6.78 (dd,
J1 = 8.0 Hz, J2 = 0.8 Hz, 1H), 6.63-6.59 (m, 1H), 5.50-3.50 (br, 2H); 13C NMR (100 MHz, DMSO) δ
160.5, 143.6, 140.3, 131.8, 129.6, 128.5, 127.4, 127.3, 123.2, 117.0, 116.7. LC/MS: [(m+H+)/z =
219.19].
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Compound 1c, N-(2-aminophenyl)-1H-pyrrole-2-carboxamide, white solid,

O
N
H

NH

31% yield. 1H NMR (400 MHz, DMSO): δ 11.6 (s, 1H), 9.32 (s, 1H), 7.17-7.14

NH2

(m, 1H), 7.02-6.93 (m, 4H), 6.80-6.78 (m, 1H), 6.63-6.59 (m, 2H), 6.19-6.17 (m, 1H), 4.86 (br, 2H).
13C

NMR (100 MHz, DMSO) δ 159.8, 143.4, 126.9, 126.6, 126.4, 123.9, 122.5, 117.0, 116.7, 111.7,

109.3. LC/MS: [(m+H+)/z = 202.23].
Compound 1d, N-(2-aminophenyl)oxazole-5-carboxamide, white solid, 44%

O
N
H

N
O

yield. 1H NMR (400 MHz, DMSO): δ 9.80 (s, 1H), 8.59 (s, 1H), 7.93 (s, 1H),

NH2

7.12-7.10 (m, 1H), 7.01-6.97 (m, 1H), 6.78-6.76 (m, 1H), 6.61 (m, 1H), 4.94 (br, 2H). 13C NMR (100
MHz, DMSO) δ 155.7, 154.0, 145.8, 143.8, 130.1, 127.5, 127.4, 122.0, 116.7, 116.5. LC/MS:
[(m+H+)/z = 204.19].
Compound 1e, N-(2-aminophenyl)isoxazole-5-carboxamide, white solid,

O

N O

N
H

NH2

22% yield. 1H NMR (400 MHz, DMSO): δ 10.08 (s, 1H), 8.77 (d, J = 1.6 Hz, 1H),

7.20 (d, J = 1.6 Hz, 1H), 7.13-7.10 (m, 1H), 7.02-6.98 (m, 1H), 6.79-6.76 (m, 1H), 6.61-6.57 (m, 1H),
4.99 (br, 2H). 13C NMR (100 MHz, DMSO) δ 163.2, 154.9, 152.1, 144.0, 127.8, 127.5, 121.7, 116.6,
116.5, 106.9. LC/MS: [(m+H+)/z = 204.17].
Compound 1f, N-(2-aminophenyl)benzofuran-2-carboxamide, white

O

O

N
H

NH2

solid, 75% yield. 1H NMR (400 MHz, DMSO): δ 9.94 (s, 1H), 7.81 (d, J =
8.0 Hz, 1H), 7.73-7.69 (m, 2H), 7.51-7.47 (m, 1H), 7.37-7.33 (m, 1H),

7.23-7.21 (m, 1H), 7.03-6.99 (m, 1H), 6.84-6.81 (m, 1H), 6.65 (m, 1H), 4.98 (br, 2H). 13C NMR (100
MHz, DMSO) δ 157.4, 154.8, 149.4, 143.6, 127.6, 127.4(127.4), 127.2, 124.2, 123.3, 122.7, 116.9,
116.7, 112.3, 110.7. LC/MS: [(m+H+)/z = 253.23].
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F
O
N
H

O

Compound 2, N-(2-amino-5-fluorophenyl)benzofuran-2-carboxamide,
white solid, 80% yield. 1H NMR (400 MHz, DMSO): δ 9.88 (s, 1H), 7.83-

NH2

7.81 (m, 1H), 7.74-7.70 (m, 2H), 7.52-7.48 (m, 1H), 7.39-7.35 (m, 1H),

7.20-7.16 (m, 1H), 6.62-6.58 (m, 1H), 6.42-6.38 (m, 1H), 5.35 (s, 2H). 13C NMR (100 MHz, DMSO)
δ 161.8 (d, J = 239 Hz), 157.7, 154.8, 149.5, 146.1 (d, J = 13.3 Hz), 129.2 (d, J = 11.7 Hz), 127.6,
127.4, 124.2, 123.3, 118.6, 112.3, 110.6, 102.6 (d, J = 23.4 Hz), 102.0 (d, J = 25.1 Hz). 19F NMR
(400 MHz, DMSO): δ -115.9. LC/MS: [(m+H+)/z = 271.17].
Compound

F
O
N
H

O

2a,

N-(2-amino-4,5-difluorophenyl)benzofuran-2-

F

carboxamide, white solid, 78% yield. 1H NMR (400 MHz, DMSO): δ
NH2

9.89 (br, 1H), 7.83-7.81 (m, 1H), 7.73-7.70 (m, 2H), 7.52-7.48 (m, 1H),

7.38-7.28 (m, 2H), 6.77-6.72 (m, 1H), 5.19 (s, 2H).

13C

NMR (100 MHz, DMSO) δ 157.6, 154.8,

149.2, 141.4, 141.3, 127.6, 127.5, 124.3, 123.3, 118.1, 116.0, 115.8, 112.3, 111.0, 103.6, 103.4.
19F

NMR (400 MHz, DMSO): δ -140.9, -153.8. LC/MS: [(m+H+)/z = 289.08]
F
O

O

Compound

2b,

N-(6-amino-2,3-difluorophenyl)benzofuran-2-

F
N
H

carboxamide, white solid, 66% yield. 1H NMR (400 MHz, DMSO): δ 10.0
NH2

(s, 1H), 7.83 (d, J = 3.86 Hz, 1H), 7.2 (d, J = 5.40 Hz, 2H), 7.51 (t, J = 2.74

Hz, 1H), 7.37 (t, J = 2.75 Hz, 1H), 7.02-6.98 (m, 1H), 6.58 (q, J = 6.85 Hz, 1H), 5.41 (s, 2H). 13C NMR
(100 MHz, DMSO): δ 157.8, 154.8, 149.3, 140.5, 138.2, 135.0, 127.6, 127.5, 124.2, 123.3, 119.9,
112.3, 110.8, 102.7, 102.5.

19F

NMR (400 MHz, DMSO): δ -141.5, -158.2. LC/MS [(m+H+)/z =

289.08].
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Compound

F
O

O

N
H

F
NH2

2c,

N-(2-amino-3,5-difluorophenyl)benzofuran-2-

carboxamide, light orange solid, 54% yield. 1H NMR (400 MHz,
DMSO): δ 9.72 (s, 1H), 7.82 (d, J = 3.72 Hz, 1H), 7.72-7.70 (m, 2H),

7.50 (t, J = 5.66 Hz, 1H), 7.37 (t, J = 5.66 Hz, 1H), 6.39-6.33 (m, 2H), 5.73 (s, 1H). 13C NMR (100
MHz, DMSO): δ 163.0, 160.8, 158.1, 154.8, 149.2, 127.6, 127.5, 124.2, 123.3, 112.3, 110.8, 106.0,
105.8, 96.8, 90.9. 19F NMR (400 MHz, DMSO): δ -112.7, -117.2. LC/MS [(m+H+)/z = 289.08].
Synthesis of butylhydrazide derivatives (11a-11l).
Series 11 General Procedure. Once the corresponding hydrazide was generated, 1.1 equivalents
of butaldehyde and 10 equivalents of magnesium sulfate were stirred in 10 mL of ethanol with
the hydrazide. The reaction was stirred at room temperature and monitored via TLC. After
disappearance of starting material, the excess magnesium sulfate was removed via vacuum
filtration, and the collected solution condensed under vacuum.

The intermediate was

resuspended in 4 mL of methanol followed by addition of 1.2 equivalents of sodium
cyanoborohydride and a pinch of methyl orange. Argon was bubbled through the resulting
yellow solution for 5 minutes. At this time a solution of concentrated HCl in methanol (1:1 v/v)
was added dropwise until the solution turned and stayed red. The mixture was allowed to stir
overnight under argon. Volatiles were removed under vacuum and purified on C18 reverse phase
columns eluted with acetonitrile and water to yield the desired product.
O
N
H
O

H
N

N’-butyl-4-methoxybenzohydrazide (11a). 498.54 mg (3 mmol) of
4-methoxybenzohydrazide was reacted as described in Series 11

General Procedure to yield 317.9 mg of dry product (48% yield). 1H NMR (400 MHz, DMSO): δ
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9.89 (s, 1H), 7.82 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 4.99 (s, 1H), 3.81 (s, 3H), 2.79-2.76
(m, 2H), 1.48-1.40 (m, 2H), 1.38-1.32 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO):
δ 165.4, 162.0, 129.3, 125.9, 114.0, 55.8, 51.5, 30.3, 20.3, 14.3. [(m+H+)/z = 223.25]. (λ254) purity
95.4%, tR 9.28 mins.
O

O

N
H

H
N

N’-butylbenzofuran-2-carbohydrazide (11b). 324.0 mg (2 mmol) of
benzofuran-2-carboxylic acid was suspended in 5 mL of methylene
chloride. The flask was flushed with argon for 10 minutes before

injection of 0.4 mL (4 mmol) oxalyl chloride. Two drops of dimethylformamide were injected and
furious bubbling began. The sealed vessel was continuously flushed with argon and vented for 2
hours at room temperature. 10 mL of sieve dried ethanol was slowly injected and allowed to stir
for an additional hour. Volatiles were removed under vacuum and the crude intermediate was
resuspended in 5 mL ethanol. To this solution was added 250 mg (5 mmol) of hydrazine water
salt. The reaction was refluxed for 3 hours to give the corresponding hydrazide. Volatiles were
removed under vacuum and the product suspended in 10 mL of ethanol. From here the reaction
proceeded as described in Series 11 General Procedure to yield 369.1 mg of dry product (72%
yield). 1H NMR (400 MHz, DMSO): δ 10.26 (d, J = 6.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.66 (d, J =
8.4 Hz, 1H), 7.54 (s, 1H), 7.49-7.45 (m, 1H), 7.36-7.32 (m, 1H), 5.16-5.13 (m, 1H), 2.84-2.79 (m,
2H), 1.48-1.41 (m, 2H), 1.39-1.33 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ
157.7, 154.7, 148.7, 127.5, 127.2, 124.2, 123.1, 112.2, 109.6, 51.2, 30.2, 20.3, 14.4. [(m+H+)/z =
233.25]. (λ254) purity 98.8%, tR 11.53 mins.
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O
N
H
O

H
N

N’-butyl-4-phenoxybenzohydrazide (11c). 685 mg (3 mmol)
of 4-phenoxybenzohydrazide was suspended in 10 mL of

ethanol. From here the reaction proceeded as described in Series 11 General Procedure to yield
596.7 mg of dry product (70% yield). 1H NMR (400 MHz, DMSO): δ 9.99 (s, 1H), 7.88 (d, J = 8.8 Hz,
2H), 7.46-7.42 (m, 2H), 7.23-7.20 (m, 1H), 7.09 (d, J = 8.0 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 5.07 (s,
1H), 2.81-2.77 (m, 2H), 1.47-1.41 (m, 2H), 1.38-1.32 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, DMSO): δ 165.1, 159.9, 156.1, 130.7, 129.7, 128.4, 124.7, 119.9, 117.9, 51.4, 30.3, 20.3,
14.4. [(m+H+)/z = 285.25]. (λ254) purity 98.2%, tR 12.60 mins.
O
N

N
H

H
N

N’-butylnicotinohydrazide (11d). 1068 mg (6 mmol) of nicotinoyl
chloride was suspended in 20 mL of methanol. To this solution was

added 1.7 mL (12 mmol) of triethylamine. The reaction was stirred at room temperature for 1
hour. 750 mg (15 mmol) hydrazine water salt was added and the solution was refluxed for 3
hours yielding the corresponding hydrazide. Volatiles were removed under vacuum and the
intermediate was resuspended in 30 mL of methanol. From here the reaction proceeded as
described in Series 11 General Procedure to yield 721.7 mg of dry product (62% yield). 1H NMR
(400 MHz, DMSO): δ 10.21 (s, 1H), 8.99 (s, 1H), 8.72-8.70 (m, 1H), 8.19-8.10 (m, 1H), 7.52-7.49
(m, 1H), 5.15 (s, 1H), 2.83-2.79 (m, 2H), 1.48-1.42 (m, 2H), 1.38-1.32 (m, 2H), 0.89 (t, J = 7.2 Hz,
3H); 13C NMR (100 MHz, DMSO): δ 164.2, 152.3, 148.6, 135.2, 129.3, 124.0, 51.3, 30.2, 20.3, 14.4.
[(m+H+)/z = 194.25]. (λ254) purity 95.6%, tR 6.17 mins.
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O
N
H

H
N

N’-butyl-[1,1’-biphenyl]-4-carbohydrazide (11e). 890 mg (3.8
mmol) of methyl [1,1’]-biphenyl-4-carboxylate was suspended
in 20 mL of methanol. To this solution, 945 mg (18.9 mmol) of

hydrazine water salt was added. The solution was brought to reflux and reacted for 3 hours. The
solution was cooled and volatiles evaporated under vacuum. From here the reaction proceeded
as described in Series 11 General Procedure to yield 555.1 mg of dry product (54% yield). 1H NMR
(400 MHz, DMSO): δ 10.08 (d, J = 6 Hz, 1H), 7.94-7.92 (m, 2H), 7.78-7.73 (m, 4H), 7.52-7.48 (m,
2H), 7.44-7.40 (m, 1H), 5.13-5.09 (m, 1H), 2.84-2.79 (m, 2H), 1.49-1.42 (m, 2H), 1.40-1.35 (m, 2H),
0.91 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 165.4, 143.2, 139.6, 132.5, 129.5, 128.5,
128.2, 127.3, 127.0, 51.4, 30.3, 20.3, 14.4. [(m+H+)/z = 269.25]. (λ254) purity 96.7%, tR 12.82 mins.
O
S

N
H

H
N

N’-butylthiophene-2-carbohydrazide (11f). 1500 mg (10 mmol) of
thiophene-2-carbonyl chloride was injected into 10 mL of sieve dried

methanol and bubbled with argon for 10 minutes. To this mixture was injected two drops of
dimethylformamide. The reaction proceeded at room temperature for 1 hour before addition of
600 mg (12 mmol) hydrazine water salt. The solution was refluxed for 3 hours before being
cooled and condensed in vacuo. The reaction then proceeded as described in Series 11 General
Procedure to yield 1235 mg of dry product (62% yield). 1H NMR (400 MHz, DMSO): δ 10.02 (s,
1H), 7.76-7.74 (m, 2H), 7.15-7.13 (m, 1H), 5.03 (s, 1H), 2.80-2.77 (m, 2H), 1.45-1.40 (m, 2H), 1.371.32 (m, 2H), 0.89 (m, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 161.0, 138.8, 131.0, 128.4,
128.2, 51.3, 30.3, 20.3, 14.4. [(m+H+)/z = 199.17]. (λ254) purity 97.5%, tR 8.47 mins.
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O
O

N
H

N’-butylfuran-2-carbohydrazide (11g). 1100 mg (8.4 mmol) of furan-

H
N

2-carbonyl chloride was injected into 10 mL of sieve dried methanol

that was bubbled with argon for 10 minutes prior to addition. To this mixture was injected 1780
mg (17.6 mmol) of triethylamine. After 60 minutes, 1000 mg (20 mmol) of hydrazine water salt
was added, and heated to reflux for 3 hours. The reaction was cooled and condensed under
vacuum. From here the reaction proceeded as described in Series 11 General Procedure to yield
861 mg of dry product (56% yield). 1H NMR (400 MHz, DMSO): δ 9.90 (s, 1H), 7.83-7.82 (m, 1),
7.11-7.10 (m, 1H), 6.62-6.60 (m, 1H), 5.00 (s, 1H), 2.79-2.74 (m, 2H), 1.44-1.40 (m, 2H), 1.38-1.30
(m, 2H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 157.6, 147.3, 145.4, 113.6, 112.1,
51.3, 30.2, 20.3, 14.4. [(m+H+)/z = 183.17]. (λ254) purity 98.4%, tR 7.43 mins.
O
N
H

H
N

N’-butyl-3-phenylpropanehydrazide (11h). 1012 mg (6 mmol) of
3-phenylpropanoyl chloride was injected into 10 mL of argon

bubbled, sieve dried methanol. The reaction was allowed to stir for 1 hour before addition of
900 mg (18 mmol) hydrazine water salt. The mixture was brought to reflux for 3 hours before
being cooled to room temperature and condensed under vacuum. From here the reaction
proceeded as described in Series 11 General Procedure to yield 911 mg of dry product (68%
yield). 1H NMR (400 MHz, DMSO): δ 9.25 (s, 1H), 7.29-7.25 (m, 2H), 7.21-7.26 (m, 3H), 4.77 (s,
1H), 2.82 (t, J = 7.6 Hz, 2H), 2.63-2.59 (m, 2H), 2.33 (t, J = 7.6 Hz, 2H), 1.31-1.25 (m, 4H), 0.85 (t, J
= 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 170.5, 141.5, 128.7 (d), 126.3, 51.2, 35.6, 31.5, 30.1,
20.2, 14.4. [(m+H+)/z = 221.25]. (λ254) purity 98.9%, tR 8.56 mins.
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O
N
H

H
N

N’-butylcinnamohydrazide (11i). 1480 mg (10 mmol) of transcinnamic acid was suspended in 50 mL of acetonitrile. To this

solution was added 1620 mg (12 mmol) of 1-hydroxybenzotriazole and 2478 mg (12 mmol) N, N'
–dicyclohexylcarbodiimide. The solution stirred overnight at room temperature before addition
of 600 mg (12 mmol) hydrazine water salt, which was refluxed for 3 hours. The solution was
brought to room temperature and condensed under vacuum. From here the reaction proceeded
as described in Series 11 General Procedure to yield 885 mg of dry product (40% yield). 1H NMR
(400 MHz, DMSO): δ 9.62 (s, 1H), 7.58-7.56 (m, 2H), 7.45-7.38 (m, 4H), 6.57 (d, J = 16.0 Hz, 1H),
5.05 (s, 1H), 2.76-2.72 (m, 2H), 1.44-1.28 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H);

13C

NMR (100 MHz,

DMSO): δ 164.3, 139.0, 135.4, 129.9, 129.4, 127.9, 120.8, 51.4, 30.2, 20.2, 14.4. [(m+H+)/z =
219.25]. (λ254) purity 97.5%, tR 10.95 mins.
O
N
H

H
N

N’-butyl-1-naphthohydrazide (11j). 1033 mg (6 mmol) of 1-napthoic
acid was suspended in 20 mL of argon flushed methylene chloride.

To this solution was injected 1143 mg (9 mmol) of oxalyl chloride followed by injection of 2 drops
of dimethylformamide. Furious bubbling was seen, with gas being exhausted and argon flushing
continually throughout the room temperature reaction. After one hour, 20 mL of sieve dried
methanol was injected slowly. After reacting for an additional hour at room temperature, the
solution was condensed under vacuum and resuspended in 30 mL of methanol. To this was
added 1500 mg (30 mmol) of hydrazine water salt. The reaction was brought to reflux for 3 hours
before being cooled and condensed under vacuum. From here the reaction proceeded as
described in Series 11 General Procedure to yield 1050 mg of dry product (72% yield). 1H NMR
(400 MHz, DMSO): δ 9.97 (s, 1H), 8.22-8.19 (m, 1H), 8.04-7.98 (m, 2H), 7.61-7.53 (m, 4H), 5.23 (s,
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1H), 2.92-2.87 (m, 2H), 1.53-1.42 (m, 2H), 1.40-1.38 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, DMSO): δ 167.8, 133.7, 133.6, 130.4, 130.4, 128.7, 127.2, 126.7, 125.8, 125.7, 125.5, 51.3,
30.3, 20.3, 14.4. [(m+H+)/z = 243.25]. (λ254) purity >99%, tR 11.00 mins.
O
N
H

N’-butyl-2-naphthohydrazide (11k). 1120 mg (6 mmol) of 2-

H
N

napthohydrazide was reacted as described in Series 11 General

Procedure to yield 1016 mg of dry product (70% yield). 1H NMR (400 MHz, DMSO): δ 10.2 (s, 1H),
8.46 (s, 1H), 8.04 -7.93 (m, 4H), 7.64-7.58 (m, 2H), 5.17 (s, 1H), 2.87-2.83 (m, 2H), 1.51-1.46 (m,
2H), 1.41-1.35 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 165.8, 134.6, 132.6,
131.1, 129.3, 128.4, 128.1, 128.0, 127.8, 127.2, 124.4, 51.4, 30.3, 20.3, 14.4. [(m+H+)/z = 243.25].
(λ254) purity >99%, tR 11.42 mins.
N-(4-(2-butylhydrazine-1-carbonyl)benzyl)benzamide

O
N
H

H
N
O

(11l). To a mixture of sieve dried methylene chloride,
N
H

was added 711 mg (4 mmol) of methyl 4-

(aminoethyl)benzoate. This vessel was flushed with argon for 30 minutes before injection of 560
mg (4 mmol) of benzoyl chloride and 607 mg (6 mmol) of trimethylamine. The reaction was
stirred at room temperature for 2 hours before being condensed under vacuum. The crude
intermediate was resuspended in 30 mL of methanol and 1000 mg (20 mmol) of hydrazine water
salt was added as one portion. The solution was refluxed for 3 hours before being cooled and
condensed under vacuum. From here the reaction proceeded as described in Series 11 General
Procedure to yield 601 mg of dry product (46% yield). 1H NMR (400 MHz, DMSO): δ 9.99 (s, 1H),
9.13-9.10 (t, J = 6.0 Hz, 1H), 7.93-7.91 (m, 2H), 7.81-7.79 (m, 2H), 7.57-7.47 (m, 3H), 7.41-7.39 (m,
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2H), 5.07 (s, 1H), 4.54 (d, J = 6.0 Hz, 2H); 13C NMR (100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7,
132.2, 131.8, 128.8, 12.7, 127.6, 127.5, 51.4, 42.9, 30.3, 20.3, 14.4. HRMS-ESI [(m+H+)/z]
calculated for C19H23N3O2: 326.18697; found, 326.18622. (λ254) purity 96.3%, tR 11.92 mins.
Synthesis of N-(4-(hydrazide)benzyl)benzamide derivatives (12a-12m).
Intermediate formation. 6050 mg (40 mmol) of 4-(aminomethyl)benzoic acid was dissolved in
200 mL of methanol, to which was added 6 mL of concentrated HCl in one portion. The mixture
was refluxed overnight and the volatiles condensed under vacuum. The resulting white solid was
suspended in ethyl ether and separated via vacuum filtration to yield the benzoate HCl salt. This
compound was dissolved in a 1:2 mixture of ethyl acetate and water and chilled to 0°C to which
11040 mg (80 mmol) was added followed by addition of 5623 mg benzoyl chloride (40 mmol).
The vessel was warmed to room temperature and stirred for 2 additional hours. The mixture was
separated via acid/base extraction, washing the water phase twice with ethyl acetate. All organic
phases were combined and condensed under vacuum to yield a white solid. This was suspended
in 200 mL of methanol and 10000 mg (200 mmol) of hydrazine water salt was added. The solution
was refluxed for 48 hours, cooled to room temperature, and volatiles were removed under
vacuum. This intermediate (12sm) was used as the starting material for all further reactions for
this family.
Series 12 General Procedure. The mixture of 12sm and aldehyde of interest were stirred at room
temperature overnight; vacuum filtration afforded the desired intermediate, which was
dissolved in 30 mL of methanol. To this solution was added a pinch of methyl orange, and the
solution’s color turned yellow. The solution was bubbled under argon for 5 minutes, and 2.2
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mmol of sodium cyanoborohydride was then added to it. A 1:1 mixture of methanol and
concentrated HCl was added dropwise until the solution turned red. After addition, the mixture
was stirred at room temperature for 6 hours. The reaction was quenched with sodium hydroxide,
and organic solvents were removed under vacuum. The residues were extracted twice with ethyl
acetate, and organic phases were combined and dried over magnesium sulfate. After filtration,
organic solvents were removed and the residues were purified by flash chromatography.
(E)-N-(4-(2-(but-2-en-1-yl)hydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12a). 2 mmol of 12sm was
N
H

dissolved in 100 mL ethanol with ultra-sonication aid.

To this solution was added 40 mmol of magnesium sulfate and 2 mmol of (E)-but-2-enal. From
here the reaction proceeded as described in Series 12 General Procedure to yield 208 mg (32%
yield). 1H NMR (400 MHz, DMSO): δ 9.97 (d, J = 5.6 Hz, 1H), 9.12 (t, J = 6.0 Hz, 1H), 7.93-7.91 (m,
2H), 7.81-7.78 (m, 2H), 7.58-7.48 (m, 3H), 7.41-7.39 (m, 2H), 5.63-5.50 (m, 2H), 5.11-5.07 (m, 1H),
4.54 (d, J = 6.0 Hz, 2H), 3.37-3.35 (m, 2H), 1.65 (d, J = 5.6 Hz, 3H); 13C NMR (100 MHz, DMSO): δ
166.8, 165.7, 143.5, 134.7, 132.2, 131.8, 128.8, 128.4, 128.2, 127.7, 127.6, 127.5, 53.6, 42.9, 18.2.
[(m+H+)/z = 324.17]. (λ254) purity >99%, tR 10.00 mins.
N-(4-(2-isopropylhydrazine-1-carbonyl)benzyl)benzamide

O
N
H

H
N
O

(12b). 2 mmol of 12sm was dissolved in 100 mL ethanol with
N
H

ultra-sonication aid. To this solution was added 40 mmol of

magnesium sulfate and 2 mmol of isopropanal. From here the reaction proceeded as described
in Series 12 General Procedure to yield yielded 324 mg (52% yield). 1H NMR (400 MHz, DMSO):
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δ 9.95 (d, J = 6.8 Hz, 1H), 9.11 (t, J = 6.0 Hz, 1H), 7.92-7.90 (m, 2H), 7.82-7.80 (m, 2H), 7.58-7.48
(m, 3H), 7.41-7.39 (m, 2H), 4.95-4.92 (m, 1H), 4.53 (d, J = 6.0 Hz, 2H), 3.11-3.03 (m, 1H), 1.02 (d,
J = 10.4 Hz, 6H); 13C NMR (100 MHz, DMSO): δ 166.8, 166.0, 143.5, 134.7, 132.2, 131.8, 128.8,
127.7, 127.6, 127.4, 50.8, 42.9, 21.4. [(m+H+)/z = 312.25]. (λ254) purity 98.8%, tR 8.68 mins.
(E)-N-(4-(2-propylidenehydrazine-1-

O
N
H

H
N

carbonyl)benzyl)benzamide (12c). 2 mmol of 12sm was
N

dissolved in 100 mL ethanol with ultra-sonication aid. To

O

this solution was added 40 mmol of magnesium sulfate and 2 mmol of propanal. From here the
reaction proceeded as described in Series 12 General Procedure to yield 347 mg (56% yield). 1H
NMR (400 MHz, DMSO): δ 11.39 (s, 1H), 9.13 (t, J = 6.0 Hz, 1H), 7.93-7.90 (m, 2H), 7.84-7.75 (m,
3H), 7.58-7.38 (m, 5H), 4.56-4.53 (m, 2H), 2.30-2.25 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, DMSO): δ 166.8, 163.1, 153.5, 143.9, 134.7, 131.8, 128.8, 128.1, 127.7, 127.5(d), 42.9, 25.9,
11.1. HRMS-ESI [(m+H+)/z] calculated for C18H19N3O2: 310.15567; found, 310.15529. (λ254) purity
97.5%, tR 11.60 mins.
N-(4-(2-propylhydrazine-1-carbonyl)benzyl)benzamide

O
N
H

H
N
O

(12d). 2 mmol of 12sm was dissolved in 100 mL ethanol
N
H

with ultra-sonication aid. To this solution was added 40

mmol of magnesium sulfate and 2 mmol of propanal. From here the reaction proceeded as
described in Series 12 General Procedure to yield 318 mg (51% yield). 1H NMR (400 MHz, DMSO):
δ 9.98 (d, J = 6.0 Hz, 1H), 9.11 (t, J = 6.0 Hz, 1H), 7.92-7.91 (m, 2H), 7.81-7.79 (m, 2H), 7.56-7.48
(m, 3H), 7.41-7.39 (m, 2H), 5.11-5.07 (m, 1H), 4.53 (d, J = 6.0 Hz, 2H), 2.78-2.73 (m, 2H), 1.49-1.44
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(m, 2H), 0.92 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2,
131.8, 128.8, 127.7, 127.6, 127.4, 53.6, 42.9, 21.3, 12.1. HRMS-ESI [(m+H+)/z] calculated for
C18H21N3O2: 312.17132; found, 312.17127. (λ254) purity >99%, tR 12.28 mins.
N-(4-(2-pentylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12e). 2 mmol of 12sm
N
H

was dissolved in 100 mL ethanol with ultra-

sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
pentanal. From here the reaction proceeded as described in Series 12 General Procedure to
yield 312 mg (46% yield). 1H NMR (400 MHz, DMSO): δ 9.99 (s, 1H), 9.11 (t, J = 6.0 Hz, 1H), 7.937.91 (m, 2H), 7.81-7.79 (m, 2H), 7.57-7.47 (m, 3H), 7.41-7.39 (m, 2H), 5.07 (s, 1H), 4.53 (d, J = 6.0
Hz, 2H), 2.78 (s, 2H), 1.48-1.44 (m, 2H), 1,33-1.29 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100
MHz, DMSO): δ 166.8, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.5, 51.7, 42.9,
29.4, 27.8, 22.5, 14.4. [(m+H+)/z = 340.25]. (λ254) purity >99%, tR 11.30 mins.
N-(4-(2-(3,3,3-trifluoropropyl)hydrazine-1-

O
N
H

H
N
O

aid.

F
N
H

F
F

carbonyl)benzyl)benzamide (12f). 2 mmol of 12sm
was dissolved in 100 mL ethanol with ultra-sonication

To this solution was added 40 mmol of magnesium sulfate and 2 mmol of 3,3,3-

trifluoropropanal.

From here the reaction proceeded as described in Series 12 General

Procedure to yield 445 mg (61% yield). 1H NMR (400 MHz, DMSO): δ 10.03 (d, J = 6.0 Hz, 1H),
9.11 (t, J = 6.0 Hz, 1H), 7.92-7.90 (m, 2H), 7.82-7.80 (m, 2H), 7.58-7.48 (m, 3H), 7.42-7.40 (m, 2H),
5.43-5.39 (m, 1H), 4.54 (d, J = 6.0 Hz, 2H), 3.05-3.00 (m, 2H), 2.54-2.44 (m, 2H);

137

13C-HSQC

(100MHz, 400 MHz, DMSO) δ 131.8, 128.8, 127.7, 127.6, 127.5, 44.55, 42.8, 32.1. [(m+H+)/z =
366.25]. (λ254) purity 97.7%, tR 10.85 mins.
N-(4-(2-(cyclopropylmethyl)hydrazine-1-

O
N
H

H
N
O

this

solution

was

carbonyl)benzyl)benzamide (12g). 2 mmol of 12sm was
N
H

added

dissolved in 100 mL ethanol with ultra-sonication aid. To
40

mmol

of

magnesium

sulfate

and

2

mmol

of

cyclopropanecarbaldehyde. From here the reaction proceeded as described in Series 12 General
Procedure to yield 415 mg (64% yield). 1H NMR (400 MHz, DMSO): δ 10.06 (s, 1H), 9.13 (s, 1H),
7.93-7.92 (m, 2H), 7.85-7.80 (m, 2H), 7.57-7.47 (m, 3H), 7.41-7.39 (m, 2H), 5.12 (s, 1H), 4.55 (s,
2H), 2.66 (s, 2H), 0.93-0.91 (m, 1H), 0.46-0.44 (m, 2H), 0.16-0.15 (m, 2H);

13C

NMR (100 MHz,

DMSO): δ 166.8, 165.5, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.5, 56.6, 42.9, 9.95,
3.61. [(m+H+)/z = 324.17]. (λ254) purity 97.4%, tR 9.27 mins.
N-(4-(2-heptylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12h). 2 mmol of
N
H

12sm was dissolved in 100 mL ethanol with

ultra-sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
heptanal. From here the reaction proceeded as described in Series 12 General Procedure to
yield 345 mg (47% yield). 1H NMR (400 MHz, DMSO): δ 10.00 (s, 1H), 9.12 (t, J = 6.0 Hz, 1H), 7.937.91 (m, 2H), 7.82-7.80 (m, 2H), 7.57-7.47 (m, 3H), 7.41-7.39 (m, 2H), 5.08-5.05 (m, 1H), 4.54 (d,
J = 6.0 Hz, 2H), 2.81-2.76 (m, 2H), 1,48-1.44 (m, 2H), 1.34-1.26 (m, 8H), 0.86 (t, J = 6.4 Hz, 3H); 13C
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NMR (100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.4,
51.7, 42.9, 31.8, 29.1, 28.1, 27.1, 22.6, 14.4. [(m+H+)/z = 368.33]. (λ254) purity >99%, tR 13.25 mins.
N-(4-(2-octylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12i). 2 mmol of
N
H

12sm was dissolved in 100 mL ethanol with

ultra-sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
octanal. From here the reaction proceeded as described in Series 12 General Procedure to yield
305 mg (40% yield). 1H NMR (400 MHz, DMSO): δ 10.00 (s, 1H), 9.12 (t, J = 6.0 Hz, 1H), 7.93-7.91
(m, 2H), 7.82-7.80 (m, 2H), 7.55-7.46 (m, 3H), 7.41-7.39 (m, 2H), 5.07-5.06 (m, 1H), 4.54 (d, J =
5.6 Hz, 2H), 2.80-2.76 (m, 2H), 1.47-1.42 (m, 2H), 1.34-1.25 (m, 10H), 0.86 (t, J = 6.4 Hz, 3H); 13C
NMR (100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.4,
51.7, 42.9, 31.7, 29.4, 29.2, 28.1, 27.2, 22.6, 14.4. [(m+H+)/z = 382.33]. (λ254) purity 95.8%, tR 13.97
mins.
N-(4-(2-hexylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12j).
N
H

2 mmol of

12sm was dissolved in 100 mL ethanol with ultra-

sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of hexanal.
From here the reaction proceeded as described in Series 12 General Procedure to yield 367 mg
(52% yield). 1H NMR (400 MHz, DMSO): δ 9.99 (s, 1H), 9.12 (t, J = 6.0 Hz, 1H), 7.93-7.91 (m, 2H),
7.81-7.79 (m, 2H), 7.58-7.47 (m, 3H), 7.41-7.39 (m, 2H), 5.08-5.05 (m, 1H), 4.54 (d, J = 6.0 Hz, 2H),
2.81-2.76 (m, 2H), 1.49-1.42 (m, 2H), 1.37-1.26 (m, 6H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (100
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MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.4, 51.7, 42.9,
31.7, 28.1, 26.8, 22.6, 14.4. [(m+H+)/z = 354.33]. (λ254) purity 98.8%, tR 12.45 mins.
N-(4-(2-decylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12k).
N
H

2

mmol of 12sm was dissolved in 100 mL

ethanol with ultra-sonication aid. To this solution was added 40 mmol of magnesium sulfate and
2 mmol of decanal. From here the reaction proceeded as described in Series 12 General
Procedure to yield 295 mg (36% yield). 1H NMR (400 MHz, DMSO): δ 9.99 (s, 1H), 9.12 (t, J = 6.0
Hz, 1H), 7.93-7.91 (m, 2H), 7.81-7.79 (m, 2H), 7.57-7.54 (m, 3H), 7.41-7.39 (m, 2H), 5.07-5.05 (m,
1H), 4.54 (d, J = 6.0 Hz, 2H), 2.80-2.75 (m, 2H), 1.48-1.42 (m, 2H), 1.33-1.25 (m, 14H), 0.86 (t, J =
6.8 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7,
127.5, 127.4, 51.7, 42.9, 31.8, 29.5(d), 29.2, 28.1, 27.2, 22.6, 14.4. [(m+H+)/z = 410.33]. (λ254)
purity 98.2%, tR 15.01 mins.
N-(4-(2-ethylhydrazine-1-carbonyl)benzyl)benzamide (12l).

O
N
H

H
N
O

2 mmol of 12sm was dissolved in 100 mL ethanol with ultraN
H

sonication aid. To this solution was added 40 mmol of

magnesium sulfate and 2 mmol of acetaldehyde. From here the reaction proceeded as described
in Series 12 General Procedure to yield 404 mg (68% yield). 1H NMR (400 MHz, DMSO): δ 10.00
(s, 1H), 9.13-9.11 (m, 1H), 7.93-7.90 (m, 2H), 7.81-7.89 (m, 2H), 7.56-7.47 (m, 3H), 7.42-7.39 (m,
2H), 5.07 (s, 1H), 4.54 (s, 2H), 2.83-2.80 (m, 2H), 1.06-1.02 (m, 3H); 13C NMR (100 MHz, DMSO): δ
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166.8, 165.7, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.6, 127.5, 46.0, 42.9, 13.6. [(m+H+)/z =
298.25]. (λ254) purity 95.6%, tR 7.71 mins.
N-(4-(2-(cyclobutylmethyl)hydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)benzamide (12m). 2 mmol of 12sm was
N
H

dissolved in 100 mL ethanol with ultra-sonication aid. To

this solution was added 40 mmol of magnesium sulfate and 2 mmol of cyclobutanecarbaldehyde.
From here the reaction proceeded as described in Series 12 General Procedure to yield 438 mg
(65% yield). 1H NMR (400 MHz, DMSO): δ 9.97 (s, 1H), 9.14-9.10 (m, 1H), 7.93-7.91 (m, 2H), 7.807.78 (m, 2H), 7.58-7.48 (m, 3H), 7.40-7.38 (m, 2H), 5.06 (s, 1H), 4.53 (d, J = 6.0 Hz, 2H), 2.83 (d, J
= 7.2 Hz, 2H), 2.49-2.43 (m, 1H), 2.05-2.03 (m, 2H), 1.89-1.78 (m, 2H), 1.74-1.65 (m, 2H); 13C NMR
(100 MHz, DMSO): δ 166.7, 165.6, 143.5, 134.7, 132.2, 131.8, 128.8, 127.7, 127.5, 127.4, 57.5,
42.9, 34.2, 26.5, 18.8. [(m+H+)/z = 338.17]. (λ254) purity 96.7%, tR 10.55 mins.
Synthesis of N-(4-(hydrazide)benzyl)cinnamamide Derivatives (13a-13e).
Intermediate formation. Transcinnamic acid (40 mmol) was dissolved in 500 mL of methylene
chloride. The apparatus was purged with argon and bubbled through the solution. To this
solution was injected 60 mmol of oxalyl chloride and 10 drops of dimethylformamide. The
mixture was stirred at room temperature for 3 hours under constant argon flush. The solution
was condensed under vacuum and brought to 0°C. A pre-chilled 1:2 mixture of ethyl acetate and
water was slowly added followed by addition of potassium carbonate (80 mmol) and methyl 4(aminomethyl)benzoate HCl (40 mmol). The reaction was brought to room temperature slowly
and allowed to stir for 2 additional hours. The water and organic phases were separated, and
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the water phase washed twice with ethyl acetate. The organic phases were combined and dried
under vacuum. A white solid was obtained and used in the next step without further purification.
The product was resuspended in a 2:2:1 solution of methanol, tetrahydrofuran, and water at 0°C.
To this solution was cautiously added 48 lithium hydroxide (48 mmol). The solution was allowed
to warm to room temperature and stir overnight. Volatiles were removed under vacuum and the
residue was acidified with 1 M HCl before extraction with ethyl acetate; volatiles were once again
removed under vacuum and lyophilized. The resulting white crystalline powder was used in the
next step without further purification. The 4-(cinnamamidomethyl)benzoic acid generated in the
above steps was suspended in 400 mL of dimethylformamide, to which was added
Hydroxybenzotriazole (80 mmol) and N-N’-Dicyclochexylcarbodiimide (80 mmol). This solution
was stirred for 6 hours at RT before addition of hydrazine water salt (48 mmol) at 0°C in one
portion. The mixture was allowed to warm to room temperature and stir overnight before being
extracted with 1200 mL of water. The water phase was extracted with ethyl acetate twice, and
the organic layers were combined and condensed under vacuum. The product (13sm) was
purified via flash chromatography to yield the corresponding hydrazide that will be used as a
starting material for all further reactions for this family (13a-13e).
O
H
N
O

N
H

N-(4-(2-ethylhydrazine-1-

H
N

carbonyl)benzyl)cinnamamide (13a). 2 mmol of 13sm
was dissolved in 100 mL ethanol with ultra-sonication

aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of ethanal. From here
the reaction proceeded as described in Series 12 General Procedure to yield 454 mg (70% yield).
1H

NMR (400 MHz, DMSO): δ 10.0 (s, 1H), 8.70 (t, J = 5.9 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.58 (d,
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J = 6.8 Hz, 2H), 7.49 (d, J = 15.8 Hz, 1H), 7.43-7.36 (m, 5H), 6.72 (d, J = 15.8 Hz, 1H), 5.06 (s, 1H),
4.46 (d, J = 6.0 Hz, 2H), 2.85-2.79 (m, 2H), 2.51 (t, J = 1.7 Hz, 2H), 1.04 (t, J = 7.2 Hz, 3H); 13C NMR
(100MHz, DMSO): δ 165.6, 165.5, 143.2, 139.6, 135.3, 132.3, 130.0, 129.4, 128.0, 127.6, 122.4,
46.0, 42.5, 13.6. [(m+H+)/z = 324.25]. (λ254) purity 97.5%, tR 10.38 mins.
N-(4-(2-propylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)cinnamamide (13b).
N
H

2 mmol of

13sm was dissolved in 100 mL ethanol with ultra-

sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
propanal. From here the reaction proceeded as described in Series 12 General Procedure to
yield 546 mg (81% yield). 1H NMR (400 MHz, DMSO): δ 10.00 (s, 1H), 8.70 (t, J = 6.0 Hz, 1H), 7.827.80 (m, 2H), 7.60-7.58 (m, 2H), 7.50 (d, J = 16 Hz, 1H), 7.45-7.37 (m, 5H), 6.72 (d, J = 15.6, 1H),
5.11-5.08 (m, 1H), 4.47 (d, J = 5.6 Hz, 2H), 2.78-2.74 (m, 2H), 1.51-1.45 (m, 2H), 0.92 (t, J = 7.2 Hz,
3H); 13C NMR (100 MHz, DMSO): δ 165.6, 165.5, 143.2, 139.6, 135.3, 132.3, 130.0, 129.4, 128.0,
127.6 (d), 122.4, 53.6, 42.5, 21.3, 12.1. HRMS-ESI [(m+H+)/z] calculated for C20H23N3O2:
338.18697; found, 338.18726. (λ254) purity 98.4%, tR 12.42 mins.
N-(4-(2-butylhydrazine-1-

O
N
H

H
N
O

N
H

carbonyl)benzyl)cinnamamide (13c). 2 mmol of
13sm was dissolved in 100 mL ethanol with ultra-

sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of butanal.
From here the reaction proceeded as described in Series 12 General Procedure to yield 576 mg
(82% yield). 1H NMR (400 MHz, DMSO): δ 10.0 (s, 1H), 8.7 (t, J = 6.0 Hz, 1H), 7.8 (d, J = 8.3 Hz, 2H),
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7.58 (d, J = 6.8 Hz, 2H), 7.49 (d, J = 15.8 Hz, 1H), 7.43-7.36 (m, 5H), 6.71 (d, J = 15.8 Hz, 1H), 5.06
(s, 1H), 4.45 (d, J = 6.0 Hz, 2H), 2.80-2.76 (m, 2H), 2.51 (t, J = 1.8 Hz, 2H), 1.48-1.41 (m, 2H), 1.401.30 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz, DMSO): δ 165.5, 165.5, 143.2, 139.6,
135.3, 132.3, 130.0, 129.4, 128.0, 127.6, 122.4, 51.4, 42.5, 30.3, 20.3, 14.4. [(m+H+)/z = 352.25].
(λ254) purity 98.9%, tR 12.67 mins.
N-(4-(2-pentylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)cinnamamide (13d). 2 mmol of
N
H

13sm was dissolved in 100 mL ethanol with

ultra-sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
pentanal. From here the reaction proceeded as described in Series 12 General Procedure to
yield 584 mg (80% yield). 1H NMR (400 MHz, DMSO): δ 10.0 (s, 1H), 8.7 (t, J = 6.0 Hz, 1H), 7.8 (d,
J = 8.3 Hz, 2H), 7.58 (d, J = 6.8 Hz, 2H), 7.49 (d, J = 15.8 Hz, 1H), 7.45-7.35 (m, 5H), 6.71 (d, J = 15.8
Hz, 1H), 5.06 (s, 1H), 4.45 (d, J = 6.0 Hz, 2H), 2.80-2.75 (m, 2H), 2.51 (t, J = 1.8 Hz, 2H), 1.47-1.44
(m, 2H), 1.33-1.29 (m, 4H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz, DMSO): δ 165.5, 165.5,
143.2, 139.6, 135.3, 132.3, 130.0, 129.4, 128.0, 127.6, 122.4, 51.7, 42.5, 29.3, 27.8, 22.5, 14.4.
[(m+H+)/z = 366.25]. (λ254) purity 97.5%, tR 13.34 mins.
N-(4-(2-hexylhydrazine-1-

O
N
H

H
N
O

carbonyl)benzyl)cinnamamide (13e). 2 mmol

N
H

of 13sm was dissolved in 100 mL ethanol with

ultra-sonication aid. To this solution was added 40 mmol of magnesium sulfate and 2 mmol of
hexanal. From here the reaction proceeded as described in Series 12 General Procedure to yield
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616 mg (81% yield). 1H NMR (400 MHz, DMSO): δ 10.00 (s, 1H), 8.71 (t, J = 6.0 Hz, 1H), 7.82-7.82
(m, 2H), 7.60-7.58 (m, 2H), 7.55 (d, J = 16 Hz, 1H), 7.45-7.36 (m, 5H), 6.73 (d, J = 15.6 Hz, 1H), 5.07
(s, 1H), 4.47 (d, J = 6.0 Hz, 2H), 2.81-2.76 (m, 2H), 1.49-1.41 (m, 2H), 1.37-1.27 (m, 6H), 0.86 (t, J
= 6.8 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 165.6, 165.5, 143.2, 139.6, 135.3, 132.3, 130.0, 129.4,
128.0, 127.6 (d), 122.4, 51.7, 42.5, 31.7, 28.1, 26.8, 22.6, 14.4. [(m+H+)/z = 380.33]. (λ254) purity
95.5%, tR 13.62 mins.
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